id	sid	tid	token	lemma	pos
admet-328	1	1	doi	doi	NOUN
admet-328	1	2	:	:	PUNCT
admet-328	1	3	10.5599	10.5599	NUM
admet-328	1	4	/	/	SYM
admet-328	1	5	admet.4.3.328	admet.4.3.328	NUM
admet-328	1	6	269	269	NUM
admet-328	1	7	admet	admet	X
admet-328	1	8	&	&	CCONJ
admet-328	1	9	dmpk	dmpk	PROPN
admet-328	1	10	4(3	4(3	NUM
admet-328	1	11	)	)	PUNCT
admet-328	1	12	(	(	PUNCT
admet-328	1	13	2016	2016	NUM
admet-328	1	14	)	)	PUNCT
admet-328	1	15	269	269	NUM
admet-328	1	16	-	-	SYM
admet-328	1	17	279	279	NUM
admet-328	1	18	;	;	PUNCT
admet-328	1	19	doi	doi	NOUN
admet-328	1	20	:	:	PUNCT
admet-328	1	21	10.5599	10.5599	NUM
admet-328	1	22	/	/	SYM
admet-328	1	23	admet.4.3.328	admet.4.3.328	X
admet-328	1	24	open	open	ADJ
admet-328	1	25	access	access	NOUN
admet-328	1	26	:	:	PUNCT
admet-328	1	27	issn	issn	PROPN
admet-328	1	28	:	:	PUNCT
admet-328	1	29	1848	1848	NUM
admet-328	1	30	-	-	SYM
admet-328	1	31	7718	7718	NUM
admet-328	1	32	http://www.pub.iapchem.org/ojs/index.php/admet/index	http://www.pub.iapchem.org/ojs/index.php/admet/index	NOUN
admet-328	1	33	original	original	ADJ
admet-328	1	34	scientific	scientific	ADJ
admet-328	1	35	paper	paper	NOUN
admet-328	1	36	evaluation	evaluation	NOUN
admet-328	1	37	of	of	ADP
admet-328	1	38	pharmacokinetic	pharmacokinetic	ADJ
admet-328	1	39	and	and	CCONJ
admet-328	1	40	pharmacodynamic	pharmacodynamic	ADJ
admet-328	1	41	interaction	interaction	NOUN
admet-328	1	42	between	between	ADP
admet-328	1	43	repaglinide	repaglinide	NOUN
admet-328	1	44	and	and	CCONJ
admet-328	1	45	atazanavir	atazanavir	PROPN
admet-328	1	46	in	in	ADP
admet-328	1	47	healthy	healthy	ADJ
admet-328	1	48	,	,	PUNCT
admet-328	1	49	diabetic	diabetic	ADJ
admet-328	1	50	and	and	CCONJ
admet-328	1	51	hepatic	hepatic	ADJ
admet-328	1	52	impaired	impaired	ADJ
admet-328	1	53	rats	rat	NOUN
admet-328	1	54	:	:	PUNCT
admet-328	1	55	possible	possible	ADJ
admet-328	1	56	inhibition	inhibition	NOUN
admet-328	1	57	of	of	ADP
admet-328	1	58	cyp3a	cyp3a	NOUN
admet-328	1	59	,	,	PUNCT
admet-328	1	60	oatp	oatp	ADJ
admet-328	1	61	,	,	PUNCT
admet-328	1	62	and	and	CCONJ
admet-328	1	63	p	p	X
admet-328	1	64	-	-	PUNCT
admet-328	1	65	glycoprotein	glycoprotein	NOUN
admet-328	1	66	transporters	transporter	NOUN
admet-328	1	67	thirumaleswara	thirumaleswara	ADP
admet-328	1	68	goud*1	goud*1	NOUN
admet-328	1	69	,	,	PUNCT
admet-328	1	70	srinivas	srinivas	PROPN
admet-328	1	71	maddi2	maddi2	PROPN
admet-328	1	72	,	,	PUNCT
admet-328	1	73	nayakanti	nayakanti	ADJ
admet-328	1	74	devanna3	devanna3	NOUN
admet-328	1	75	,	,	PUNCT
admet-328	1	76	thatipamula	thatipamula	NOUN
admet-328	1	77	rajendra	rajendra	PROPN
admet-328	1	78	prasad4	prasad4	NOUN
admet-328	1	79	1	1	NUM
admet-328	1	80	creative	creative	ADJ
admet-328	1	81	educational	educational	ADJ
admet-328	1	82	society	society	NOUN
admet-328	1	83	’s	’s	PART
admet-328	1	84	college	college	PROPN
admet-328	1	85	of	of	ADP
admet-328	1	86	pharmacy	pharmacy	NOUN
admet-328	1	87	,	,	PUNCT
admet-328	1	88	chinnatekur	chinnatekur	NOUN
admet-328	1	89	,	,	PUNCT
admet-328	1	90	kurnool	kurnool	PROPN
admet-328	1	91	,	,	PUNCT
admet-328	1	92	andhra	andhra	PROPN
admet-328	1	93	pradesh	pradesh	PROPN
admet-328	1	94	,	,	PUNCT
admet-328	1	95	india	india	PROPN
admet-328	1	96	2	2	NUM
admet-328	1	97	gvk	gvk	NOUN
admet-328	1	98	bio	bio	PROPN
admet-328	1	99	sciences	sciences	PROPN
admet-328	1	100	,	,	PUNCT
admet-328	1	101	hyderabad	hyderabad	PROPN
admet-328	1	102	,	,	PUNCT
admet-328	1	103	telangana	telangana	PROPN
admet-328	1	104	,	,	PUNCT
admet-328	1	105	india	india	PROPN
admet-328	1	106	3	3	PROPN
admet-328	1	107	department	department	NOUN
admet-328	1	108	of	of	ADP
admet-328	1	109	chemistry	chemistry	NOUN
admet-328	1	110	,	,	PUNCT
admet-328	1	111	jntu	jntu	PROPN
admet-328	1	112	anantapur	anantapur	PROPN
admet-328	1	113	,	,	PUNCT
admet-328	1	114	anantapuramu	anantapuramu	PROPN
admet-328	1	115	,	,	PUNCT
admet-328	1	116	andhra	andhra	PROPN
admet-328	1	117	pradesh	pradesh	PROPN
admet-328	1	118	,	,	PUNCT
admet-328	1	119	india	india	PROPN
admet-328	1	120	4	4	NUM
admet-328	1	121	jawaharlal	jawaharlal	PROPN
admet-328	1	122	nehru	nehru	PROPN
admet-328	1	123	technological	technological	ADJ
admet-328	1	124	university	university	NOUN
admet-328	1	125	,	,	PUNCT
admet-328	1	126	anantapur	anantapur	PROPN
admet-328	1	127	,	,	PUNCT
admet-328	1	128	anantapuramu	anantapuramu	PROPN
admet-328	1	129	,	,	PUNCT
admet-328	1	130	andhra	andhra	PROPN
admet-328	1	131	pradesh	pradesh	PROPN
admet-328	1	132	,	,	PUNCT
admet-328	1	133	india	india	PROPN
admet-328	1	134	.	.	PUNCT
admet-328	2	1	*	*	PUNCT
admet-328	2	2	corresponding	correspond	VERB
admet-328	2	3	author	author	NOUN
admet-328	2	4	.	.	PUNCT
admet-328	3	1	e	e	X
admet-328	3	2	-	-	NOUN
admet-328	3	3	mail	mail	NOUN
admet-328	3	4	:	:	PUNCT
admet-328	4	1	thirumalram@gmail.com	thirumalram@gmail.com	NUM
admet-328	4	2	;	;	PUNCT
admet-328	4	3	tel	tel	PROPN
admet-328	4	4	.	.	PROPN
admet-328	4	5	:	:	PUNCT
admet-328	4	6	+919705058169	+919705058169	NUM
admet-328	4	7	received	receive	VERB
admet-328	4	8	:	:	PUNCT
admet-328	4	9	july	july	PROPN
admet-328	4	10	14	14	NUM
admet-328	4	11	,	,	PUNCT
admet-328	4	12	2016	2016	NUM
admet-328	4	13	;	;	PUNCT
admet-328	4	14	revised	revise	VERB
admet-328	4	15	:	:	PUNCT
admet-328	4	16	september	september	PROPN
admet-328	4	17	11	11	NUM
admet-328	4	18	,	,	PUNCT
admet-328	4	19	2016	2016	NUM
admet-328	4	20	;	;	PUNCT
admet-328	4	21	published	publish	VERB
admet-328	4	22	:	:	PUNCT
admet-328	4	23	september	september	PROPN
admet-328	4	24	30	30	NUM
admet-328	4	25	,	,	PUNCT
admet-328	4	26	2016	2016	NUM
admet-328	4	27	abstract	abstract	NOUN
admet-328	4	28	the	the	DET
admet-328	4	29	metabolic	metabolic	NOUN
admet-328	4	30	syndrome	syndrome	NOUN
admet-328	4	31	in	in	ADP
admet-328	4	32	hiv	hiv	PROPN
admet-328	4	33	infected	infect	VERB
admet-328	4	34	patients	patient	NOUN
admet-328	4	35	is	be	AUX
admet-328	4	36	particularly	particularly	ADV
admet-328	4	37	associated	associate	VERB
admet-328	4	38	with	with	ADP
admet-328	4	39	the	the	DET
admet-328	4	40	use	use	NOUN
admet-328	4	41	protease	protease	NOUN
admet-328	4	42	inhibitors	inhibitor	NOUN
admet-328	4	43	.	.	PUNCT
admet-328	5	1	atazanavir	atazanavir	PROPN
admet-328	5	2	is	be	AUX
admet-328	5	3	an	an	DET
admet-328	5	4	inhibitor	inhibitor	NOUN
admet-328	5	5	of	of	ADP
admet-328	5	6	the	the	DET
admet-328	5	7	cytochrome	cytochrome	NOUN
admet-328	5	8	p	p	NOUN
admet-328	5	9	450	450	NUM
admet-328	5	10	(	(	PUNCT
admet-328	5	11	cyp	cyp	ADJ
admet-328	5	12	)	)	PUNCT
admet-328	5	13	system	system	NOUN
admet-328	5	14	,	,	PUNCT
admet-328	5	15	in	in	ADP
admet-328	5	16	particular	particular	ADJ
admet-328	5	17	cyp3a4	cyp3a4	NOUN
admet-328	5	18	and	and	CCONJ
admet-328	5	19	cyp2c9	cyp2c9	NOUN
admet-328	5	20	which	which	PRON
admet-328	5	21	can	can	AUX
admet-328	5	22	affect	affect	VERB
admet-328	5	23	the	the	DET
admet-328	5	24	metabolism	metabolism	NOUN
admet-328	5	25	of	of	ADP
admet-328	5	26	several	several	ADJ
admet-328	5	27	drugs	drug	NOUN
admet-328	5	28	.	.	PUNCT
admet-328	6	1	to	to	PART
admet-328	6	2	treat	treat	VERB
admet-328	6	3	metabolic	metabolic	NOUN
admet-328	6	4	syndrome	syndrome	NOUN
admet-328	6	5	in	in	ADP
admet-328	6	6	hiv	hiv	PROPN
admet-328	6	7	patients	patient	NOUN
admet-328	6	8	repaglinide	repaglinide	VERB
admet-328	6	9	is	be	AUX
admet-328	6	10	used	use	VERB
admet-328	6	11	and	and	CCONJ
admet-328	6	12	it	it	PRON
admet-328	6	13	is	be	AUX
admet-328	6	14	a	a	DET
admet-328	6	15	short	short	ADJ
admet-328	6	16	acting	act	VERB
admet-328	6	17	insulin	insulin	NOUN
admet-328	6	18	secretagogues	secretagogue	NOUN
admet-328	6	19	undergoing	undergo	VERB
admet-328	6	20	metabolism	metabolism	NOUN
admet-328	6	21	with	with	ADP
admet-328	6	22	cyp	cyp	ADJ
admet-328	6	23	3a4	3a4	NUM
admet-328	6	24	and	and	CCONJ
admet-328	6	25	cyp	cyp	ADJ
admet-328	6	26	2c8	2c8	NUM
admet-328	6	27	enzyme	enzyme	NOUN
admet-328	6	28	system	system	NOUN
admet-328	6	29	.	.	PUNCT
admet-328	7	1	the	the	DET
admet-328	7	2	purpose	purpose	NOUN
admet-328	7	3	of	of	ADP
admet-328	7	4	this	this	DET
admet-328	7	5	study	study	NOUN
admet-328	7	6	was	be	AUX
admet-328	7	7	to	to	PART
admet-328	7	8	assess	assess	VERB
admet-328	7	9	the	the	DET
admet-328	7	10	possible	possible	ADJ
admet-328	7	11	pharmacokinetic	pharmacokinetic	ADJ
admet-328	7	12	and	and	CCONJ
admet-328	7	13	pharmacodynamic	pharmacodynamic	ADJ
admet-328	7	14	drug	drug	NOUN
admet-328	7	15	interaction	interaction	NOUN
admet-328	7	16	of	of	ADP
admet-328	7	17	repaglinide	repaglinide	NOUN
admet-328	7	18	and	and	CCONJ
admet-328	7	19	atazanavir	atazanavir	PROPN
admet-328	7	20	in	in	ADP
admet-328	7	21	healthy	healthy	ADJ
admet-328	7	22	,	,	PUNCT
admet-328	7	23	diabetic	diabetic	ADJ
admet-328	7	24	and	and	CCONJ
admet-328	7	25	impaired	impaired	ADJ
admet-328	7	26	hepatic	hepatic	ADJ
admet-328	7	27	function	function	NOUN
admet-328	7	28	rats	rat	NOUN
admet-328	7	29	.	.	PUNCT
admet-328	8	1	human	human	ADJ
admet-328	8	2	oral	oral	ADJ
admet-328	8	3	therapeutic	therapeutic	ADJ
admet-328	8	4	doses	dose	NOUN
admet-328	8	5	of	of	ADP
admet-328	8	6	atazanavir	atazanavir	PROPN
admet-328	8	7	and	and	CCONJ
admet-328	8	8	repaglinide	repaglinide	NOUN
admet-328	8	9	were	be	AUX
admet-328	8	10	extrapolated	extrapolate	VERB
admet-328	8	11	to	to	ADP
admet-328	8	12	rats	rat	NOUN
admet-328	8	13	based	base	VERB
admet-328	8	14	on	on	ADP
admet-328	8	15	the	the	DET
admet-328	8	16	body	body	NOUN
admet-328	8	17	surface	surface	NOUN
admet-328	8	18	area	area	NOUN
admet-328	8	19	.	.	PUNCT
admet-328	9	1	the	the	DET
admet-328	9	2	pharmacokinetic	pharmacokinetic	ADJ
admet-328	9	3	parameters	parameter	NOUN
admet-328	9	4	and	and	CCONJ
admet-328	9	5	blood	blood	NOUN
admet-328	9	6	glucose	glucose	NOUN
admet-328	9	7	concentrations	concentration	NOUN
admet-328	9	8	of	of	ADP
admet-328	9	9	repaglinide	repaglinide	NOUN
admet-328	9	10	were	be	AUX
admet-328	9	11	determined	determine	VERB
admet-328	9	12	after	after	ADP
admet-328	9	13	oral	oral	ADJ
admet-328	9	14	administration	administration	NOUN
admet-328	9	15	of	of	ADP
admet-328	9	16	repaglinide	repaglinide	NOUN
admet-328	9	17	alone	alone	ADV
admet-328	9	18	(	(	PUNCT
admet-328	9	19	0.5	0.5	NUM
admet-328	9	20	mg	mg	PROPN
admet-328	9	21	/	/	SYM
admet-328	9	22	kg	kg	PROPN
admet-328	9	23	)	)	PUNCT
admet-328	9	24	and	and	CCONJ
admet-328	9	25	in	in	ADP
admet-328	9	26	the	the	DET
admet-328	9	27	presence	presence	NOUN
admet-328	9	28	of	of	ADP
admet-328	9	29	atazanavir	atazanavir	PROPN
admet-328	9	30	(	(	PUNCT
admet-328	9	31	36	36	NUM
admet-328	9	32	mg	mg	PROPN
admet-328	9	33	/	/	SYM
admet-328	9	34	kg	kg	NOUN
admet-328	9	35	)	)	PUNCT
admet-328	9	36	in	in	ADP
admet-328	9	37	normal	normal	ADJ
admet-328	9	38	,	,	PUNCT
admet-328	9	39	diabetic	diabetic	ADJ
admet-328	9	40	and	and	CCONJ
admet-328	9	41	hepatic	hepatic	ADJ
admet-328	9	42	impaired	impaired	ADJ
admet-328	9	43	rats	rat	NOUN
admet-328	9	44	.	.	PUNCT
admet-328	10	1	the	the	DET
admet-328	10	2	pharmacokinetics	pharmacokinetic	NOUN
admet-328	10	3	(	(	PUNCT
admet-328	10	4	pk	pk	NOUN
admet-328	10	5	)	)	PUNCT
admet-328	10	6	and	and	CCONJ
admet-328	10	7	blood	blood	NOUN
admet-328	10	8	glucose	glucose	NOUN
admet-328	10	9	concentrations	concentration	NOUN
admet-328	10	10	of	of	ADP
admet-328	10	11	repaglinide	repaglinide	NOUN
admet-328	10	12	were	be	AUX
admet-328	10	13	significantly	significantly	ADV
admet-328	10	14	altered	alter	VERB
admet-328	10	15	in	in	ADP
admet-328	10	16	the	the	DET
admet-328	10	17	presence	presence	NOUN
admet-328	10	18	of	of	ADP
admet-328	10	19	atazanavir	atazanavir	PROPN
admet-328	10	20	.	.	PUNCT
admet-328	11	1	the	the	DET
admet-328	11	2	peak	peak	NOUN
admet-328	11	3	plasma	plasma	NOUN
admet-328	11	4	concentration	concentration	NOUN
admet-328	11	5	(	(	PUNCT
admet-328	11	6	cmax	cmax	NOUN
admet-328	11	7	)	)	PUNCT
admet-328	11	8	,	,	PUNCT
admet-328	11	9	area	area	NOUN
admet-328	11	10	under	under	ADP
admet-328	11	11	the	the	DET
admet-328	11	12	plasma	plasma	NOUN
admet-328	11	13	concentration	concentration	NOUN
admet-328	11	14	time	time	NOUN
admet-328	11	15	profile	profile	NOUN
admet-328	11	16	(	(	PUNCT
admet-328	11	17	auc	auc	NOUN
admet-328	11	18	)	)	PUNCT
admet-328	11	19	and	and	CCONJ
admet-328	11	20	elimination	elimination	NOUN
admet-328	11	21	half	half	ADJ
admet-328	11	22	-	-	PUNCT
admet-328	11	23	life	life	NOUN
admet-328	11	24	of	of	ADP
admet-328	11	25	repaglinide	repaglinide	NOUN
admet-328	11	26	were	be	AUX
admet-328	11	27	significantly	significantly	ADV
admet-328	11	28	(	(	PUNCT
admet-328	11	29	p<0.0001	p<0.0001	NOUN
admet-328	11	30	)	)	PUNCT
admet-328	11	31	increased	increase	VERB
admet-328	11	32	.	.	PUNCT
admet-328	12	1	the	the	DET
admet-328	12	2	repaglinide	repaglinide	PROPN
admet-328	12	3	clearance	clearance	NOUN
admet-328	12	4	(	(	PUNCT
admet-328	12	5	cl	cl	NOUN
admet-328	12	6	)	)	PUNCT
admet-328	12	7	was	be	AUX
admet-328	12	8	significantly	significantly	ADV
admet-328	12	9	(	(	PUNCT
admet-328	12	10	p<0.0001	p<0.0001	NOUN
admet-328	12	11	)	)	PUNCT
admet-328	12	12	decreased	decrease	VERB
admet-328	12	13	in	in	ADP
admet-328	12	14	the	the	DET
admet-328	12	15	presence	presence	NOUN
admet-328	12	16	of	of	ADP
admet-328	12	17	atazanavir	atazanavir	PROPN
admet-328	12	18	treatment	treatment	PROPN
admet-328	12	19	.	.	PUNCT
admet-328	13	1	in	in	ADP
admet-328	13	2	the	the	DET
admet-328	13	3	presence	presence	NOUN
admet-328	13	4	of	of	ADP
admet-328	13	5	atazanavir	atazanavir	PROPN
admet-328	13	6	,	,	PUNCT
admet-328	13	7	repaglinide	repaglinide	ADJ
admet-328	13	8	hypoglycaemic	hypoglycaemic	ADJ
admet-328	13	9	activity	activity	NOUN
admet-328	13	10	was	be	AUX
admet-328	13	11	increased	increase	VERB
admet-328	13	12	significantly	significantly	ADV
admet-328	13	13	(	(	PUNCT
admet-328	13	14	p<0.0001	p<0.0001	NOUN
admet-328	13	15	)	)	PUNCT
admet-328	13	16	when	when	SCONJ
admet-328	13	17	compared	compare	VERB
admet-328	13	18	with	with	ADP
admet-328	13	19	the	the	DET
admet-328	13	20	repaglinide	repaglinide	PROPN
admet-328	13	21	control	control	PROPN
admet-328	13	22	group	group	PROPN
admet-328	13	23	.	.	PUNCT
admet-328	14	1	the	the	DET
admet-328	14	2	present	present	ADJ
admet-328	14	3	study	study	NOUN
admet-328	14	4	demonstrated	demonstrate	VERB
admet-328	14	5	the	the	DET
admet-328	14	6	significant	significant	ADJ
admet-328	14	7	difference	difference	NOUN
admet-328	14	8	in	in	ADP
admet-328	14	9	the	the	DET
admet-328	14	10	pk	pk	NOUN
admet-328	14	11	/	/	SYM
admet-328	14	12	pd	pd	NOUN
admet-328	14	13	changes	change	NOUN
admet-328	14	14	due	due	ADJ
admet-328	14	15	to	to	ADP
admet-328	14	16	the	the	DET
admet-328	14	17	enhanced	enhanced	ADJ
admet-328	14	18	bioavailability	bioavailability	NOUN
admet-328	14	19	and	and	CCONJ
admet-328	14	20	decreased	decrease	VERB
admet-328	14	21	total	total	ADJ
admet-328	14	22	body	body	NOUN
admet-328	14	23	clearance	clearance	NOUN
admet-328	14	24	of	of	ADP
admet-328	14	25	repaglinide	repaglinide	NOUN
admet-328	14	26	may	may	AUX
admet-328	14	27	be	be	AUX
admet-328	14	28	due	due	ADJ
admet-328	14	29	to	to	ADP
admet-328	14	30	the	the	DET
admet-328	14	31	inhibition	inhibition	NOUN
admet-328	14	32	of	of	ADP
admet-328	14	33	the	the	DET
admet-328	14	34	cyp	cyp	ADJ
admet-328	14	35	p450	p450	PROPN
admet-328	14	36	metabolic	metabolic	NOUN
admet-328	14	37	system	system	NOUN
admet-328	14	38	,	,	PUNCT
admet-328	14	39	oatp	oatp	ADJ
admet-328	14	40	and	and	CCONJ
admet-328	14	41	p	p	ADJ
admet-328	14	42	-	-	PUNCT
admet-328	14	43	gp	gp	NOUN
admet-328	14	44	transporters	transporter	NOUN
admet-328	14	45	by	by	ADP
admet-328	14	46	atazanavir	atazanavir	PROPN
admet-328	14	47	.	.	PUNCT
admet-328	15	1	keywords	keyword	VERB
admet-328	15	2	aids	aid	NOUN
admet-328	15	3	;	;	PUNCT
admet-328	15	4	drug	drug	NOUN
admet-328	15	5	drug	drug	NOUN
admet-328	15	6	interaction	interaction	NOUN
admet-328	15	7	;	;	PUNCT
admet-328	15	8	hypoglycaemic	hypoglycaemic	ADJ
admet-328	15	9	activity	activity	NOUN
admet-328	15	10	;	;	PUNCT
admet-328	15	11	liver	liver	NOUN
admet-328	15	12	dysfunction	dysfunction	NOUN
admet-328	15	13	;	;	PUNCT
admet-328	15	14	peak	peak	NOUN
admet-328	15	15	plasma	plasma	NOUN
admet-328	15	16	concentration	concentration	NOUN
admet-328	15	17	cmax	cmax	NOUN
admet-328	15	18	;	;	PUNCT
admet-328	15	19	area	area	NOUN
admet-328	15	20	under	under	ADP
admet-328	15	21	the	the	DET
admet-328	15	22	curve	curve	NOUN
admet-328	15	23	auc	auc	NOUN
admet-328	15	24	;	;	PUNCT
admet-328	15	25	clearance	clearance	NOUN
admet-328	15	26	;	;	PUNCT
admet-328	15	27	elimination	elimination	NOUN
admet-328	15	28	half	half	NOUN
admet-328	15	29	life	life	NOUN
admet-328	15	30	.	.	PUNCT
admet-328	16	1	introduction	introduction	NOUN
admet-328	16	2	the	the	DET
admet-328	16	3	prevalence	prevalence	NOUN
admet-328	16	4	and	and	CCONJ
admet-328	16	5	incidence	incidence	NOUN
admet-328	16	6	of	of	ADP
admet-328	16	7	metabolic	metabolic	NOUN
admet-328	16	8	syndrome	syndrome	NOUN
admet-328	16	9	,	,	PUNCT
admet-328	16	10	particularly	particularly	ADV
admet-328	16	11	diabetes	diabete	NOUN
admet-328	16	12	mellitus	mellitus	NOUN
admet-328	16	13	,	,	PUNCT
admet-328	16	14	was	be	AUX
admet-328	16	15	increasing	increase	VERB
admet-328	16	16	in	in	ADP
admet-328	16	17	hiv	hiv	PROPN
admet-328	16	18	patients	patient	NOUN
admet-328	16	19	.	.	PUNCT
admet-328	17	1	treatment	treatment	NOUN
admet-328	17	2	of	of	ADP
admet-328	17	3	hiv	hiv	PROPN
admet-328	17	4	-	-	PUNCT
admet-328	17	5	infected	infect	VERB
admet-328	17	6	patients	patient	NOUN
admet-328	17	7	with	with	ADP
admet-328	17	8	hiv-1	hiv-1	PUNCT
admet-328	17	9	protease	protease	NOUN
admet-328	17	10	inhibitors	inhibitor	NOUN
admet-328	17	11	(	(	PUNCT
admet-328	17	12	pis	pis	NOUN
admet-328	17	13	)	)	PUNCT
admet-328	17	14	as	as	ADP
admet-328	17	15	part	part	NOUN
admet-328	17	16	of	of	ADP
admet-328	17	17	highly	highly	ADV
admet-328	17	18	active	active	ADJ
admet-328	17	19	http://www.pub.iapchem.org/ojs/index.php/admet/index	http://www.pub.iapchem.org/ojs/index.php/admet/index	NOUN
admet-328	17	20	mailto:thirumalram@gmail.com	mailto:thirumalram@gmail.com	PROPN
admet-328	17	21	thirumaleswara	thirumaleswara	PROPN
admet-328	17	22	goud	goud	PROPN
admet-328	17	23	et	et	PROPN
admet-328	17	24	al	al	PROPN
admet-328	17	25	.	.	PROPN
admet-328	17	26	admet	admet	PROPN
admet-328	17	27	&	&	CCONJ
admet-328	17	28	dmpk	dmpk	PROPN
admet-328	17	29	4(3	4(3	NUM
admet-328	17	30	)	)	PUNCT
admet-328	17	31	(	(	PUNCT
admet-328	17	32	2016	2016	NUM
admet-328	17	33	)	)	PUNCT
admet-328	17	34	269	269	NUM
admet-328	17	35	-	-	SYM
admet-328	17	36	279	279	NUM
admet-328	17	37	270	270	NUM
admet-328	17	38	antiretroviral	antiretroviral	ADJ
admet-328	17	39	therapy	therapy	NOUN
admet-328	17	40	(	(	PUNCT
admet-328	17	41	haart	haart	PROPN
admet-328	17	42	)	)	PUNCT
admet-328	17	43	has	have	AUX
admet-328	17	44	contributed	contribute	VERB
admet-328	17	45	considerable	considerable	ADJ
admet-328	17	46	reductions	reduction	NOUN
admet-328	17	47	in	in	ADP
admet-328	17	48	hiv	hiv	PROPN
admet-328	17	49	viral	viral	ADJ
admet-328	17	50	load	load	NOUN
admet-328	17	51	and	and	CCONJ
admet-328	17	52	increased	increase	VERB
admet-328	17	53	in	in	ADP
admet-328	17	54	cd4	cd4	PROPN
admet-328	17	55	lymphocyte	lymphocyte	ADJ
admet-328	17	56	numbers	number	NOUN
admet-328	17	57	,	,	PUNCT
admet-328	17	58	thereby	thereby	ADV
admet-328	17	59	slowing	slow	VERB
admet-328	17	60	disease	disease	NOUN
admet-328	17	61	progression	progression	NOUN
admet-328	17	62	and	and	CCONJ
admet-328	17	63	improving	improve	VERB
admet-328	17	64	patient	patient	ADJ
admet-328	17	65	survival	survival	NOUN
admet-328	17	66	.	.	PUNCT
admet-328	18	1	however	however	ADV
admet-328	18	2	,	,	PUNCT
admet-328	18	3	despite	despite	SCONJ
admet-328	18	4	this	this	DET
admet-328	18	5	clinical	clinical	ADJ
admet-328	18	6	success	success	NOUN
admet-328	18	7	,	,	PUNCT
admet-328	18	8	it	it	PRON
admet-328	18	9	is	be	AUX
admet-328	18	10	recognized	recognize	VERB
admet-328	18	11	that	that	SCONJ
admet-328	18	12	pi	pi	NOUN
admet-328	18	13	-	-	PUNCT
admet-328	18	14	based	base	VERB
admet-328	18	15	therapy	therapy	NOUN
admet-328	18	16	is	be	AUX
admet-328	18	17	correlated	correlate	VERB
admet-328	18	18	with	with	ADP
admet-328	18	19	a	a	DET
admet-328	18	20	number	number	NOUN
admet-328	18	21	of	of	ADP
admet-328	18	22	significant	significant	ADJ
admet-328	18	23	metabolic	metabolic	NOUN
admet-328	18	24	complications	complication	NOUN
admet-328	18	25	,	,	PUNCT
admet-328	18	26	including	include	VERB
admet-328	18	27	lipodystrophy	lipodystrophy	NOUN
admet-328	18	28	,	,	PUNCT
admet-328	18	29	hyperlipidaemia	hyperlipidaemia	NOUN
admet-328	18	30	,	,	PUNCT
admet-328	18	31	and	and	CCONJ
admet-328	18	32	insulin	insulin	NOUN
admet-328	18	33	resistance	resistance	NOUN
admet-328	18	34	.	.	PUNCT
admet-328	19	1	around	around	ADV
admet-328	19	2	80	80	NUM
admet-328	19	3	%	%	NOUN
admet-328	19	4	of	of	ADP
admet-328	19	5	patients	patient	NOUN
admet-328	19	6	who	who	PRON
admet-328	19	7	receive	receive	VERB
admet-328	19	8	pis	pis	NOUN
admet-328	19	9	develop	develop	VERB
admet-328	19	10	insulin	insulin	NOUN
admet-328	19	11	resistance	resistance	NOUN
admet-328	19	12	leading	lead	VERB
admet-328	19	13	to	to	ADP
admet-328	19	14	diabetes	diabetes	NOUN
admet-328	19	15	mellitus	mellitus	NOUN
admet-328	20	1	[	[	X
admet-328	20	2	1	1	NUM
admet-328	20	3	]	]	PUNCT
admet-328	20	4	.	.	PUNCT
admet-328	21	1	drugs	drug	NOUN
admet-328	21	2	are	be	AUX
admet-328	21	3	primarily	primarily	ADV
admet-328	21	4	eliminated	eliminate	VERB
admet-328	21	5	from	from	ADP
admet-328	21	6	the	the	DET
admet-328	21	7	body	body	NOUN
admet-328	21	8	by	by	ADP
admet-328	21	9	metabolism	metabolism	NOUN
admet-328	21	10	and	and	CCONJ
admet-328	21	11	excretion	excretion	NOUN
admet-328	21	12	.	.	PUNCT
admet-328	22	1	in	in	ADP
admet-328	22	2	these	these	DET
admet-328	22	3	two	two	NUM
admet-328	22	4	biologic	biologic	NOUN
admet-328	22	5	processes	process	NOUN
admet-328	22	6	,	,	PUNCT
admet-328	22	7	the	the	DET
admet-328	22	8	liver	liver	NOUN
admet-328	22	9	plays	play	VERB
admet-328	22	10	a	a	DET
admet-328	22	11	vital	vital	ADJ
admet-328	22	12	role	role	NOUN
admet-328	22	13	in	in	ADP
admet-328	22	14	the	the	DET
admet-328	22	15	metabolism	metabolism	NOUN
admet-328	22	16	of	of	ADP
admet-328	22	17	parent	parent	NOUN
admet-328	22	18	drugs	drug	NOUN
admet-328	22	19	and	and	CCONJ
admet-328	22	20	formation	formation	NOUN
admet-328	22	21	of	of	ADP
admet-328	22	22	metabolites	metabolite	NOUN
admet-328	22	23	prior	prior	ADV
admet-328	22	24	to	to	ADP
admet-328	22	25	their	their	PRON
admet-328	22	26	excretion	excretion	NOUN
admet-328	22	27	by	by	ADP
admet-328	22	28	the	the	DET
admet-328	22	29	kidneys	kidney	NOUN
admet-328	22	30	.	.	PUNCT
admet-328	23	1	the	the	DET
admet-328	23	2	overall	overall	ADJ
admet-328	23	3	capacity	capacity	NOUN
admet-328	23	4	of	of	ADP
admet-328	23	5	the	the	DET
admet-328	23	6	liver	liver	NOUN
admet-328	23	7	to	to	PART
admet-328	23	8	carry	carry	VERB
admet-328	23	9	out	out	ADP
admet-328	23	10	its	its	PRON
admet-328	23	11	metabolic	metabolic	ADJ
admet-328	23	12	role	role	NOUN
admet-328	23	13	is	be	AUX
admet-328	23	14	primarily	primarily	ADV
admet-328	23	15	dependent	dependent	ADJ
admet-328	23	16	on	on	ADP
admet-328	23	17	three	three	NUM
admet-328	23	18	factors	factor	NOUN
admet-328	23	19	:	:	PUNCT
admet-328	23	20	activity	activity	NOUN
admet-328	23	21	of	of	ADP
admet-328	23	22	the	the	DET
admet-328	23	23	metabolizing	metabolize	VERB
admet-328	23	24	enzymes	enzyme	NOUN
admet-328	23	25	within	within	ADP
admet-328	23	26	the	the	DET
admet-328	23	27	smooth	smooth	ADJ
admet-328	23	28	endoplasmic	endoplasmic	ADJ
admet-328	23	29	reticulum	reticulum	NOUN
admet-328	23	30	and	and	CCONJ
admet-328	23	31	the	the	DET
admet-328	23	32	cytosol	cytosol	NOUN
admet-328	23	33	of	of	ADP
admet-328	23	34	the	the	DET
admet-328	23	35	hepatocytes	hepatocyte	NOUN
admet-328	23	36	;	;	PUNCT
admet-328	23	37	the	the	DET
admet-328	23	38	degree	degree	NOUN
admet-328	23	39	of	of	ADP
admet-328	23	40	protein	protein	NOUN
admet-328	23	41	binding	bind	VERB
admet-328	23	42	in	in	ADP
admet-328	23	43	the	the	DET
admet-328	23	44	blood	blood	NOUN
admet-328	23	45	,	,	PUNCT
admet-328	23	46	which	which	PRON
admet-328	23	47	affects	affect	VERB
admet-328	23	48	the	the	DET
admet-328	23	49	amount	amount	NOUN
admet-328	23	50	of	of	ADP
admet-328	23	51	unbound	unbound	NOUN
admet-328	23	52	drugs	drug	NOUN
admet-328	23	53	available	available	ADJ
admet-328	23	54	for	for	ADP
admet-328	23	55	uptake	uptake	NOUN
admet-328	23	56	into	into	ADP
admet-328	23	57	the	the	DET
admet-328	23	58	hepatocytes	hepatocyte	NOUN
admet-328	23	59	;	;	PUNCT
admet-328	23	60	and	and	CCONJ
admet-328	23	61	liver	liver	NOUN
admet-328	23	62	blood	blood	NOUN
admet-328	23	63	flow	flow	NOUN
admet-328	23	64	,	,	PUNCT
admet-328	23	65	which	which	PRON
admet-328	23	66	delivers	deliver	VERB
admet-328	23	67	drugs	drug	NOUN
admet-328	23	68	to	to	ADP
admet-328	23	69	the	the	DET
admet-328	23	70	hepatocytes	hepatocyte	NOUN
admet-328	23	71	via	via	ADP
admet-328	23	72	the	the	DET
admet-328	23	73	portal	portal	ADJ
admet-328	23	74	vein	vein	NOUN
admet-328	23	75	for	for	ADP
admet-328	23	76	orally	orally	ADV
admet-328	23	77	administered	administer	VERB
admet-328	23	78	drugs	drug	NOUN
admet-328	23	79	and	and	CCONJ
admet-328	23	80	via	via	ADP
admet-328	23	81	the	the	DET
admet-328	23	82	systemic	systemic	ADJ
admet-328	23	83	circulation	circulation	NOUN
admet-328	23	84	for	for	ADP
admet-328	23	85	all	all	DET
admet-328	23	86	administered	administer	VERB
admet-328	23	87	drugs	drug	NOUN
admet-328	23	88	.	.	PUNCT
admet-328	24	1	in	in	ADP
admet-328	24	2	hepatic	hepatic	ADJ
admet-328	24	3	impairment	impairment	NOUN
admet-328	24	4	,	,	PUNCT
admet-328	24	5	patient	patient	NOUN
admet-328	24	6	-	-	PUNCT
admet-328	24	7	specific	specific	ADJ
admet-328	24	8	factors	factor	NOUN
admet-328	24	9	that	that	PRON
admet-328	24	10	affect	affect	VERB
admet-328	24	11	enzymatic	enzymatic	ADJ
admet-328	24	12	activity	activity	NOUN
admet-328	24	13	,	,	PUNCT
admet-328	24	14	protein	protein	NOUN
admet-328	24	15	binding	binding	NOUN
admet-328	24	16	,	,	PUNCT
admet-328	24	17	or	or	CCONJ
admet-328	24	18	liver	liver	NOUN
admet-328	24	19	blood	blood	NOUN
admet-328	24	20	flow	flow	NOUN
admet-328	24	21	would	would	AUX
admet-328	24	22	potentially	potentially	ADV
admet-328	24	23	result	result	VERB
admet-328	24	24	in	in	ADP
admet-328	24	25	significant	significant	ADJ
admet-328	24	26	alterations	alteration	NOUN
admet-328	24	27	in	in	ADP
admet-328	24	28	drug	drug	NOUN
admet-328	24	29	disposition	disposition	NOUN
admet-328	24	30	and	and	CCONJ
admet-328	24	31	therapeutic	therapeutic	ADJ
admet-328	24	32	response	response	NOUN
admet-328	24	33	.	.	PUNCT
admet-328	25	1	an	an	DET
admet-328	25	2	understanding	understanding	NOUN
admet-328	25	3	of	of	ADP
admet-328	25	4	the	the	DET
admet-328	25	5	pharmacokinetic	pharmacokinetic	ADJ
admet-328	25	6	basis	basis	NOUN
admet-328	25	7	of	of	ADP
admet-328	25	8	hepatic	hepatic	ADJ
admet-328	25	9	drug	drug	NOUN
admet-328	25	10	elimination	elimination	NOUN
admet-328	25	11	is	be	AUX
admet-328	25	12	helpful	helpful	ADJ
admet-328	25	13	to	to	PART
admet-328	25	14	conceptualize	conceptualize	VERB
admet-328	25	15	and	and	CCONJ
admet-328	25	16	quantify	quantify	VERB
admet-328	25	17	altered	altered	ADJ
admet-328	25	18	drug	drug	NOUN
admet-328	25	19	disposition	disposition	NOUN
admet-328	25	20	in	in	ADP
admet-328	25	21	patients	patient	NOUN
admet-328	25	22	with	with	ADP
admet-328	25	23	liver	liver	NOUN
admet-328	25	24	dysfunction	dysfunction	NOUN
admet-328	25	25	[	[	X
admet-328	25	26	2	2	NUM
admet-328	25	27	]	]	PUNCT
admet-328	25	28	.	.	PUNCT
admet-328	26	1	in	in	ADP
admet-328	26	2	hepatic	hepatic	ADJ
admet-328	26	3	dysfunction	dysfunction	NOUN
admet-328	26	4	,	,	PUNCT
admet-328	26	5	the	the	DET
admet-328	26	6	disruption	disruption	NOUN
admet-328	26	7	of	of	ADP
admet-328	26	8	the	the	DET
admet-328	26	9	liver	liver	NOUN
admet-328	26	10	vascular	vascular	ADJ
admet-328	26	11	architecture	architecture	NOUN
admet-328	26	12	may	may	AUX
admet-328	26	13	lead	lead	VERB
admet-328	26	14	to	to	ADP
admet-328	26	15	increased	increase	VERB
admet-328	26	16	blood	blood	NOUN
admet-328	26	17	flow	flow	NOUN
admet-328	26	18	resistance	resistance	NOUN
admet-328	26	19	,	,	PUNCT
admet-328	26	20	which	which	PRON
admet-328	26	21	limits	limit	VERB
admet-328	26	22	blood	blood	NOUN
admet-328	26	23	flow	flow	NOUN
admet-328	26	24	through	through	ADP
admet-328	26	25	the	the	DET
admet-328	26	26	liver	liver	NOUN
admet-328	26	27	and	and	CCONJ
admet-328	26	28	causes	cause	VERB
admet-328	26	29	portal	portal	ADJ
admet-328	26	30	vein	vein	ADJ
admet-328	26	31	pressure	pressure	NOUN
admet-328	26	32	to	to	PART
admet-328	26	33	rise	rise	VERB
admet-328	26	34	.	.	PUNCT
admet-328	27	1	as	as	ADP
admet-328	27	2	a	a	DET
admet-328	27	3	consequence	consequence	NOUN
admet-328	27	4	,	,	PUNCT
admet-328	27	5	the	the	DET
admet-328	27	6	formation	formation	NOUN
admet-328	27	7	of	of	ADP
admet-328	27	8	portocaval	portocaval	ADJ
admet-328	27	9	shunts	shunt	NOUN
admet-328	27	10	may	may	AUX
admet-328	27	11	occur	occur	VERB
admet-328	27	12	that	that	PRON
admet-328	27	13	allow	allow	VERB
admet-328	27	14	the	the	DET
admet-328	27	15	drug	drug	NOUN
admet-328	27	16	to	to	PART
admet-328	27	17	bypass	bypass	VERB
admet-328	27	18	the	the	DET
admet-328	27	19	first	first	ADJ
admet-328	27	20	pass	pass	NOUN
admet-328	27	21	in	in	ADP
admet-328	27	22	the	the	DET
admet-328	27	23	liver	liver	NOUN
admet-328	27	24	,	,	PUNCT
admet-328	27	25	which	which	PRON
admet-328	27	26	increase	increase	VERB
admet-328	27	27	the	the	DET
admet-328	27	28	systemic	systemic	ADJ
admet-328	27	29	bioavailability	bioavailability	NOUN
admet-328	27	30	of	of	ADP
admet-328	27	31	drugs	drug	NOUN
admet-328	27	32	.	.	PUNCT
admet-328	28	1	chronic	chronic	ADJ
admet-328	28	2	hepatic	hepatic	NOUN
admet-328	28	3	disease	disease	NOUN
admet-328	28	4	causes	cause	VERB
admet-328	28	5	damage	damage	NOUN
admet-328	28	6	to	to	ADP
admet-328	28	7	hepatocytes	hepatocyte	NOUN
admet-328	28	8	;	;	PUNCT
admet-328	28	9	this	this	PRON
admet-328	28	10	in	in	ADP
admet-328	28	11	turn	turn	NOUN
admet-328	28	12	may	may	AUX
admet-328	28	13	cause	cause	VERB
admet-328	28	14	a	a	DET
admet-328	28	15	decreased	decrease	VERB
admet-328	28	16	intrinsic	intrinsic	ADJ
admet-328	28	17	clearance	clearance	NOUN
admet-328	28	18	of	of	ADP
admet-328	28	19	the	the	DET
admet-328	28	20	drug	drug	NOUN
admet-328	28	21	metabolizing	metabolize	VERB
admet-328	28	22	liver	liver	NOUN
admet-328	28	23	enzymes	enzyme	NOUN
admet-328	28	24	.	.	PUNCT
admet-328	29	1	different	different	ADJ
admet-328	29	2	cyp	cyp	NOUN
admet-328	29	3	may	may	AUX
admet-328	29	4	be	be	AUX
admet-328	29	5	affected	affect	VERB
admet-328	29	6	differently	differently	ADV
admet-328	29	7	by	by	ADP
admet-328	29	8	the	the	DET
admet-328	29	9	hepatocytes	hepatocytes	PROPN
admet-328	29	10	damage	damage	NOUN
admet-328	29	11	.	.	PUNCT
admet-328	30	1	in	in	ADP
admet-328	30	2	addition	addition	NOUN
admet-328	30	3	,	,	PUNCT
admet-328	30	4	the	the	DET
admet-328	30	5	damage	damage	NOUN
admet-328	30	6	may	may	AUX
admet-328	30	7	also	also	ADV
admet-328	30	8	be	be	AUX
admet-328	30	9	different	different	ADJ
admet-328	30	10	in	in	ADP
admet-328	30	11	the	the	DET
admet-328	30	12	different	different	ADJ
admet-328	30	13	regions	region	NOUN
admet-328	30	14	of	of	ADP
admet-328	30	15	the	the	DET
admet-328	30	16	liver	liver	NOUN
admet-328	30	17	.	.	PUNCT
admet-328	31	1	cholestasis	cholestasis	NOUN
admet-328	31	2	will	will	AUX
admet-328	31	3	impair	impair	VERB
admet-328	31	4	the	the	DET
admet-328	31	5	elimination	elimination	NOUN
admet-328	31	6	of	of	ADP
admet-328	31	7	drugs	drug	NOUN
admet-328	31	8	that	that	PRON
admet-328	31	9	are	be	AUX
admet-328	31	10	excreted	excrete	VERB
admet-328	31	11	in	in	ADP
admet-328	31	12	the	the	DET
admet-328	31	13	bile	bile	NOUN
admet-328	31	14	.	.	PUNCT
admet-328	32	1	liver	liver	NOUN
admet-328	32	2	dysfunction	dysfunction	NOUN
admet-328	32	3	causes	cause	VERB
admet-328	32	4	a	a	DET
admet-328	32	5	decrease	decrease	NOUN
admet-328	32	6	of	of	ADP
admet-328	32	7	albumin	albumin	NOUN
admet-328	32	8	in	in	ADP
admet-328	32	9	serum	serum	NOUN
admet-328	32	10	,	,	PUNCT
admet-328	32	11	which	which	PRON
admet-328	32	12	implies	imply	VERB
admet-328	32	13	variation	variation	NOUN
admet-328	32	14	of	of	ADP
admet-328	32	15	the	the	DET
admet-328	32	16	binding	binding	NOUN
admet-328	32	17	of	of	ADP
admet-328	32	18	drugs	drug	NOUN
admet-328	32	19	to	to	ADP
admet-328	32	20	the	the	DET
admet-328	32	21	circulating	circulate	VERB
admet-328	32	22	proteins	protein	NOUN
admet-328	32	23	and	and	CCONJ
admet-328	32	24	can	can	AUX
admet-328	32	25	potentially	potentially	ADV
admet-328	32	26	affect	affect	VERB
admet-328	32	27	the	the	DET
admet-328	32	28	distribution	distribution	NOUN
admet-328	32	29	volume	volume	NOUN
admet-328	32	30	of	of	ADP
admet-328	32	31	certain	certain	ADJ
admet-328	32	32	drugs	drug	NOUN
admet-328	32	33	[	[	X
admet-328	32	34	3	3	NUM
admet-328	32	35	]	]	PUNCT
admet-328	32	36	.	.	PUNCT
admet-328	33	1	pharmacotherapy	pharmacotherapy	NOUN
admet-328	33	2	in	in	ADP
admet-328	33	3	patients	patient	NOUN
admet-328	33	4	with	with	ADP
admet-328	33	5	impaired	impaired	ADJ
admet-328	33	6	hepatic	hepatic	ADJ
admet-328	33	7	function	function	NOUN
admet-328	33	8	is	be	AUX
admet-328	33	9	an	an	DET
admet-328	33	10	important	important	ADJ
admet-328	33	11	and	and	CCONJ
admet-328	33	12	difficult	difficult	ADJ
admet-328	33	13	aspect	aspect	NOUN
admet-328	33	14	of	of	ADP
admet-328	33	15	medical	medical	ADJ
admet-328	33	16	practice	practice	NOUN
admet-328	33	17	.	.	PUNCT
admet-328	34	1	the	the	DET
admet-328	34	2	elimination	elimination	NOUN
admet-328	34	3	of	of	ADP
admet-328	34	4	many	many	ADJ
admet-328	34	5	drugs	drug	NOUN
admet-328	34	6	takes	take	VERB
admet-328	34	7	place	place	NOUN
admet-328	34	8	by	by	ADP
admet-328	34	9	inactive	inactive	ADJ
admet-328	34	10	,	,	PUNCT
admet-328	34	11	active	active	ADJ
admet-328	34	12	,	,	PUNCT
admet-328	34	13	or	or	CCONJ
admet-328	34	14	toxic	toxic	ADJ
admet-328	34	15	metabolites	metabolite	NOUN
admet-328	34	16	may	may	AUX
admet-328	34	17	be	be	AUX
admet-328	34	18	significantly	significantly	ADV
admet-328	34	19	altered	alter	VERB
admet-328	34	20	by	by	ADP
admet-328	34	21	hepatic	hepatic	ADJ
admet-328	34	22	dysfunction	dysfunction	NOUN
admet-328	34	23	and	and	CCONJ
admet-328	34	24	dosage	dosage	NOUN
admet-328	34	25	must	must	AUX
admet-328	34	26	be	be	AUX
admet-328	34	27	evaluated	evaluate	VERB
admet-328	34	28	carefully	carefully	ADV
admet-328	34	29	.	.	PUNCT
admet-328	35	1	the	the	DET
admet-328	35	2	presence	presence	NOUN
admet-328	35	3	of	of	ADP
admet-328	35	4	liver	liver	NOUN
admet-328	35	5	dysfunction	dysfunction	NOUN
admet-328	35	6	that	that	PRON
admet-328	35	7	leads	lead	VERB
admet-328	35	8	to	to	ADP
admet-328	35	9	increased	increase	VERB
admet-328	35	10	plasma	plasma	NOUN
admet-328	35	11	drug	drug	NOUN
admet-328	35	12	or	or	CCONJ
admet-328	35	13	metabolite	metabolite	NOUN
admet-328	35	14	concentrations	concentration	NOUN
admet-328	35	15	may	may	AUX
admet-328	35	16	increase	increase	VERB
admet-328	35	17	the	the	DET
admet-328	35	18	prospect	prospect	NOUN
admet-328	35	19	of	of	ADP
admet-328	35	20	toxicity	toxicity	NOUN
admet-328	35	21	which	which	PRON
admet-328	35	22	results	result	VERB
admet-328	35	23	in	in	ADP
admet-328	35	24	more	more	ADJ
admet-328	35	25	complex	complex	ADJ
admet-328	35	26	drug	drug	NOUN
admet-328	35	27	-	-	PUNCT
admet-328	35	28	drug	drug	NOUN
admet-328	35	29	interaction	interaction	NOUN
admet-328	35	30	.	.	PUNCT
admet-328	36	1	hence	hence	ADV
admet-328	36	2	,	,	PUNCT
admet-328	36	3	the	the	DET
admet-328	36	4	preferred	preferred	ADJ
admet-328	36	5	approach	approach	NOUN
admet-328	36	6	to	to	ADP
admet-328	36	7	prescribing	prescribe	VERB
admet-328	36	8	medications	medication	NOUN
admet-328	36	9	for	for	ADP
admet-328	36	10	hepatic	hepatic	ADJ
admet-328	36	11	impaired	impaired	ADJ
admet-328	36	12	patients	patient	NOUN
admet-328	36	13	is	be	AUX
admet-328	36	14	to	to	PART
admet-328	36	15	select	select	VERB
admet-328	36	16	drugs	drug	NOUN
admet-328	36	17	that	that	PRON
admet-328	36	18	have	have	VERB
admet-328	36	19	predictable	predictable	ADJ
admet-328	36	20	pharmacokinetic	pharmacokinetic	ADJ
admet-328	36	21	properties	property	NOUN
admet-328	36	22	,	,	PUNCT
admet-328	36	23	are	be	AUX
admet-328	36	24	minimally	minimally	ADV
admet-328	36	25	affected	affect	VERB
admet-328	36	26	by	by	ADP
admet-328	36	27	hepatic	hepatic	ADJ
admet-328	36	28	impairment	impairment	NOUN
admet-328	36	29	and	and	CCONJ
admet-328	36	30	have	have	VERB
admet-328	36	31	a	a	DET
admet-328	36	32	low	low	ADJ
admet-328	36	33	potential	potential	NOUN
admet-328	36	34	for	for	ADP
admet-328	36	35	drug	drug	NOUN
admet-328	36	36	interactions	interaction	NOUN
admet-328	36	37	with	with	ADP
admet-328	36	38	other	other	ADJ
admet-328	36	39	drugs	drug	NOUN
admet-328	36	40	[	[	X
admet-328	36	41	4	4	NUM
admet-328	36	42	]	]	PUNCT
admet-328	36	43	.	.	PUNCT
admet-328	37	1	safe	safe	ADJ
admet-328	37	2	pharmacological	pharmacological	ADJ
admet-328	37	3	treatment	treatment	NOUN
admet-328	37	4	of	of	ADP
admet-328	37	5	these	these	DET
admet-328	37	6	complications	complication	NOUN
admet-328	37	7	requires	require	VERB
admet-328	37	8	an	an	DET
admet-328	37	9	understanding	understanding	NOUN
admet-328	37	10	of	of	ADP
admet-328	37	11	the	the	DET
admet-328	37	12	drug	drug	NOUN
admet-328	37	13	-	-	PUNCT
admet-328	37	14	drug	drug	NOUN
admet-328	37	15	interactions	interaction	NOUN
admet-328	37	16	between	between	ADP
admet-328	37	17	antiretroviral	antiretroviral	ADJ
admet-328	37	18	drugs	drug	NOUN
admet-328	37	19	and	and	CCONJ
admet-328	37	20	the	the	DET
admet-328	37	21	drugs	drug	NOUN
admet-328	37	22	used	use	VERB
admet-328	37	23	in	in	ADP
admet-328	37	24	the	the	DET
admet-328	37	25	treatment	treatment	NOUN
admet-328	37	26	of	of	ADP
admet-328	37	27	diabetes	diabetes	NOUN
admet-328	37	28	[	[	X
admet-328	37	29	5	5	NUM
admet-328	37	30	]	]	PUNCT
admet-328	37	31	.	.	PUNCT
admet-328	38	1	repaglinide	repaglinide	PROPN
admet-328	38	2	is	be	AUX
admet-328	38	3	short	short	ADJ
admet-328	38	4	acting	act	VERB
admet-328	38	5	anti	anti	X
admet-328	38	6	diabetic	diabetic	ADJ
admet-328	38	7	drug	drug	NOUN
admet-328	38	8	used	use	VERB
admet-328	38	9	to	to	PART
admet-328	38	10	normalize	normalize	VERB
admet-328	38	11	postprandial	postprandial	ADJ
admet-328	38	12	glucose	glucose	NOUN
admet-328	38	13	concentrations	concentration	NOUN
admet-328	38	14	in	in	ADP
admet-328	38	15	patients	patient	NOUN
admet-328	38	16	with	with	ADP
admet-328	38	17	type	type	NOUN
admet-328	38	18	ii	ii	NOUN
admet-328	38	19	diabetes	diabetes	NOUN
admet-328	38	20	mellitus	mellitus	NOUN
admet-328	39	1	[	[	X
admet-328	39	2	6	6	NUM
admet-328	39	3	]	]	PUNCT
admet-328	39	4	.	.	PUNCT
admet-328	40	1	repaglinide	repaglinide	PROPN
admet-328	40	2	is	be	AUX
admet-328	40	3	a	a	DET
admet-328	40	4	substrate	substrate	NOUN
admet-328	40	5	of	of	ADP
admet-328	40	6	the	the	DET
admet-328	40	7	influx	influx	NOUN
admet-328	40	8	transporter	transporter	NOUN
admet-328	40	9	oatp1b1	oatp1b1	PUNCT
admet-328	40	10	and	and	CCONJ
admet-328	40	11	metabolized	metabolize	VERB
admet-328	40	12	mainly	mainly	ADV
admet-328	40	13	by	by	ADP
admet-328	40	14	cyp3a4	cyp3a4	NOUN
admet-328	40	15	and	and	CCONJ
admet-328	40	16	cyp2c8	cyp2c8	ADV
admet-328	40	17	.	.	PUNCT
admet-328	41	1	pharmacokinetic	pharmacokinetic	ADJ
admet-328	41	2	drug	drug	NOUN
admet-328	41	3	interactions	interaction	NOUN
admet-328	41	4	were	be	AUX
admet-328	41	5	observed	observe	VERB
admet-328	41	6	in	in	ADP
admet-328	41	7	repaglinide	repaglinide	NOUN
admet-328	41	8	with	with	ADP
admet-328	41	9	drugs	drug	NOUN
admet-328	41	10	which	which	PRON
admet-328	41	11	are	be	AUX
admet-328	41	12	inhibitors	inhibitor	NOUN
admet-328	41	13	of	of	ADP
admet-328	41	14	cyp3a4	cyp3a4	NOUN
admet-328	41	15	,	,	PUNCT
admet-328	41	16	cyp2c8	cyp2c8	ADV
admet-328	41	17	and	and	CCONJ
admet-328	41	18	oatp1b1	oatp1b1	X
admet-328	41	19	.	.	PUNCT
admet-328	42	1	recently	recently	ADV
admet-328	42	2	,	,	PUNCT
admet-328	42	3	a	a	DET
admet-328	42	4	number	number	NOUN
admet-328	42	5	of	of	ADP
admet-328	42	6	ddis	ddi	NOUN
admet-328	42	7	caused	cause	VERB
admet-328	42	8	by	by	ADP
admet-328	42	9	the	the	DET
admet-328	42	10	inhibition	inhibition	NOUN
admet-328	42	11	and	and	CCONJ
admet-328	42	12	induction	induction	NOUN
admet-328	42	13	of	of	ADP
admet-328	42	14	drug	drug	NOUN
admet-328	42	15	transporters	transporter	NOUN
admet-328	42	16	have	have	AUX
admet-328	42	17	also	also	ADV
admet-328	42	18	been	be	AUX
admet-328	42	19	reported	report	VERB
admet-328	42	20	.	.	PUNCT
admet-328	43	1	among	among	ADP
admet-328	43	2	these	these	DET
admet-328	43	3	transporters	transporter	NOUN
admet-328	43	4	,	,	PUNCT
admet-328	43	5	oatp1b1	oatp1b1	X
admet-328	43	6	is	be	AUX
admet-328	43	7	responsible	responsible	ADJ
admet-328	43	8	for	for	ADP
admet-328	43	9	the	the	DET
admet-328	43	10	influx	influx	NOUN
admet-328	43	11	of	of	ADP
admet-328	43	12	many	many	ADJ
admet-328	43	13	therapeutic	therapeutic	ADJ
admet-328	43	14	drugs	drug	NOUN
admet-328	43	15	in	in	ADP
admet-328	43	16	the	the	DET
admet-328	43	17	liver	liver	NOUN
admet-328	43	18	;	;	PUNCT
admet-328	43	19	there	there	PRON
admet-328	43	20	have	have	AUX
admet-328	43	21	been	be	AUX
admet-328	43	22	a	a	DET
admet-328	43	23	large	large	ADJ
admet-328	43	24	number	number	NOUN
admet-328	43	25	of	of	ADP
admet-328	43	26	reports	report	NOUN
admet-328	43	27	on	on	ADP
admet-328	43	28	ddi	ddi	PROPN
admet-328	43	29	caused	cause	VERB
admet-328	43	30	by	by	ADP
admet-328	43	31	inhibition	inhibition	NOUN
admet-328	43	32	and	and	CCONJ
admet-328	43	33	induction	induction	NOUN
admet-328	43	34	of	of	ADP
admet-328	43	35	this	this	DET
admet-328	43	36	transporter	transporter	NOUN
admet-328	43	37	[	[	X
admet-328	43	38	7	7	NUM
admet-328	43	39	-	-	SYM
admet-328	43	40	8	8	NUM
admet-328	43	41	]	]	PUNCT
admet-328	43	42	.	.	PUNCT
admet-328	44	1	protease	protease	NOUN
admet-328	44	2	admet	admet	PROPN
admet-328	44	3	&	&	CCONJ
admet-328	44	4	dmpk	dmpk	PROPN
admet-328	44	5	4(3	4(3	NUM
admet-328	44	6	)	)	PUNCT
admet-328	44	7	(	(	PUNCT
admet-328	44	8	2016	2016	NUM
admet-328	44	9	)	)	PUNCT
admet-328	44	10	269	269	NUM
admet-328	44	11	-	-	SYM
admet-328	44	12	279	279	NUM
admet-328	44	13	pk	pk	NOUN
admet-328	44	14	and	and	CCONJ
admet-328	44	15	pd	pd	NOUN
admet-328	44	16	interaction	interaction	NOUN
admet-328	44	17	between	between	ADP
admet-328	44	18	repaglinide	repaglinide	NOUN
admet-328	44	19	and	and	CCONJ
admet-328	44	20	atazanavir	atazanavir	PROPN
admet-328	44	21	doi	doi	PROPN
admet-328	44	22	:	:	PUNCT
admet-328	44	23	10.5599	10.5599	NUM
admet-328	44	24	/	/	SYM
admet-328	44	25	admet.4.3.328	admet.4.3.328	NUM
admet-328	44	26	271	271	NUM
admet-328	44	27	inhibitors	inhibitor	NOUN
admet-328	44	28	are	be	AUX
admet-328	44	29	the	the	DET
admet-328	44	30	potent	potent	ADJ
admet-328	44	31	inhibitors	inhibitor	NOUN
admet-328	44	32	of	of	ADP
admet-328	44	33	cyp	cyp	ADJ
admet-328	44	34	3a4	3a4	NUM
admet-328	44	35	and	and	CCONJ
admet-328	44	36	oatp	oatp	ADJ
admet-328	44	37	transporters	transporter	NOUN
admet-328	44	38	.	.	PUNCT
admet-328	45	1	several	several	ADJ
admet-328	45	2	ddis	ddi	NOUN
admet-328	45	3	were	be	AUX
admet-328	45	4	noticed	notice	VERB
admet-328	45	5	when	when	SCONJ
admet-328	45	6	protease	protease	NOUN
admet-328	45	7	inhibitors	inhibitor	NOUN
admet-328	45	8	(	(	PUNCT
admet-328	45	9	pis	pis	NOUN
admet-328	45	10	)	)	PUNCT
admet-328	45	11	co	co	VERB
admet-328	45	12	-	-	VERB
admet-328	45	13	administered	administer	VERB
admet-328	45	14	with	with	ADP
admet-328	45	15	drugs	drug	NOUN
admet-328	45	16	metabolized	metabolize	VERB
admet-328	45	17	by	by	ADP
admet-328	45	18	cyp	cyp	ADJ
admet-328	45	19	3a4	3a4	NUM
admet-328	45	20	.	.	PUNCT
admet-328	46	1	repaglinide	repaglinide	PROPN
admet-328	46	2	also	also	ADV
admet-328	46	3	has	have	VERB
admet-328	46	4	an	an	DET
admet-328	46	5	affinity	affinity	NOUN
admet-328	46	6	for	for	ADP
admet-328	46	7	p	p	NOUN
admet-328	46	8	-	-	PUNCT
admet-328	46	9	gp	gp	NOUN
admet-328	46	10	and	and	CCONJ
admet-328	46	11	it	it	PRON
admet-328	46	12	can	can	AUX
admet-328	46	13	contribute	contribute	VERB
admet-328	46	14	significantly	significantly	ADV
admet-328	46	15	to	to	ADP
admet-328	46	16	potential	potential	ADJ
admet-328	46	17	drug	drug	NOUN
admet-328	46	18	-	-	PUNCT
admet-328	46	19	drug	drug	NOUN
admet-328	46	20	interactions	interaction	NOUN
admet-328	46	21	with	with	ADP
admet-328	46	22	other	other	ADJ
admet-328	46	23	p	p	NOUN
admet-328	46	24	-	-	PUNCT
admet-328	46	25	gp	gp	NOUN
admet-328	46	26	substrates	substrate	NOUN
admet-328	46	27	or	or	CCONJ
admet-328	46	28	inhibitors	inhibitor	NOUN
admet-328	46	29	,	,	PUNCT
admet-328	46	30	hence	hence	ADV
admet-328	46	31	the	the	DET
admet-328	46	32	co	co	NOUN
admet-328	46	33	-	-	NOUN
admet-328	46	34	administration	administration	NOUN
admet-328	46	35	of	of	ADP
admet-328	46	36	repaglinide	repaglinide	NOUN
admet-328	46	37	with	with	ADP
admet-328	46	38	the	the	DET
admet-328	46	39	known	know	VERB
admet-328	46	40	p	p	NOUN
admet-328	46	41	-	-	PUNCT
admet-328	46	42	gp	gp	NOUN
admet-328	46	43	inhibitor	inhibitor	NOUN
admet-328	46	44	,	,	PUNCT
admet-328	46	45	cyclosporine	cyclosporine	VERB
admet-328	46	46	a	a	DET
admet-328	46	47	resulted	result	VERB
admet-328	46	48	in	in	ADP
admet-328	46	49	a	a	DET
admet-328	46	50	significant	significant	ADJ
admet-328	46	51	increase	increase	NOUN
admet-328	46	52	in	in	ADP
admet-328	46	53	the	the	DET
admet-328	46	54	plasma	plasma	NOUN
admet-328	46	55	concentrations	concentration	NOUN
admet-328	46	56	of	of	ADP
admet-328	46	57	repaglinide	repaglinide	NOUN
admet-328	46	58	in	in	ADP
admet-328	46	59	human	human	NOUN
admet-328	46	60	[	[	X
admet-328	46	61	9	9	NUM
admet-328	46	62	]	]	PUNCT
admet-328	46	63	.	.	PUNCT
admet-328	47	1	the	the	DET
admet-328	47	2	protease	protease	NOUN
admet-328	47	3	inhibitors	inhibitor	NOUN
admet-328	47	4	(	(	PUNCT
admet-328	47	5	pis	pis	NOUN
admet-328	47	6	)	)	PUNCT
admet-328	47	7	are	be	AUX
admet-328	47	8	also	also	ADV
admet-328	47	9	potent	potent	ADJ
admet-328	47	10	mechanism	mechanism	NOUN
admet-328	47	11	based	base	VERB
admet-328	47	12	inhibitors	inhibitor	NOUN
admet-328	47	13	,	,	PUNCT
admet-328	47	14	of	of	ADP
admet-328	47	15	which	which	PRON
admet-328	47	16	atazanavir	atazanavir	PROPN
admet-328	47	17	is	be	AUX
admet-328	47	18	most	most	ADV
admet-328	47	19	potent	potent	ADJ
admet-328	47	20	substrate	substrate	NOUN
admet-328	47	21	and	and	CCONJ
admet-328	47	22	potent	potent	ADJ
admet-328	47	23	inhibitor	inhibitor	NOUN
admet-328	47	24	of	of	ADP
admet-328	47	25	the	the	DET
admet-328	47	26	cytochrome	cytochrome	NOUN
admet-328	47	27	p450	p450	PROPN
admet-328	47	28	(	(	PUNCT
admet-328	47	29	cyp	cyp	ADJ
admet-328	47	30	)	)	PUNCT
admet-328	47	31	system	system	NOUN
admet-328	47	32	,	,	PUNCT
admet-328	47	33	in	in	ADP
admet-328	47	34	particular	particular	ADJ
admet-328	47	35	cyp3a4	cyp3a4	NOUN
admet-328	47	36	and	and	CCONJ
admet-328	47	37	cyp2c9	cyp2c9	NOUN
admet-328	47	38	and	and	CCONJ
admet-328	47	39	affect	affect	VERB
admet-328	47	40	the	the	DET
admet-328	47	41	metabolism	metabolism	NOUN
admet-328	47	42	of	of	ADP
admet-328	47	43	several	several	ADJ
admet-328	47	44	drugs	drug	NOUN
admet-328	47	45	[	[	X
admet-328	47	46	10	10	NUM
admet-328	47	47	]	]	PUNCT
admet-328	47	48	.	.	PUNCT
admet-328	48	1	atazanavir	atazanavir	PROPN
admet-328	48	2	is	be	AUX
admet-328	48	3	an	an	DET
admet-328	48	4	azapeptide	azapeptide	ADJ
admet-328	48	5	hiv	hiv	PROPN
admet-328	48	6	-	-	PUNCT
admet-328	48	7	i	i	PROPN
admet-328	48	8	protease	protease	NOUN
admet-328	48	9	inhibitor	inhibitor	NOUN
admet-328	48	10	approved	approve	VERB
admet-328	48	11	by	by	ADP
admet-328	48	12	fda	fda	PROPN
admet-328	48	13	for	for	ADP
admet-328	48	14	the	the	DET
admet-328	48	15	combination	combination	NOUN
admet-328	48	16	of	of	ADP
admet-328	48	17	hiv	hiv	PROPN
admet-328	48	18	-	-	PUNCT
admet-328	48	19	i	i	PRON
admet-328	48	20	infection	infection	NOUN
admet-328	48	21	.	.	PUNCT
admet-328	49	1	atazanavir	atazanavir	PROPN
admet-328	49	2	is	be	AUX
admet-328	49	3	metabolized	metabolize	VERB
admet-328	49	4	by	by	ADP
admet-328	49	5	cyp3a4	cyp3a4	NOUN
admet-328	49	6	,	,	PUNCT
admet-328	49	7	as	as	ADP
admet-328	49	8	a	a	DET
admet-328	49	9	substrate	substrate	NOUN
admet-328	49	10	;	;	PUNCT
admet-328	49	11	however	however	ADV
admet-328	49	12	atazanavir	atazanavir	PROPN
admet-328	49	13	interacts	interact	VERB
admet-328	49	14	with	with	ADP
admet-328	49	15	drug	drug	NOUN
admet-328	49	16	transporter	transporter	NOUN
admet-328	49	17	proteins	protein	NOUN
admet-328	49	18	.	.	PUNCT
admet-328	50	1	the	the	DET
admet-328	50	2	study	study	NOUN
admet-328	50	3	by	by	ADP
admet-328	50	4	mothanje	mothanje	PROPN
admet-328	50	5	barabara	barabara	PROPN
admet-328	50	6	lucia	lucia	PROPN
admet-328	50	7	et	et	PROPN
admet-328	50	8	al	al	PROPN
admet-328	50	9	indicated	indicate	VERB
admet-328	50	10	that	that	SCONJ
admet-328	50	11	atazanavir	atazanavir	PROPN
admet-328	50	12	is	be	AUX
admet-328	50	13	a	a	DET
admet-328	50	14	possible	possible	ADJ
admet-328	50	15	inhibitor	inhibitor	NOUN
admet-328	50	16	for	for	ADP
admet-328	50	17	p	p	NOUN
admet-328	50	18	-	-	PUNCT
admet-328	50	19	glycoprotein	glycoprotein	NOUN
admet-328	50	20	and	and	CCONJ
admet-328	50	21	competitively	competitively	ADV
admet-328	50	22	inhibits	inhibit	VERB
admet-328	50	23	their	their	PRON
admet-328	50	24	efflux	efflux	ADJ
admet-328	50	25	activity	activity	NOUN
admet-328	50	26	in	in	ADP
admet-328	50	27	a	a	DET
admet-328	50	28	dose	dose	ADJ
admet-328	50	29	dependent	dependent	ADJ
admet-328	50	30	manner	manner	NOUN
admet-328	51	1	[	[	X
admet-328	51	2	11	11	NUM
admet-328	51	3	]	]	PUNCT
admet-328	51	4	.	.	PUNCT
admet-328	52	1	in	in	ADP
admet-328	52	2	the	the	DET
admet-328	52	3	present	present	ADJ
admet-328	52	4	study	study	NOUN
admet-328	52	5	,	,	PUNCT
admet-328	52	6	we	we	PRON
admet-328	52	7	hypothesize	hypothesize	VERB
admet-328	52	8	that	that	SCONJ
admet-328	52	9	the	the	DET
admet-328	52	10	repaglinide	repaglinide	NOUN
admet-328	52	11	elimination	elimination	NOUN
admet-328	52	12	would	would	AUX
admet-328	52	13	be	be	AUX
admet-328	52	14	effected	effect	VERB
admet-328	52	15	by	by	ADP
admet-328	52	16	oatp	oatp	ADJ
admet-328	52	17	and	and	CCONJ
admet-328	52	18	pgp	pgp	NOUN
admet-328	52	19	transporters	transporter	NOUN
admet-328	52	20	,	,	PUNCT
admet-328	52	21	which	which	PRON
admet-328	52	22	makes	make	VERB
admet-328	52	23	available	available	ADJ
admet-328	52	24	for	for	ADP
admet-328	52	25	the	the	DET
admet-328	52	26	metabolism	metabolism	NOUN
admet-328	52	27	by	by	ADP
admet-328	52	28	cyp3a4	cyp3a4	PROPN
admet-328	52	29	.	.	PUNCT
admet-328	53	1	atazanavir	atazanavir	PROPN
admet-328	53	2	can	can	AUX
admet-328	53	3	inhibit	inhibit	VERB
admet-328	53	4	cyp	cyp	ADJ
admet-328	53	5	3a4	3a4	NUM
admet-328	53	6	,	,	PUNCT
admet-328	53	7	cyp2c9	cyp2c9	NOUN
admet-328	53	8	enzymes	enzyme	NOUN
admet-328	53	9	and	and	CCONJ
admet-328	53	10	it	it	PRON
admet-328	53	11	is	be	AUX
admet-328	53	12	oatp	oatp	ADJ
admet-328	53	13	,	,	PUNCT
admet-328	53	14	p	p	NOUN
admet-328	53	15	-	-	PUNCT
admet-328	53	16	gp	gp	NOUN
admet-328	53	17	inhibitor	inhibitor	NOUN
admet-328	53	18	.	.	PUNCT
admet-328	54	1	hence	hence	ADV
admet-328	54	2	,	,	PUNCT
admet-328	54	3	the	the	DET
admet-328	54	4	inhibition	inhibition	NOUN
admet-328	54	5	of	of	ADP
admet-328	54	6	transporter	transporter	NOUN
admet-328	54	7	mediated	mediate	VERB
admet-328	54	8	hepatic	hepatic	ADJ
admet-328	54	9	uptake	uptake	NOUN
admet-328	54	10	and	and	CCONJ
admet-328	54	11	metabolism	metabolism	NOUN
admet-328	54	12	may	may	AUX
admet-328	54	13	change	change	VERB
admet-328	54	14	the	the	DET
admet-328	54	15	pharmacokinetics	pharmacokinetic	NOUN
admet-328	54	16	of	of	ADP
admet-328	54	17	repaglinide	repaglinide	NOUN
admet-328	54	18	.	.	PUNCT
admet-328	55	1	however	however	ADV
admet-328	55	2	,	,	PUNCT
admet-328	55	3	there	there	PRON
admet-328	55	4	seem	seem	VERB
admet-328	55	5	to	to	PART
admet-328	55	6	be	be	AUX
admet-328	55	7	no	no	DET
admet-328	55	8	published	publish	VERB
admet-328	55	9	studies	study	NOUN
admet-328	55	10	reported	report	VERB
admet-328	55	11	so	so	ADV
admet-328	55	12	far	far	ADV
admet-328	55	13	,	,	PUNCT
admet-328	55	14	so	so	CCONJ
admet-328	55	15	in	in	ADP
admet-328	55	16	the	the	DET
admet-328	55	17	current	current	ADJ
admet-328	55	18	study	study	NOUN
admet-328	55	19	we	we	PRON
admet-328	55	20	have	have	AUX
admet-328	55	21	evaluated	evaluate	VERB
admet-328	55	22	the	the	DET
admet-328	55	23	influence	influence	NOUN
admet-328	55	24	of	of	ADP
admet-328	55	25	atazanavir	atazanavir	PROPN
admet-328	55	26	on	on	ADP
admet-328	55	27	the	the	DET
admet-328	55	28	pharmacokinetics	pharmacokinetic	NOUN
admet-328	55	29	and	and	CCONJ
admet-328	55	30	pharmacodyamics	pharmacodyamic	NOUN
admet-328	55	31	of	of	ADP
admet-328	55	32	repaglinide	repaglinide	NOUN
admet-328	55	33	in	in	ADP
admet-328	55	34	normal	normal	ADJ
admet-328	55	35	,	,	PUNCT
admet-328	55	36	diabetic	diabetic	ADJ
admet-328	55	37	and	and	CCONJ
admet-328	55	38	hepatic	hepatic	ADJ
admet-328	55	39	impaired	impaired	ADJ
admet-328	55	40	rats	rat	NOUN
admet-328	55	41	.	.	PUNCT
admet-328	56	1	experimental	experimental	ADJ
admet-328	56	2	drugs	drug	NOUN
admet-328	56	3	and	and	CCONJ
admet-328	56	4	chemicals	chemical	NOUN
admet-328	56	5	repaglinide	repaglinide	VERB
admet-328	56	6	a	a	DET
admet-328	56	7	gift	gift	NOUN
admet-328	56	8	sample	sample	NOUN
admet-328	56	9	obtained	obtain	VERB
admet-328	56	10	from	from	ADP
admet-328	56	11	dr	dr	PROPN
admet-328	56	12	.	.	PROPN
admet-328	56	13	reddy	reddy	PROPN
admet-328	56	14	’s	’s	PART
admet-328	56	15	lab	lab	NOUN
admet-328	56	16	(	(	PUNCT
admet-328	56	17	hyderabad	hyderabad	PROPN
admet-328	56	18	,	,	PUNCT
admet-328	56	19	india	india	PROPN
admet-328	56	20	)	)	PUNCT
admet-328	56	21	and	and	CCONJ
admet-328	56	22	atazanavir	atazanavir	PROPN
admet-328	56	23	from	from	ADP
admet-328	56	24	aurobindo	aurobindo	PROPN
admet-328	56	25	labs	labs	PROPN
admet-328	56	26	(	(	PUNCT
admet-328	56	27	hyderabad	hyderabad	PROPN
admet-328	56	28	,	,	PUNCT
admet-328	56	29	india	india	PROPN
admet-328	56	30	)	)	PUNCT
admet-328	56	31	.	.	PUNCT
admet-328	57	1	alloxan	alloxan	PROPN
admet-328	57	2	monohydrate	monohydrate	PROPN
admet-328	57	3	was	be	AUX
admet-328	57	4	purchased	purchase	VERB
admet-328	57	5	from	from	ADP
admet-328	57	6	sigma	sigma	PROPN
admet-328	57	7	aldrich	aldrich	PROPN
admet-328	57	8	,	,	PUNCT
admet-328	57	9	bangalore	bangalore	PROPN
admet-328	57	10	(	(	PUNCT
admet-328	57	11	bangalore	bangalore	PROPN
admet-328	57	12	,	,	PUNCT
admet-328	57	13	india	india	PROPN
admet-328	57	14	)	)	PUNCT
admet-328	57	15	.	.	PUNCT
admet-328	58	1	glucose	glucose	NOUN
admet-328	58	2	kits	kit	NOUN
admet-328	58	3	purchased	purchase	VERB
admet-328	58	4	from	from	ADP
admet-328	58	5	agappe	agappe	PROPN
admet-328	58	6	diagnostics	diagnostic	NOUN
admet-328	58	7	,	,	PUNCT
admet-328	58	8	(	(	PUNCT
admet-328	58	9	mumbai	mumbai	PROPN
admet-328	58	10	,	,	PUNCT
admet-328	58	11	india	india	PROPN
admet-328	58	12	)	)	PUNCT
admet-328	58	13	.	.	PUNCT
admet-328	59	1	acetonitrile	acetonitrile	ADJ
admet-328	59	2	hplc	hplc	PROPN
admet-328	59	3	grade	grade	NOUN
admet-328	59	4	and	and	CCONJ
admet-328	59	5	formic	formic	PROPN
admet-328	59	6	acid	acid	PROPN
admet-328	59	7	were	be	AUX
admet-328	59	8	obtained	obtain	VERB
admet-328	59	9	from	from	ADP
admet-328	59	10	merck	merck	PROPN
admet-328	59	11	chemicals	chemical	NOUN
admet-328	59	12	(	(	PUNCT
admet-328	59	13	mumbai	mumbai	PROPN
admet-328	59	14	,	,	PUNCT
admet-328	59	15	india	india	PROPN
admet-328	59	16	)	)	PUNCT
admet-328	59	17	.	.	PUNCT
admet-328	60	1	hplc	hplc	NOUN
admet-328	60	2	system	system	NOUN
admet-328	60	3	:	:	PUNCT
admet-328	60	4	agilent	agilent	PROPN
admet-328	60	5	technologies	technologies	PROPN
admet-328	60	6	(	(	PUNCT
admet-328	60	7	california	california	PROPN
admet-328	60	8	,	,	PUNCT
admet-328	60	9	usa	usa	PROPN
admet-328	60	10	)	)	PUNCT
admet-328	60	11	and	and	CCONJ
admet-328	60	12	ms	ms	PROPN
admet-328	60	13	/	/	SYM
admet-328	60	14	ms	ms	PROPN
admet-328	60	15	api-3200	api-3200	PROPN
admet-328	60	16	mass	mass	PROPN
admet-328	60	17	spectrometer	spectrometer	NOUN
admet-328	60	18	sciex	sciex	NOUN
admet-328	60	19	technologies	technology	NOUN
admet-328	60	20	(	(	PUNCT
admet-328	60	21	foster	foster	ADJ
admet-328	60	22	city	city	NOUN
admet-328	60	23	,	,	PUNCT
admet-328	60	24	ca	ca	PROPN
admet-328	60	25	,	,	PUNCT
admet-328	60	26	usa	usa	PROPN
admet-328	60	27	)	)	PUNCT
admet-328	60	28	,	,	PUNCT
admet-328	60	29	hplc	hplc	NOUN
admet-328	60	30	column	column	NOUN
admet-328	60	31	:	:	PUNCT
admet-328	60	32	hypersil	hypersil	NOUN
admet-328	60	33	gold	gold	NOUN
admet-328	60	34	c18	c18	NOUN
admet-328	60	35	,	,	PUNCT
admet-328	60	36	5µ	5µ	PROPN
admet-328	60	37	column	column	NOUN
admet-328	60	38	4.6	4.6	NUM
admet-328	60	39	*	*	SYM
admet-328	60	40	100	100	NUM
admet-328	60	41	mm	mm	PROPN
admet-328	60	42	internal	internal	ADJ
admet-328	60	43	diameter	diameter	NOUN
admet-328	60	44	thermo	thermo	NOUN
admet-328	60	45	scientific	scientific	NOUN
admet-328	60	46	,	,	PUNCT
admet-328	60	47	(	(	PUNCT
admet-328	60	48	north	north	PROPN
admet-328	60	49	america	america	PROPN
admet-328	60	50	)	)	PUNCT
admet-328	60	51	.	.	PUNCT
admet-328	61	1	vortex	vortex	NOUN
admet-328	61	2	mixer	mixer	NOUN
admet-328	61	3	and	and	CCONJ
admet-328	61	4	centrifuge	centrifuge	NOUN
admet-328	61	5	were	be	AUX
admet-328	61	6	obtained	obtain	VERB
admet-328	61	7	from	from	ADP
admet-328	61	8	remi	remi	PROPN
admet-328	61	9	laboratory	laboratory	PROPN
admet-328	61	10	instruments	instrument	NOUN
admet-328	61	11	(	(	PUNCT
admet-328	61	12	mumbai	mumbai	PROPN
admet-328	61	13	,	,	PUNCT
admet-328	61	14	india	india	PROPN
admet-328	61	15	)	)	PUNCT
admet-328	61	16	.	.	PUNCT
admet-328	62	1	hematocrit	hematocrit	PROPN
admet-328	62	2	heparinized	heparinized	ADJ
admet-328	62	3	rat	rat	NOUN
admet-328	62	4	bleeding	bleeding	NOUN
admet-328	62	5	capillaries	capillary	NOUN
admet-328	62	6	was	be	AUX
admet-328	62	7	purchased	purchase	VERB
admet-328	62	8	from	from	ADP
admet-328	62	9	top	top	ADJ
admet-328	62	10	-	-	PUNCT
admet-328	62	11	tech	tech	NOUN
admet-328	62	12	lab	lab	NOUN
admet-328	62	13	equipments	equipment	NOUN
admet-328	62	14	pvt	pvt	PROPN
admet-328	62	15	ltd	ltd	PROPN
admet-328	62	16	(	(	PUNCT
admet-328	62	17	hyderabad	hyderabad	PROPN
admet-328	62	18	)	)	PUNCT
admet-328	62	19	.	.	PUNCT
admet-328	63	1	pharmacokinetics	pharmacokinetic	NOUN
admet-328	63	2	and	and	CCONJ
admet-328	63	3	pharmacodynamic	pharmacodynamic	ADJ
admet-328	63	4	interaction	interaction	NOUN
admet-328	63	5	study	study	NOUN
admet-328	63	6	in	in	ADP
admet-328	63	7	normal	normal	ADJ
admet-328	63	8	rats	rat	NOUN
admet-328	63	9	male	male	ADJ
admet-328	63	10	albino	albino	NOUN
admet-328	63	11	wistar	wistar	PROPN
admet-328	63	12	rats	rat	NOUN
admet-328	63	13	weighing	weigh	VERB
admet-328	63	14	200	200	NUM
admet-328	63	15	-	-	SYM
admet-328	63	16	250	250	NUM
admet-328	63	17	gm	gm	PROPN
admet-328	63	18	were	be	AUX
admet-328	63	19	obtained	obtain	VERB
admet-328	63	20	from	from	ADP
admet-328	63	21	the	the	DET
admet-328	63	22	mahaveera	mahaveera	NOUN
admet-328	63	23	enterprises	enterprise	NOUN
admet-328	63	24	(	(	PUNCT
admet-328	63	25	hyderabad	hyderabad	PROPN
admet-328	63	26	,	,	PUNCT
admet-328	63	27	india	india	PROPN
admet-328	63	28	)	)	PUNCT
admet-328	63	29	.	.	PUNCT
admet-328	64	1	they	they	PRON
admet-328	64	2	were	be	AUX
admet-328	64	3	housed	house	VERB
admet-328	64	4	under	under	ADP
admet-328	64	5	standard	standard	ADJ
admet-328	64	6	conditions	condition	NOUN
admet-328	64	7	and	and	CCONJ
admet-328	64	8	were	be	AUX
admet-328	64	9	maintained	maintain	VERB
admet-328	64	10	under	under	ADP
admet-328	64	11	a	a	DET
admet-328	64	12	12	12	NUM
admet-328	64	13	hour	hour	NOUN
admet-328	64	14	light	light	ADJ
admet-328	64	15	/	/	SYM
admet-328	64	16	dark	dark	ADJ
admet-328	64	17	cycle	cycle	NOUN
admet-328	64	18	in	in	ADP
admet-328	64	19	the	the	DET
admet-328	64	20	laboratory	laboratory	NOUN
admet-328	64	21	animal	animal	NOUN
admet-328	64	22	recourses	recourse	NOUN
admet-328	64	23	facilities	facility	NOUN
admet-328	64	24	,	,	PUNCT
admet-328	64	25	creative	creative	ADJ
admet-328	64	26	educational	educational	ADJ
admet-328	64	27	society	society	NOUN
admet-328	64	28	’s	’s	PART
admet-328	64	29	college	college	PROPN
admet-328	64	30	of	of	ADP
admet-328	64	31	pharmacy	pharmacy	PROPN
admet-328	64	32	,	,	PUNCT
admet-328	64	33	kurnool	kurnool	PROPN
admet-328	64	34	,	,	PUNCT
admet-328	64	35	india	india	PROPN
admet-328	64	36	.	.	PUNCT
admet-328	65	1	rats	rat	NOUN
admet-328	65	2	were	be	AUX
admet-328	65	3	fasted	fast	VERB
admet-328	65	4	overnight	overnight	ADV
admet-328	65	5	before	before	ADP
admet-328	65	6	dosing	dose	VERB
admet-328	65	7	and	and	CCONJ
admet-328	65	8	until	until	ADP
admet-328	65	9	4	4	NUM
admet-328	65	10	hours	hour	NOUN
admet-328	65	11	after	after	ADP
admet-328	65	12	dosing	dose	VERB
admet-328	65	13	.	.	PUNCT
admet-328	66	1	water	water	NOUN
admet-328	66	2	was	be	AUX
admet-328	66	3	allowed	allow	VERB
admet-328	66	4	ad	ad	NOUN
admet-328	66	5	libitum	libitum	NOUN
admet-328	66	6	during	during	ADP
admet-328	66	7	the	the	DET
admet-328	66	8	fasting	fasting	NOUN
admet-328	66	9	period	period	NOUN
admet-328	66	10	.	.	PUNCT
admet-328	67	1	the	the	DET
admet-328	67	2	experiments	experiment	NOUN
admet-328	67	3	were	be	AUX
admet-328	67	4	performed	perform	VERB
admet-328	67	5	after	after	ADP
admet-328	67	6	prior	prior	ADJ
admet-328	67	7	approval	approval	NOUN
admet-328	67	8	of	of	ADP
admet-328	67	9	the	the	DET
admet-328	67	10	study	study	NOUN
admet-328	67	11	protocol	protocol	NOUN
admet-328	67	12	by	by	ADP
admet-328	67	13	the	the	DET
admet-328	67	14	institutional	institutional	ADJ
admet-328	67	15	animal	animal	NOUN
admet-328	67	16	ethics	ethic	NOUN
admet-328	67	17	committee	committee	NOUN
admet-328	67	18	.	.	PUNCT
admet-328	68	1	the	the	DET
admet-328	68	2	study	study	NOUN
admet-328	68	3	was	be	AUX
admet-328	68	4	conducted	conduct	VERB
admet-328	68	5	in	in	ADP
admet-328	68	6	accordance	accordance	NOUN
admet-328	68	7	with	with	ADP
admet-328	68	8	the	the	DET
admet-328	68	9	guidelines	guideline	NOUN
admet-328	68	10	provided	provide	VERB
admet-328	68	11	by	by	ADP
admet-328	68	12	the	the	DET
admet-328	68	13	committee	committee	NOUN
admet-328	68	14	for	for	ADP
admet-328	68	15	the	the	DET
admet-328	68	16	purpose	purpose	NOUN
admet-328	68	17	of	of	ADP
admet-328	68	18	control	control	NOUN
admet-328	68	19	and	and	CCONJ
admet-328	68	20	supervision	supervision	NOUN
admet-328	68	21	of	of	ADP
admet-328	68	22	experiments	experiment	NOUN
admet-328	68	23	and	and	CCONJ
admet-328	68	24	animals	animal	NOUN
admet-328	68	25	(	(	PUNCT
admet-328	68	26	cpcsea	cpcsea	NOUN
admet-328	68	27	)	)	PUNCT
admet-328	68	28	.	.	PUNCT
admet-328	69	1	rats	rat	NOUN
admet-328	69	2	were	be	AUX
admet-328	69	3	divided	divide	VERB
admet-328	69	4	into	into	ADP
admet-328	69	5	5	5	NUM
admet-328	69	6	groups	group	NOUN
admet-328	69	7	(	(	PUNCT
admet-328	69	8	n=6	n=6	NOUN
admet-328	69	9	,	,	PUNCT
admet-328	69	10	each	each	PRON
admet-328	69	11	):	):	PUNCT
admet-328	69	12	group-1	group-1	NOUN
admet-328	69	13	:	:	PUNCT
admet-328	69	14	repaglinide	repaglinide	PROPN
admet-328	69	15	oral	oral	PROPN
admet-328	69	16	control	control	PROPN
admet-328	69	17	group	group	NOUN
admet-328	69	18	administered	administer	VERB
admet-328	69	19	0.5	0.5	NUM
admet-328	69	20	mg	mg	PROPN
admet-328	69	21	/	/	SYM
admet-328	69	22	kg	kg	X
admet-328	70	1	[	[	X
admet-328	70	2	12	12	NUM
admet-328	70	3	]	]	PUNCT
admet-328	70	4	,	,	PUNCT
admet-328	70	5	group-2	group-2	PROPN
admet-328	70	6	:	:	PUNCT
admet-328	70	7	atazanavir	atazanavir	PROPN
admet-328	70	8	oral	oral	PROPN
admet-328	70	9	control	control	PROPN
admet-328	70	10	group	group	NOUN
admet-328	70	11	administered	administer	VERB
admet-328	70	12	36	36	NUM
admet-328	70	13	mg	mg	NOUN
admet-328	70	14	/	/	SYM
admet-328	70	15	kg	kg	PROPN
admet-328	71	1	[	[	X
admet-328	71	2	13	13	NUM
admet-328	71	3	]	]	PUNCT
admet-328	71	4	,	,	PUNCT
admet-328	71	5	thirumaleswara	thirumaleswara	PROPN
admet-328	71	6	goud	goud	PROPN
admet-328	71	7	et	et	PROPN
admet-328	71	8	al	al	PROPN
admet-328	71	9	.	.	PROPN
admet-328	71	10	admet	admet	PROPN
admet-328	71	11	&	&	CCONJ
admet-328	71	12	dmpk	dmpk	PROPN
admet-328	71	13	4(3	4(3	NUM
admet-328	71	14	)	)	PUNCT
admet-328	71	15	(	(	PUNCT
admet-328	71	16	2016	2016	NUM
admet-328	71	17	)	)	PUNCT
admet-328	71	18	269	269	NUM
admet-328	71	19	-	-	SYM
admet-328	71	20	279	279	NUM
admet-328	71	21	272	272	NUM
admet-328	71	22	group-3	group-3	NOUN
admet-328	71	23	:	:	PUNCT
admet-328	71	24	atazanavir	atazanavir	PROPN
admet-328	71	25	(	(	PUNCT
admet-328	71	26	36	36	NUM
admet-328	71	27	mg	mg	PROPN
admet-328	71	28	/	/	SYM
admet-328	71	29	kg	kg	NOUN
admet-328	71	30	)	)	PUNCT
admet-328	71	31	administered	administer	VERB
admet-328	71	32	,	,	PUNCT
admet-328	71	33	followed	follow	VERB
admet-328	71	34	by	by	ADP
admet-328	71	35	repaglinide	repaglinide	NOUN
admet-328	71	36	(	(	PUNCT
admet-328	71	37	0.5	0.5	NUM
admet-328	71	38	mg	mg	PROPN
admet-328	71	39	/	/	SYM
admet-328	71	40	kg	kg	NOUN
admet-328	71	41	)	)	PUNCT
admet-328	71	42	to	to	ADP
admet-328	71	43	normal	normal	ADJ
admet-328	71	44	rats	rat	NOUN
admet-328	71	45	,	,	PUNCT
admet-328	71	46	group-4	group-4	NUM
admet-328	71	47	:	:	PUNCT
admet-328	71	48	atazanavir	atazanavir	PROPN
admet-328	71	49	(	(	PUNCT
admet-328	71	50	36	36	NUM
admet-328	71	51	mg	mg	PROPN
admet-328	71	52	/	/	SYM
admet-328	71	53	kg	kg	NOUN
admet-328	71	54	)	)	PUNCT
admet-328	71	55	administered	administer	VERB
admet-328	71	56	,	,	PUNCT
admet-328	71	57	followed	follow	VERB
admet-328	71	58	by	by	ADP
admet-328	71	59	repaglinide	repaglinide	NOUN
admet-328	71	60	(	(	PUNCT
admet-328	71	61	0.5	0.5	NUM
admet-328	71	62	mg	mg	PROPN
admet-328	71	63	/	/	SYM
admet-328	71	64	kg	kg	NOUN
admet-328	71	65	)	)	PUNCT
admet-328	71	66	to	to	PART
admet-328	71	67	diabetic	diabetic	ADJ
admet-328	71	68	induced	induced	ADJ
admet-328	71	69	rats	rat	NOUN
admet-328	71	70	,	,	PUNCT
admet-328	71	71	group-5	group-5	NOUN
admet-328	71	72	:	:	PUNCT
admet-328	71	73	atazanavir	atazanavir	PROPN
admet-328	71	74	(	(	PUNCT
admet-328	71	75	36	36	NUM
admet-328	71	76	mg	mg	PROPN
admet-328	71	77	/	/	SYM
admet-328	71	78	kg	kg	NOUN
admet-328	71	79	)	)	PUNCT
admet-328	71	80	administered	administer	VERB
admet-328	71	81	,	,	PUNCT
admet-328	71	82	followed	follow	VERB
admet-328	71	83	by	by	ADP
admet-328	71	84	repaglinide	repaglinide	NOUN
admet-328	71	85	(	(	PUNCT
admet-328	71	86	0.5	0.5	NUM
admet-328	71	87	mg	mg	PROPN
admet-328	71	88	/	/	SYM
admet-328	71	89	kg	kg	NOUN
admet-328	71	90	)	)	PUNCT
admet-328	71	91	to	to	ADP
admet-328	71	92	a	a	DET
admet-328	71	93	hepatic	hepatic	ADJ
admet-328	71	94	impaired	impair	VERB
admet-328	71	95	rats	rat	NOUN
admet-328	71	96	.	.	PUNCT
admet-328	72	1	required	require	VERB
admet-328	72	2	amount	amount	NOUN
admet-328	72	3	of	of	ADP
admet-328	72	4	drugs	drug	NOUN
admet-328	72	5	(	(	PUNCT
admet-328	72	6	repaglinide	repaglinide	NOUN
admet-328	72	7	and	and	CCONJ
admet-328	72	8	atazanavir	atazanavir	PROPN
admet-328	72	9	)	)	PUNCT
admet-328	72	10	were	be	AUX
admet-328	72	11	weighed	weigh	VERB
admet-328	72	12	and	and	CCONJ
admet-328	72	13	placed	place	VERB
admet-328	72	14	in	in	ADP
admet-328	72	15	two	two	NUM
admet-328	72	16	separate	separate	ADJ
admet-328	72	17	motor	motor	NOUN
admet-328	72	18	’s	’s	PART
admet-328	72	19	triturated	triturate	VERB
admet-328	72	20	with	with	ADP
admet-328	72	21	pestle	pestle	NOUN
admet-328	72	22	,	,	PUNCT
admet-328	72	23	to	to	ADP
admet-328	72	24	this	this	DET
admet-328	72	25	required	require	VERB
admet-328	72	26	amount	amount	NOUN
admet-328	72	27	of	of	ADP
admet-328	72	28	tween	tween	NOUN
admet-328	72	29	80	80	NUM
admet-328	72	30	was	be	AUX
admet-328	72	31	added	add	VERB
admet-328	72	32	as	as	ADP
admet-328	72	33	a	a	DET
admet-328	72	34	wetting	wet	VERB
admet-328	72	35	agent	agent	NOUN
admet-328	72	36	and	and	CCONJ
admet-328	72	37	triturated	triturate	VERB
admet-328	72	38	well	well	ADV
admet-328	72	39	until	until	SCONJ
admet-328	72	40	the	the	DET
admet-328	72	41	whole	whole	ADJ
admet-328	72	42	compound	compound	NOUN
admet-328	72	43	was	be	AUX
admet-328	72	44	wet	wet	ADJ
admet-328	72	45	,	,	PUNCT
admet-328	72	46	then	then	ADV
admet-328	72	47	0.5	0.5	NUM
admet-328	72	48	%	%	NOUN
admet-328	72	49	of	of	ADP
admet-328	72	50	methyl	methyl	NOUN
admet-328	72	51	cellulose	cellulose	NOUN
admet-328	72	52	was	be	AUX
admet-328	72	53	added	add	VERB
admet-328	72	54	in	in	ADP
admet-328	72	55	gravimetric	gravimetric	ADJ
admet-328	72	56	dilution	dilution	NOUN
admet-328	72	57	method	method	NOUN
admet-328	72	58	and	and	CCONJ
admet-328	72	59	triturated	triturate	VERB
admet-328	72	60	uniformly	uniformly	ADV
admet-328	72	61	.	.	PUNCT
admet-328	73	1	this	this	DET
admet-328	73	2	suspension	suspension	NOUN
admet-328	73	3	was	be	AUX
admet-328	73	4	administered	administer	VERB
admet-328	73	5	to	to	ADP
admet-328	73	6	the	the	DET
admet-328	73	7	respective	respective	ADJ
admet-328	73	8	group	group	NOUN
admet-328	73	9	of	of	ADP
admet-328	73	10	animals	animal	NOUN
admet-328	73	11	through	through	ADP
admet-328	73	12	oral	oral	ADJ
admet-328	73	13	gavage	gavage	NOUN
admet-328	73	14	[	[	X
admet-328	73	15	14	14	NUM
admet-328	73	16	]	]	PUNCT
admet-328	73	17	.	.	PUNCT
admet-328	74	1	blood	blood	NOUN
admet-328	74	2	samples	sample	NOUN
admet-328	74	3	collected	collect	VERB
admet-328	74	4	retro	retro	ADJ
admet-328	74	5	-	-	PUNCT
admet-328	74	6	orbital	orbital	ADJ
admet-328	74	7	puncture	puncture	NOUN
admet-328	74	8	at	at	ADP
admet-328	74	9	0	0	NUM
admet-328	74	10	,	,	PUNCT
admet-328	74	11	0.25	0.25	NUM
admet-328	74	12	,	,	PUNCT
admet-328	74	13	0.5	0.5	NUM
admet-328	74	14	,	,	PUNCT
admet-328	74	15	1	1	NUM
admet-328	74	16	,	,	PUNCT
admet-328	74	17	2	2	NUM
admet-328	74	18	,	,	PUNCT
admet-328	74	19	4	4	NUM
admet-328	74	20	,	,	PUNCT
admet-328	74	21	6	6	NUM
admet-328	74	22	,	,	PUNCT
admet-328	74	23	8	8	NUM
admet-328	74	24	,	,	PUNCT
admet-328	74	25	12	12	NUM
admet-328	74	26	and	and	CCONJ
admet-328	74	27	24	24	NUM
admet-328	74	28	h	h	NOUN
admet-328	75	1	[	[	X
admet-328	75	2	15	15	NUM
admet-328	75	3	]	]	PUNCT
admet-328	75	4	.	.	PUNCT
admet-328	76	1	plasma	plasma	NOUN
admet-328	76	2	was	be	AUX
admet-328	76	3	separated	separate	VERB
admet-328	76	4	by	by	ADP
admet-328	76	5	centrifugation	centrifugation	NOUN
admet-328	76	6	using	use	VERB
admet-328	76	7	remi	remi	PROPN
admet-328	76	8	research	research	NOUN
admet-328	76	9	centrifuge	centrifuge	NOUN
admet-328	76	10	at	at	ADP
admet-328	76	11	4000	4000	NUM
admet-328	76	12	rpm	rpm	NOUN
admet-328	76	13	for	for	ADP
admet-328	76	14	10	10	NUM
admet-328	76	15	-	-	SYM
admet-328	76	16	20	20	NUM
admet-328	76	17	min	min	NOUN
admet-328	76	18	.	.	PROPN
admet-328	76	19	blood	blood	NOUN
admet-328	76	20	glucose	glucose	NOUN
admet-328	76	21	levels	level	NOUN
admet-328	76	22	were	be	AUX
admet-328	76	23	determined	determine	VERB
admet-328	76	24	using	use	VERB
admet-328	76	25	glucose	glucose	NOUN
admet-328	76	26	oxidase	oxidase	NOUN
admet-328	76	27	peroxidase	peroxidase	NOUN
admet-328	76	28	(	(	PUNCT
admet-328	76	29	god	god	PROPN
admet-328	76	30	-	-	PUNCT
admet-328	76	31	pod	pod	NOUN
admet-328	76	32	)	)	PUNCT
admet-328	76	33	method	method	NOUN
admet-328	76	34	by	by	ADP
admet-328	76	35	measuring	measure	VERB
admet-328	76	36	optical	optical	ADJ
admet-328	76	37	density	density	NOUN
admet-328	76	38	spectrophotometrically	spectrophotometrically	ADV
admet-328	76	39	at	at	ADP
admet-328	76	40	510	510	NUM
admet-328	76	41	nm	nm	NOUN
admet-328	76	42	[	[	X
admet-328	76	43	16	16	NUM
admet-328	76	44	]	]	PUNCT
admet-328	76	45	and	and	CCONJ
admet-328	76	46	the	the	DET
admet-328	76	47	remaining	remain	VERB
admet-328	76	48	samples	sample	NOUN
admet-328	76	49	were	be	AUX
admet-328	76	50	stored	store	VERB
admet-328	76	51	in	in	ADP
admet-328	76	52	vials	vial	NOUN
admet-328	76	53	at	at	ADP
admet-328	76	54	-80	-80	NOUN
admet-328	76	55	°	°	ADP
admet-328	76	56	c	c	NOUN
admet-328	76	57	until	until	ADP
admet-328	76	58	lc	lc	PROPN
admet-328	76	59	/	/	SYM
admet-328	76	60	msms	msm	NOUN
admet-328	76	61	analysis	analysis	NOUN
admet-328	76	62	.	.	PUNCT
admet-328	77	1	pharmacokinetics	pharmacokinetic	NOUN
admet-328	77	2	and	and	CCONJ
admet-328	77	3	pharmacodynamic	pharmacodynamic	ADJ
admet-328	77	4	interaction	interaction	NOUN
admet-328	77	5	study	study	NOUN
admet-328	77	6	in	in	ADP
admet-328	77	7	diabetic	diabetic	ADJ
admet-328	77	8	rats	rat	NOUN
admet-328	77	9	diabetes	diabetes	NOUN
admet-328	77	10	was	be	AUX
admet-328	77	11	induced	induce	VERB
admet-328	77	12	in	in	ADP
admet-328	77	13	rats	rat	NOUN
admet-328	77	14	by	by	ADP
admet-328	77	15	the	the	DET
admet-328	77	16	administration	administration	NOUN
admet-328	77	17	of	of	ADP
admet-328	77	18	alloxan	alloxan	PROPN
admet-328	77	19	monohydrate	monohydrate	PROPN
admet-328	77	20	in	in	ADP
admet-328	77	21	ice	ice	NOUN
admet-328	77	22	cold	cold	ADJ
admet-328	77	23	normal	normal	ADJ
admet-328	77	24	saline	saline	NOUN
admet-328	77	25	,	,	PUNCT
admet-328	77	26	in	in	ADP
admet-328	77	27	two	two	NUM
admet-328	77	28	doses	dose	NOUN
admet-328	77	29	,	,	PUNCT
admet-328	77	30	that	that	PRON
admet-328	77	31	is	be	AUX
admet-328	77	32	100	100	NUM
admet-328	77	33	mg	mg	NOUN
admet-328	77	34	and	and	CCONJ
admet-328	77	35	50	50	NUM
admet-328	77	36	mg	mg	NUM
admet-328	77	37	/	/	SYM
admet-328	77	38	kg	kg	PROPN
admet-328	77	39	body	body	NOUN
admet-328	77	40	wt	wt	X
admet-328	77	41	intraperitoneally	intraperitoneally	ADV
admet-328	77	42	for	for	ADP
admet-328	77	43	two	two	NUM
admet-328	77	44	consecutive	consecutive	ADJ
admet-328	77	45	days	day	NOUN
admet-328	77	46	[	[	X
admet-328	77	47	17	17	NUM
admet-328	77	48	]	]	PUNCT
admet-328	77	49	.	.	PUNCT
admet-328	78	1	after	after	ADP
admet-328	78	2	72	72	NUM
admet-328	78	3	h	h	NOUN
admet-328	78	4	,	,	PUNCT
admet-328	78	5	the	the	DET
admet-328	78	6	samples	sample	NOUN
admet-328	78	7	were	be	AUX
admet-328	78	8	collected	collect	VERB
admet-328	78	9	from	from	ADP
admet-328	78	10	rats	rat	NOUN
admet-328	78	11	by	by	ADP
admet-328	78	12	retro	retro	ADJ
admet-328	78	13	-	-	PUNCT
admet-328	78	14	orbital	orbital	ADJ
admet-328	78	15	puncture	puncture	NOUN
admet-328	78	16	of	of	ADP
admet-328	78	17	all	all	DET
admet-328	78	18	surviving	survive	VERB
admet-328	78	19	animals	animal	NOUN
admet-328	78	20	and	and	CCONJ
admet-328	78	21	the	the	DET
admet-328	78	22	plasma	plasma	NOUN
admet-328	78	23	was	be	AUX
admet-328	78	24	analyzed	analyze	VERB
admet-328	78	25	for	for	ADP
admet-328	78	26	glucose	glucose	NOUN
admet-328	78	27	levels	level	NOUN
admet-328	78	28	.	.	PUNCT
admet-328	79	1	rats	rat	NOUN
admet-328	79	2	with	with	ADP
admet-328	79	3	blood	blood	NOUN
admet-328	79	4	glucose	glucose	NOUN
admet-328	79	5	levels	level	NOUN
admet-328	79	6	of	of	ADP
admet-328	79	7	200	200	NUM
admet-328	79	8	mg	mg	PROPN
admet-328	79	9	/	/	SYM
admet-328	79	10	dl	dl	PROPN
admet-328	79	11	and	and	CCONJ
admet-328	79	12	above	above	ADV
admet-328	79	13	were	be	AUX
admet-328	79	14	considered	consider	VERB
admet-328	79	15	as	as	ADP
admet-328	79	16	diabetic	diabetic	ADJ
admet-328	79	17	and	and	CCONJ
admet-328	79	18	selected	select	VERB
admet-328	79	19	for	for	ADP
admet-328	79	20	the	the	DET
admet-328	79	21	study	study	NOUN
admet-328	79	22	.	.	PUNCT
admet-328	80	1	similarly	similarly	ADV
admet-328	80	2	a	a	DET
admet-328	80	3	separate	separate	ADJ
admet-328	80	4	set	set	NOUN
admet-328	80	5	of	of	ADP
admet-328	80	6	one	one	NUM
admet-328	80	7	group	group	NOUN
admet-328	80	8	(	(	PUNCT
admet-328	80	9	n=6	n=6	NOUN
admet-328	80	10	)	)	PUNCT
admet-328	80	11	was	be	AUX
admet-328	80	12	used	use	VERB
admet-328	80	13	for	for	ADP
admet-328	80	14	the	the	DET
admet-328	80	15	pharmacodynamic	pharmacodynamic	ADJ
admet-328	80	16	interaction	interaction	NOUN
admet-328	80	17	study	study	NOUN
admet-328	80	18	with	with	ADP
admet-328	80	19	pretreated	pretreate	VERB
admet-328	80	20	atazanavir	atazanavir	NOUN
admet-328	80	21	(	(	PUNCT
admet-328	80	22	36	36	NUM
admet-328	80	23	mg	mg	PROPN
admet-328	80	24	/	/	SYM
admet-328	80	25	kg	kg	PROPN
admet-328	80	26	)	)	PUNCT
admet-328	80	27	followed	follow	VERB
admet-328	80	28	by	by	ADP
admet-328	80	29	0.5	0.5	NUM
admet-328	80	30	mg	mg	PROPN
admet-328	80	31	/	/	SYM
admet-328	80	32	kg	kg	PROPN
admet-328	80	33	repaglinide	repaglinide	ADV
admet-328	80	34	in	in	ADP
admet-328	80	35	diabetic	diabetic	ADJ
admet-328	80	36	rats	rat	NOUN
admet-328	80	37	.	.	PUNCT
admet-328	81	1	pharmacokinetics	pharmacokinetic	NOUN
admet-328	81	2	and	and	CCONJ
admet-328	81	3	pharmacodynamic	pharmacodynamic	ADJ
admet-328	81	4	interaction	interaction	NOUN
admet-328	81	5	study	study	NOUN
admet-328	81	6	in	in	ADP
admet-328	81	7	hepatic	hepatic	ADJ
admet-328	81	8	impaired	impaired	ADJ
admet-328	81	9	rats	rat	NOUN
admet-328	81	10	hepatic	hepatic	ADJ
admet-328	81	11	impairment	impairment	NOUN
admet-328	81	12	was	be	AUX
admet-328	81	13	induced	induce	VERB
admet-328	81	14	in	in	ADP
admet-328	81	15	rats	rat	NOUN
admet-328	81	16	by	by	ADP
admet-328	81	17	administration	administration	NOUN
admet-328	81	18	of	of	ADP
admet-328	81	19	carbon	carbon	NOUN
admet-328	81	20	tetrachloride	tetrachloride	NOUN
admet-328	81	21	in	in	ADP
admet-328	81	22	olive	olive	ADJ
admet-328	81	23	oil	oil	NOUN
admet-328	81	24	(	(	PUNCT
admet-328	81	25	2ml	2ml	NOUN
admet-328	81	26	/	/	SYM
admet-328	81	27	kg	kg	NOUN
admet-328	81	28	)	)	PUNCT
admet-328	81	29	intraperitoneally	intraperitoneally	ADV
admet-328	81	30	for	for	ADP
admet-328	81	31	one	one	NUM
admet-328	81	32	day	day	NOUN
admet-328	81	33	[	[	X
admet-328	81	34	18	18	NUM
admet-328	81	35	]	]	PUNCT
admet-328	81	36	.	.	PUNCT
admet-328	82	1	after	after	ADP
admet-328	82	2	24	24	NUM
admet-328	82	3	h	h	NOUN
admet-328	82	4	,	,	PUNCT
admet-328	82	5	blood	blood	NOUN
admet-328	82	6	samples	sample	NOUN
admet-328	82	7	were	be	AUX
admet-328	82	8	collected	collect	VERB
admet-328	82	9	from	from	ADP
admet-328	82	10	rats	rat	NOUN
admet-328	82	11	by	by	ADP
admet-328	82	12	retro	retro	ADJ
admet-328	82	13	-	-	PUNCT
admet-328	82	14	orbital	orbital	ADJ
admet-328	82	15	puncture	puncture	NOUN
admet-328	82	16	of	of	ADP
admet-328	82	17	all	all	DET
admet-328	82	18	surviving	survive	VERB
admet-328	82	19	animals	animal	NOUN
admet-328	82	20	and	and	CCONJ
admet-328	82	21	the	the	DET
admet-328	82	22	serum	serum	NOUN
admet-328	82	23	was	be	AUX
admet-328	82	24	analysed	analyse	VERB
admet-328	82	25	for	for	ADP
admet-328	82	26	total	total	ADJ
admet-328	82	27	bilirubin	bilirubin	NOUN
admet-328	82	28	(	(	PUNCT
admet-328	82	29	>	>	X
admet-328	82	30	2mg	2mg	ADJ
admet-328	82	31	/	/	SYM
admet-328	82	32	dl	dl	PROPN
admet-328	82	33	)	)	PUNCT
admet-328	82	34	,	,	PUNCT
admet-328	82	35	alanine	alanine	NOUN
admet-328	82	36	transaminase	transaminase	NOUN
admet-328	82	37	(	(	PUNCT
admet-328	82	38	>	>	SYM
admet-328	82	39	150	150	NUM
admet-328	82	40	mg	mg	PROPN
admet-328	82	41	/	/	SYM
admet-328	82	42	dl	dl	PROPN
admet-328	82	43	)	)	PUNCT
admet-328	82	44	,	,	PUNCT
admet-328	82	45	aspartate	aspartate	NOUN
admet-328	82	46	transaminase	transaminase	NOUN
admet-328	82	47	(	(	PUNCT
admet-328	82	48	>	>	SYM
admet-328	82	49	200mg	200mg	PROPN
admet-328	82	50	/	/	SYM
admet-328	82	51	dl	dl	PROPN
admet-328	82	52	)	)	PUNCT
admet-328	82	53	and	and	CCONJ
admet-328	82	54	albumin	albumin	NOUN
admet-328	82	55	(	(	PUNCT
admet-328	82	56	<3	<3	X
admet-328	82	57	mg	mg	PROPN
admet-328	82	58	/	/	SYM
admet-328	82	59	dl	dl	PROPN
admet-328	82	60	)	)	PUNCT
admet-328	82	61	were	be	AUX
admet-328	82	62	selected	select	VERB
admet-328	82	63	for	for	ADP
admet-328	82	64	the	the	DET
admet-328	82	65	study	study	NOUN
admet-328	82	66	[	[	X
admet-328	82	67	19	19	NUM
admet-328	82	68	]	]	PUNCT
admet-328	82	69	.	.	PUNCT
admet-328	83	1	similarly	similarly	ADV
admet-328	83	2	,	,	PUNCT
admet-328	83	3	a	a	DET
admet-328	83	4	separate	separate	ADJ
admet-328	83	5	set	set	NOUN
admet-328	83	6	of	of	ADP
admet-328	83	7	one	one	NUM
admet-328	83	8	group	group	NOUN
admet-328	83	9	(	(	PUNCT
admet-328	83	10	n=6	n=6	NOUN
admet-328	83	11	)	)	PUNCT
admet-328	83	12	was	be	AUX
admet-328	83	13	used	use	VERB
admet-328	83	14	for	for	ADP
admet-328	83	15	the	the	DET
admet-328	83	16	pharmacodynamic	pharmacodynamic	ADJ
admet-328	83	17	interaction	interaction	NOUN
admet-328	83	18	study	study	NOUN
admet-328	83	19	with	with	ADP
admet-328	83	20	pretreated	pretreate	VERB
admet-328	83	21	atazanavir	atazanavir	NOUN
admet-328	83	22	(	(	PUNCT
admet-328	83	23	36	36	NUM
admet-328	83	24	mg	mg	PROPN
admet-328	83	25	/	/	SYM
admet-328	83	26	kg	kg	PROPN
admet-328	83	27	)	)	PUNCT
admet-328	83	28	followed	follow	VERB
admet-328	83	29	by	by	ADP
admet-328	83	30	0.5	0.5	NUM
admet-328	83	31	mg	mg	PROPN
admet-328	83	32	/	/	SYM
admet-328	83	33	kg	kg	PROPN
admet-328	83	34	repaglinide	repaglinide	ADV
admet-328	83	35	in	in	ADP
admet-328	83	36	hepatic	hepatic	ADJ
admet-328	83	37	impaired	impaired	ADJ
admet-328	83	38	rats	rat	NOUN
admet-328	83	39	.	.	PUNCT
admet-328	84	1	liquid	liquid	ADJ
admet-328	84	2	chromatography	chromatography	NOUN
admet-328	84	3	-	-	PUNCT
admet-328	84	4	mass	mass	NOUN
admet-328	84	5	spectrometry	spectrometry	NOUN
admet-328	84	6	analysis	analysis	NOUN
admet-328	84	7	in	in	ADP
admet-328	84	8	vivo	vivo	ADJ
admet-328	84	9	samples	sample	NOUN
admet-328	84	10	were	be	AUX
admet-328	84	11	prepared	prepare	VERB
admet-328	84	12	by	by	ADP
admet-328	84	13	protein	protein	NOUN
admet-328	84	14	precipitation	precipitation	NOUN
admet-328	84	15	with	with	ADP
admet-328	84	16	the	the	DET
admet-328	84	17	addition	addition	NOUN
admet-328	84	18	of	of	ADP
admet-328	84	19	200	200	NUM
admet-328	84	20	µl	µl	ADP
admet-328	84	21	acetonitrile	acetonitrile	NOUN
admet-328	84	22	containing	contain	VERB
admet-328	84	23	an	an	DET
admet-328	84	24	internal	internal	ADJ
admet-328	84	25	standard	standard	NOUN
admet-328	84	26	(	(	PUNCT
admet-328	84	27	rosuvastatin	rosuvastatin	NOUN
admet-328	84	28	)	)	PUNCT
admet-328	84	29	to	to	ADP
admet-328	84	30	50	50	NUM
admet-328	84	31	µl	µl	ADP
admet-328	84	32	sample	sample	NOUN
admet-328	84	33	volume	volume	NOUN
admet-328	84	34	.	.	PUNCT
admet-328	85	1	samples	sample	NOUN
admet-328	85	2	were	be	AUX
admet-328	85	3	vortexed	vortexe	VERB
admet-328	85	4	and	and	CCONJ
admet-328	85	5	centrifuged	centrifuge	VERB
admet-328	85	6	at	at	ADP
admet-328	85	7	4000rpm	4000rpm	NUM
admet-328	85	8	for	for	ADP
admet-328	85	9	10	10	NUM
admet-328	85	10	min	min	NOUN
admet-328	85	11	prior	prior	ADV
admet-328	85	12	to	to	ADP
admet-328	85	13	evaporation	evaporation	NOUN
admet-328	85	14	of	of	ADP
admet-328	85	15	the	the	DET
admet-328	85	16	supernatant	supernatant	NOUN
admet-328	85	17	.	.	PUNCT
admet-328	86	1	atazanavir	atazanavir	PROPN
admet-328	86	2	and	and	CCONJ
admet-328	86	3	repaglinide	repaglinide	ADJ
admet-328	86	4	concentrations	concentration	NOUN
admet-328	86	5	from	from	ADP
admet-328	86	6	plasma	plasma	NOUN
admet-328	86	7	samples	sample	NOUN
admet-328	86	8	were	be	AUX
admet-328	86	9	measured	measure	VERB
admet-328	86	10	using	use	VERB
admet-328	86	11	validated	validate	VERB
admet-328	86	12	liquid	liquid	ADJ
admet-328	86	13	chromatography	chromatography	NOUN
admet-328	86	14	/	/	SYM
admet-328	86	15	mass	mass	NOUN
admet-328	86	16	spectrometry	spectrometry	NOUN
admet-328	86	17	(	(	PUNCT
admet-328	86	18	lc	lc	PROPN
admet-328	86	19	-	-	PUNCT
admet-328	86	20	ms	ms	PROPN
admet-328	86	21	/	/	SYM
admet-328	86	22	ms	ms	PROPN
admet-328	86	23	)	)	PUNCT
admet-328	86	24	method	method	NOUN
admet-328	86	25	.	.	PUNCT
admet-328	87	1	positive	positive	ADJ
admet-328	87	2	-	-	PUNCT
admet-328	87	3	ion	ion	NOUN
admet-328	87	4	multiple	multiple	ADJ
admet-328	87	5	reaction	reaction	NOUN
admet-328	87	6	monitoring	monitoring	NOUN
admet-328	87	7	was	be	AUX
admet-328	87	8	used	use	VERB
admet-328	87	9	for	for	ADP
admet-328	87	10	the	the	DET
admet-328	87	11	tandem	tandem	PROPN
admet-328	87	12	mass	mass	PROPN
admet-328	87	13	spectrometric	spectrometric	ADJ
admet-328	87	14	detection	detection	NOUN
admet-328	87	15	of	of	ADP
admet-328	87	16	repaglinide	repaglinide	NOUN
admet-328	87	17	,	,	PUNCT
admet-328	87	18	atazanavir	atazanavir	PROPN
admet-328	87	19	and	and	CCONJ
admet-328	87	20	rosuvastatin	rosuvastatin	NOUN
admet-328	87	21	.	.	PUNCT
admet-328	88	1	the	the	DET
admet-328	88	2	selected	select	VERB
admet-328	88	3	[	[	X
admet-328	88	4	m+h	m+h	NOUN
admet-328	88	5	]	]	X
admet-328	88	6	+	+	NUM
admet-328	88	7	precursor	precursor	NOUN
admet-328	88	8	ions	ion	NOUN
admet-328	88	9	were	be	AUX
admet-328	88	10	m	m	PROPN
admet-328	88	11	/	/	SYM
admet-328	88	12	z	z	PROPN
admet-328	88	13	453.2	453.2	NUM
admet-328	88	14	for	for	ADP
admet-328	88	15	repaglinide	repaglinide	NOUN
admet-328	88	16	,	,	PUNCT
admet-328	88	17	m	m	VERB
admet-328	88	18	/	/	SYM
admet-328	88	19	z	z	PROPN
admet-328	88	20	705.5	705.5	NUM
admet-328	88	21	for	for	ADP
admet-328	88	22	atazanavir	atazanavir	PROPN
admet-328	88	23	,	,	PUNCT
admet-328	88	24	and	and	CCONJ
admet-328	88	25	m	m	PROPN
admet-328	88	26	/	/	SYM
admet-328	88	27	z	z	PROPN
admet-328	88	28	482.3	482.3	NUM
admet-328	88	29	for	for	ADP
admet-328	88	30	rosuvastatin	rosuvastatin	NOUN
admet-328	88	31	,	,	PUNCT
admet-328	88	32	and	and	CCONJ
admet-328	88	33	the	the	DET
admet-328	88	34	product	product	NOUN
admet-328	88	35	ions	ion	NOUN
admet-328	88	36	monitored	monitor	VERB
admet-328	88	37	were	be	AUX
admet-328	88	38	at	at	ADP
admet-328	88	39	m	m	PROPN
admet-328	88	40	/	/	SYM
admet-328	88	41	z	z	PROPN
admet-328	88	42	230.3	230.3	NUM
admet-328	88	43	,	,	PUNCT
admet-328	88	44	168.2	168.2	NUM
admet-328	88	45	and	and	CCONJ
admet-328	88	46	258.15	258.15	NUM
admet-328	88	47	for	for	ADP
admet-328	88	48	repaglinide	repaglinide	NOUN
admet-328	88	49	,	,	PUNCT
admet-328	88	50	atazanavir	atazanavir	PROPN
admet-328	88	51	and	and	CCONJ
admet-328	88	52	rosuvastatin	rosuvastatin	ADJ
admet-328	88	53	(	(	PUNCT
admet-328	88	54	internal	internal	ADJ
admet-328	88	55	standard	standard	NOUN
admet-328	88	56	)	)	PUNCT
admet-328	88	57	,	,	PUNCT
admet-328	88	58	respectively	respectively	ADV
admet-328	88	59	.	.	PUNCT
admet-328	89	1	the	the	DET
admet-328	89	2	high	high	ADJ
admet-328	89	3	-	-	PUNCT
admet-328	89	4	performance	performance	NOUN
admet-328	89	5	liquid	liquid	ADJ
admet-328	89	6	chromatography	chromatography	NOUN
admet-328	89	7	column	column	NOUN
admet-328	89	8	was	be	AUX
admet-328	89	9	a	a	DET
admet-328	89	10	hypersil	hypersil	NOUN
admet-328	89	11	gold	gold	NOUN
admet-328	89	12	c18	c18	NOUN
admet-328	89	13	(	(	PUNCT
admet-328	89	14	4.6x100mm,5µ	4.6x100mm,5µ	PROPN
admet-328	89	15	)	)	PUNCT
admet-328	89	16	maintained	maintain	VERB
admet-328	89	17	at	at	ADP
admet-328	89	18	40	40	NUM
admet-328	89	19	°	°	NOUN
admet-328	89	20	c	c	NOUN
admet-328	89	21	with	with	ADP
admet-328	89	22	a	a	DET
admet-328	89	23	flow	flow	NOUN
admet-328	89	24	rate	rate	NOUN
admet-328	89	25	of	of	ADP
admet-328	89	26	1.3	1.3	NUM
admet-328	89	27	ml	ml	NOUN
admet-328	89	28	/	/	SYM
admet-328	89	29	min	min	NOUN
admet-328	89	30	.	.	PROPN
admet-328	89	31	mobile	mobile	ADJ
admet-328	89	32	phase	phase	NOUN
admet-328	89	33	consisted	consist	VERB
admet-328	89	34	of	of	ADP
admet-328	89	35	0.1	0.1	NUM
admet-328	89	36	%	%	NOUN
admet-328	89	37	formic	formic	ADJ
admet-328	89	38	acid	acid	NOUN
admet-328	89	39	in	in	ADP
admet-328	89	40	milliq	milliq	ADJ
admet-328	89	41	water	water	NOUN
admet-328	89	42	(	(	PUNCT
admet-328	89	43	a	a	NOUN
admet-328	89	44	)	)	PUNCT
admet-328	89	45	and	and	CCONJ
admet-328	89	46	acetonitrile	acetonitrile	ADJ
admet-328	89	47	(	(	PUNCT
admet-328	89	48	b	b	NOUN
admet-328	89	49	)	)	PUNCT
admet-328	89	50	.	.	PUNCT
admet-328	90	1	a	a	DET
admet-328	90	2	gradient	gradient	ADJ
admet-328	90	3	elution	elution	NOUN
admet-328	90	4	was	be	AUX
admet-328	90	5	used	use	VERB
admet-328	90	6	.	.	PUNCT
admet-328	91	1	the	the	DET
admet-328	91	2	overall	overall	ADJ
admet-328	91	3	run	run	NOUN
admet-328	91	4	time	time	NOUN
admet-328	91	5	was	be	AUX
admet-328	91	6	6.0	6.0	NUM
admet-328	91	7	min	min	NOUN
admet-328	91	8	.	.	PUNCT
admet-328	92	1	an	an	DET
admet-328	92	2	aliquot	aliquot	NOUN
admet-328	92	3	of	of	ADP
admet-328	92	4	5	5	NUM
admet-328	92	5	μl	μl	ADV
admet-328	92	6	was	be	AUX
admet-328	92	7	injected	inject	VERB
admet-328	92	8	at	at	ADP
admet-328	92	9	a	a	DET
admet-328	92	10	mobile	mobile	ADJ
admet-328	92	11	phase	phase	NOUN
admet-328	92	12	flow	flow	NOUN
admet-328	92	13	rate	rate	NOUN
admet-328	92	14	of	of	ADP
admet-328	92	15	1300	1300	NUM
admet-328	92	16	μl	μl	PROPN
admet-328	92	17	/	/	SYM
admet-328	92	18	min	min	NOUN
admet-328	92	19	.	.	PUNCT
admet-328	93	1	the	the	DET
admet-328	93	2	liquid	liquid	ADJ
admet-328	93	3	admet	admet	NOUN
admet-328	93	4	&	&	CCONJ
admet-328	93	5	dmpk	dmpk	PROPN
admet-328	93	6	4(3	4(3	NUM
admet-328	93	7	)	)	PUNCT
admet-328	93	8	(	(	PUNCT
admet-328	93	9	2016	2016	NUM
admet-328	93	10	)	)	PUNCT
admet-328	93	11	269	269	NUM
admet-328	93	12	-	-	SYM
admet-328	93	13	279	279	NUM
admet-328	93	14	pk	pk	NOUN
admet-328	93	15	and	and	CCONJ
admet-328	93	16	pd	pd	NOUN
admet-328	93	17	interaction	interaction	NOUN
admet-328	93	18	between	between	ADP
admet-328	93	19	repaglinide	repaglinide	NOUN
admet-328	93	20	and	and	CCONJ
admet-328	93	21	atazanavir	atazanavir	PROPN
admet-328	93	22	doi	doi	PROPN
admet-328	93	23	:	:	PUNCT
admet-328	93	24	10.5599	10.5599	NUM
admet-328	93	25	/	/	SYM
admet-328	93	26	admet.4.3.328	admet.4.3.328	NUM
admet-328	93	27	273	273	NUM
admet-328	93	28	chromatography	chromatography	NOUN
admet-328	93	29	was	be	AUX
admet-328	93	30	interfaced	interface	VERB
admet-328	93	31	to	to	PART
admet-328	93	32	api	api	VERB
admet-328	93	33	3200	3200	NUM
admet-328	93	34	(	(	PUNCT
admet-328	93	35	absciex	absciex	ADJ
admet-328	93	36	,	,	PUNCT
admet-328	93	37	ca	ca	NOUN
admet-328	93	38	)	)	PUNCT
admet-328	93	39	ion	ion	NOUN
admet-328	93	40	-	-	PUNCT
admet-328	93	41	trap	trap	NOUN
admet-328	93	42	mass	mass	NOUN
admet-328	93	43	spectrometer	spectrometer	NOUN
admet-328	93	44	operated	operate	VERB
admet-328	93	45	in	in	ADP
admet-328	93	46	the	the	DET
admet-328	93	47	positive	positive	ADJ
admet-328	93	48	ion	ion	NOUN
admet-328	93	49	electrospray	electrospray	NOUN
admet-328	93	50	and	and	CCONJ
admet-328	93	51	full	full	ADJ
admet-328	93	52	tandem	tandem	NOUN
admet-328	93	53	mass	mass	PROPN
admet-328	93	54	spectrometry	spectrometry	NOUN
admet-328	93	55	mode	mode	NOUN
admet-328	93	56	.	.	PUNCT
admet-328	94	1	before	before	ADP
admet-328	94	2	analyzing	analyze	VERB
admet-328	94	3	plasma	plasma	NOUN
admet-328	94	4	,	,	PUNCT
admet-328	94	5	atazanavir	atazanavir	PROPN
admet-328	94	6	and	and	CCONJ
admet-328	94	7	repaglinide	repaglinide	PROPN
admet-328	94	8	standard	standard	ADJ
admet-328	94	9	solutions	solution	NOUN
admet-328	94	10	prepared	prepare	VERB
admet-328	94	11	in	in	ADP
admet-328	94	12	acetonitrile	acetonitrile	NOUN
admet-328	94	13	were	be	AUX
admet-328	94	14	run	run	VERB
admet-328	94	15	on	on	ADP
admet-328	94	16	lc	lc	PROPN
admet-328	94	17	to	to	PART
admet-328	94	18	optimize	optimize	VERB
admet-328	94	19	the	the	DET
admet-328	94	20	analysis	analysis	NOUN
admet-328	94	21	and	and	CCONJ
admet-328	94	22	standardize	standardize	VERB
admet-328	94	23	calibration	calibration	NOUN
admet-328	94	24	.	.	PUNCT
admet-328	95	1	standard	standard	ADJ
admet-328	95	2	concentrations	concentration	NOUN
admet-328	95	3	were	be	AUX
admet-328	95	4	chosen	choose	VERB
admet-328	95	5	on	on	ADP
admet-328	95	6	the	the	DET
admet-328	95	7	basis	basis	NOUN
admet-328	95	8	of	of	ADP
admet-328	95	9	levels	level	NOUN
admet-328	95	10	found	find	VERB
admet-328	95	11	in	in	ADP
admet-328	95	12	plasma	plasma	NOUN
admet-328	95	13	samples	sample	NOUN
admet-328	95	14	.	.	PUNCT
admet-328	96	1	the	the	DET
admet-328	96	2	peak	peak	NOUN
admet-328	96	3	area	area	NOUN
admet-328	96	4	ratio	ratio	NOUN
admet-328	96	5	of	of	ADP
admet-328	96	6	analyte	analyte	NOUN
admet-328	96	7	(	(	PUNCT
admet-328	96	8	repaglinide	repaglinide	PROPN
admet-328	96	9	,	,	PUNCT
admet-328	96	10	atazanavir	atazanavir	PROPN
admet-328	96	11	)	)	PUNCT
admet-328	96	12	to	to	ADP
admet-328	96	13	internal	internal	ADJ
admet-328	96	14	standard	standard	NOUN
admet-328	96	15	was	be	AUX
admet-328	96	16	plotted	plot	VERB
admet-328	96	17	against	against	ADP
admet-328	96	18	analyte	analyte	NOUN
admet-328	96	19	concentrations	concentration	NOUN
admet-328	96	20	,	,	PUNCT
admet-328	96	21	and	and	CCONJ
admet-328	96	22	standard	standard	ADJ
admet-328	96	23	curves	curve	NOUN
admet-328	96	24	were	be	AUX
admet-328	96	25	fitted	fit	VERB
admet-328	96	26	by	by	ADP
admet-328	96	27	weighted	weight	VERB
admet-328	96	28	(	(	PUNCT
admet-328	96	29	1	1	NUM
admet-328	96	30	/	/	SYM
admet-328	96	31	x	x	SYM
admet-328	96	32	2	2	NUM
admet-328	96	33	)	)	PUNCT
admet-328	96	34	least	least	ADJ
admet-328	96	35	-	-	PUNCT
admet-328	96	36	squares	square	NOUN
admet-328	96	37	linear	linear	PROPN
admet-328	96	38	regression	regression	NOUN
admet-328	96	39	in	in	ADP
admet-328	96	40	the	the	DET
admet-328	96	41	concentration	concentration	NOUN
admet-328	96	42	of	of	ADP
admet-328	96	43	9	9	NUM
admet-328	96	44	-	-	SYM
admet-328	96	45	20000	20000	NUM
admet-328	96	46	ng	ng	NOUN
admet-328	96	47	/	/	SYM
admet-328	96	48	ml	ml	NOUN
admet-328	96	49	for	for	ADP
admet-328	96	50	repaglinide	repaglinide	NOUN
admet-328	96	51	and	and	CCONJ
admet-328	96	52	19.5–20000	19.5–20000	NUM
admet-328	96	53	ng	ng	PROPN
admet-328	96	54	/	/	SYM
admet-328	96	55	ml	ml	PROPN
admet-328	96	56	for	for	ADP
admet-328	96	57	atazanavir	atazanavir	PROPN
admet-328	96	58	.	.	PUNCT
admet-328	97	1	a	a	DET
admet-328	97	2	correlation	correlation	NOUN
admet-328	97	3	of	of	ADP
admet-328	97	4	0.994	0.994	NUM
admet-328	97	5	was	be	AUX
admet-328	97	6	desirable	desirable	ADJ
admet-328	97	7	for	for	ADP
admet-328	97	8	all	all	DET
admet-328	97	9	the	the	DET
admet-328	97	10	calibration	calibration	NOUN
admet-328	97	11	curves	curve	NOUN
admet-328	97	12	.	.	PUNCT
admet-328	98	1	the	the	DET
admet-328	98	2	limit	limit	NOUN
admet-328	98	3	of	of	ADP
admet-328	98	4	quantitation	quantitation	NOUN
admet-328	98	5	for	for	ADP
admet-328	98	6	the	the	DET
admet-328	98	7	purposes	purpose	NOUN
admet-328	98	8	of	of	ADP
admet-328	98	9	this	this	DET
admet-328	98	10	assay	assay	NOUN
admet-328	98	11	was	be	AUX
admet-328	98	12	9	9	NUM
admet-328	98	13	ng	ng	NOUN
admet-328	98	14	/	/	SYM
admet-328	98	15	ml	ml	PROPN
admet-328	98	16	and	and	CCONJ
admet-328	98	17	19.5	19.5	NUM
admet-328	98	18	ng	ng	NOUN
admet-328	98	19	/	/	SYM
admet-328	98	20	ml	ml	X
admet-328	98	21	for	for	ADP
admet-328	98	22	repaglinide	repaglinide	NOUN
admet-328	98	23	and	and	CCONJ
admet-328	98	24	atazanavir	atazanavir	PROPN
admet-328	98	25	,	,	PUNCT
admet-328	98	26	respectively	respectively	ADV
admet-328	98	27	[	[	X
admet-328	98	28	20	20	NUM
admet-328	98	29	-	-	SYM
admet-328	98	30	21	21	NUM
admet-328	98	31	]	]	PUNCT
admet-328	98	32	.	.	PUNCT
admet-328	99	1	pharmacokinetic	pharmacokinetic	ADJ
admet-328	99	2	and	and	CCONJ
admet-328	99	3	statistical	statistical	ADJ
admet-328	99	4	analysis	analysis	NOUN
admet-328	99	5	the	the	DET
admet-328	99	6	pharmacokinetic	pharmacokinetic	ADJ
admet-328	99	7	parameters	parameter	NOUN
admet-328	99	8	were	be	AUX
admet-328	99	9	obtained	obtain	VERB
admet-328	99	10	by	by	ADP
admet-328	99	11	fitting	fit	VERB
admet-328	99	12	the	the	DET
admet-328	99	13	plasma	plasma	NOUN
admet-328	99	14	concentration	concentration	NOUN
admet-328	99	15	-	-	PUNCT
admet-328	99	16	time	time	NOUN
admet-328	99	17	data	datum	NOUN
admet-328	99	18	to	to	ADP
admet-328	99	19	noncompartmental	noncompartmental	ADJ
admet-328	99	20	model	model	NOUN
admet-328	99	21	by	by	ADP
admet-328	99	22	using	use	VERB
admet-328	99	23	(	(	PUNCT
admet-328	99	24	phoenix	phoenix	PROPN
admet-328	99	25	-v6.3.0.395	-v6.3.0.395	PROPN
admet-328	99	26	;	;	PUNCT
admet-328	99	27	pharsight	pharsight	NOUN
admet-328	99	28	,	,	PUNCT
admet-328	99	29	mountain	mountain	NOUN
admet-328	99	30	view	view	NOUN
admet-328	99	31	,	,	PUNCT
admet-328	99	32	ca	ca	NOUN
admet-328	99	33	)	)	PUNCT
admet-328	99	34	.	.	PUNCT
admet-328	100	1	the	the	DET
admet-328	100	2	maximum	maximum	ADJ
admet-328	100	3	plasma	plasma	NOUN
admet-328	100	4	concentration	concentration	NOUN
admet-328	100	5	(	(	PUNCT
admet-328	100	6	cmax	cmax	NOUN
admet-328	100	7	)	)	PUNCT
admet-328	100	8	and	and	CCONJ
admet-328	100	9	the	the	DET
admet-328	100	10	time	time	NOUN
admet-328	100	11	to	to	PART
admet-328	100	12	reach	reach	VERB
admet-328	100	13	the	the	DET
admet-328	100	14	same	same	ADJ
admet-328	100	15	(	(	PUNCT
admet-328	100	16	tmax	tmax	ADV
admet-328	100	17	)	)	PUNCT
admet-328	100	18	,	,	PUNCT
admet-328	100	19	the	the	DET
admet-328	100	20	half	half	ADJ
admet-328	100	21	-	-	PUNCT
admet-328	100	22	life	life	NOUN
admet-328	100	23	of	of	ADP
admet-328	100	24	plasma	plasma	NOUN
admet-328	100	25	drug	drug	NOUN
admet-328	100	26	elimination	elimination	NOUN
admet-328	100	27	(	(	PUNCT
admet-328	100	28	t1/2	t1/2	NOUN
admet-328	100	29	)	)	PUNCT
admet-328	100	30	was	be	AUX
admet-328	100	31	the	the	DET
admet-328	100	32	ratio	ratio	NOUN
admet-328	100	33	of	of	ADP
admet-328	100	34	0.693	0.693	NUM
admet-328	100	35	to	to	ADP
admet-328	100	36	the	the	DET
admet-328	100	37	slope	slope	NOUN
admet-328	100	38	obtained	obtain	VERB
admet-328	100	39	by	by	ADP
admet-328	100	40	log	log	NOUN
admet-328	100	41	-	-	PUNCT
admet-328	100	42	linear	linear	NOUN
admet-328	100	43	regression	regression	NOUN
admet-328	100	44	of	of	ADP
admet-328	100	45	the	the	DET
admet-328	100	46	terminal	terminal	ADJ
admet-328	100	47	phase	phase	NOUN
admet-328	100	48	of	of	ADP
admet-328	100	49	the	the	DET
admet-328	100	50	drug	drug	NOUN
admet-328	100	51	plasma	plasma	NOUN
admet-328	100	52	profile	profile	NOUN
admet-328	100	53	and	and	CCONJ
admet-328	100	54	the	the	DET
admet-328	100	55	area	area	NOUN
admet-328	100	56	under	under	ADP
admet-328	100	57	the	the	DET
admet-328	100	58	concentration	concentration	NOUN
admet-328	100	59	-	-	PUNCT
admet-328	100	60	time	time	NOUN
admet-328	100	61	curve	curve	NOUN
admet-328	100	62	to	to	ADP
admet-328	100	63	terminal	terminal	ADJ
admet-328	100	64	time	time	NOUN
admet-328	100	65	(	(	PUNCT
admet-328	100	66	auc0	auc0	NOUN
admet-328	100	67	-	-	PUNCT
admet-328	100	68	t),area	t),area	NOUN
admet-328	100	69	under	under	ADP
admet-328	100	70	the	the	DET
admet-328	100	71	concentration	concentration	NOUN
admet-328	100	72	-	-	PUNCT
admet-328	100	73	time	time	NOUN
admet-328	100	74	curve	curve	NOUN
admet-328	100	75	to	to	PART
admet-328	100	76	infinite	infinite	VERB
admet-328	100	77	time	time	NOUN
admet-328	100	78	(	(	PUNCT
admet-328	100	79	auc0-∞	auc0-∞	NUM
admet-328	100	80	)	)	PUNCT
admet-328	100	81	was	be	AUX
admet-328	100	82	calculated	calculate	VERB
admet-328	100	83	by	by	ADP
admet-328	100	84	the	the	DET
admet-328	100	85	linear	linear	PROPN
admet-328	100	86	/	/	SYM
admet-328	100	87	log	log	NOUN
admet-328	100	88	trapezoidal	trapezoidal	ADJ
admet-328	100	89	rule	rule	NOUN
admet-328	100	90	and	and	CCONJ
admet-328	100	91	the	the	DET
admet-328	100	92	total	total	ADJ
admet-328	100	93	plasma	plasma	NOUN
admet-328	100	94	clearance	clearance	NOUN
admet-328	100	95	(	(	PUNCT
admet-328	100	96	cl	cl	NOUN
admet-328	100	97	)	)	PUNCT
admet-328	100	98	were	be	AUX
admet-328	100	99	calculated	calculate	VERB
admet-328	100	100	by	by	ADP
admet-328	100	101	phoenix	phoenix	PROPN
admet-328	100	102	software	software	PROPN
admet-328	100	103	.	.	PUNCT
admet-328	101	1	data	datum	NOUN
admet-328	101	2	were	be	AUX
admet-328	101	3	expressed	express	VERB
admet-328	101	4	as	as	ADP
admet-328	101	5	a	a	DET
admet-328	101	6	mean±standard	mean±standard	NOUN
admet-328	101	7	deviation	deviation	NOUN
admet-328	101	8	(	(	PUNCT
admet-328	101	9	sd	sd	NOUN
admet-328	101	10	)	)	PUNCT
admet-328	101	11	.	.	PUNCT
admet-328	102	1	the	the	DET
admet-328	102	2	significance	significance	NOUN
admet-328	102	3	was	be	AUX
admet-328	102	4	determined	determine	VERB
admet-328	102	5	by	by	ADP
admet-328	102	6	applying	apply	VERB
admet-328	102	7	one	one	NUM
admet-328	102	8	way	way	NOUN
admet-328	102	9	anova	anova	PROPN
admet-328	102	10	analysis	analysis	NOUN
admet-328	102	11	.	.	PUNCT
admet-328	103	1	the	the	DET
admet-328	103	2	results	result	NOUN
admet-328	103	3	were	be	AUX
admet-328	103	4	considered	consider	VERB
admet-328	103	5	to	to	PART
admet-328	103	6	be	be	AUX
admet-328	103	7	statistically	statistically	ADV
admet-328	103	8	significant	significant	ADJ
admet-328	103	9	when	when	SCONJ
admet-328	103	10	p<0.0001	p<0.0001	NOUN
admet-328	103	11	.	.	PUNCT
admet-328	104	1	glucose	glucose	NOUN
admet-328	104	2	reduction	reduction	NOUN
admet-328	104	3	calculations	calculation	NOUN
admet-328	104	4	percentage	percentage	NOUN
admet-328	104	5	reduction	reduction	NOUN
admet-328	104	6	in	in	ADP
admet-328	104	7	bgl	bgl	PROPN
admet-328	104	8	=	=	PRON
admet-328	104	9	{	{	PUNCT
admet-328	104	10	(	(	PUNCT
admet-328	104	11	ibgl	ibgl	NOUN
admet-328	104	12	–	–	PUNCT
admet-328	104	13	fbgl	fbgl	NOUN
admet-328	104	14	)	)	PUNCT
admet-328	104	15	/	/	SYM
admet-328	104	16	ibgl	ibgl	NOUN
admet-328	104	17	}	}	PUNCT
admet-328	104	18	x	x	SYM
admet-328	104	19	100	100	NUM
admet-328	104	20	where	where	SCONJ
admet-328	104	21	bgl	bgl	PROPN
admet-328	104	22	=	=	NOUN
admet-328	104	23	blood	blood	NOUN
admet-328	104	24	glucose	glucose	NOUN
admet-328	104	25	level	level	NOUN
admet-328	104	26	;	;	PUNCT
admet-328	104	27	ibgl	ibgl	NOUN
admet-328	104	28	=	=	SYM
admet-328	104	29	initial	initial	ADJ
admet-328	104	30	blood	blood	NOUN
admet-328	104	31	glucose	glucose	NOUN
admet-328	104	32	level	level	NOUN
admet-328	104	33	;	;	PUNCT
admet-328	104	34	fbgl	fbgl	ADJ
admet-328	104	35	=	=	PUNCT
admet-328	104	36	final	final	ADJ
admet-328	104	37	blood	blood	NOUN
admet-328	104	38	glucose	glucose	NOUN
admet-328	104	39	level	level	NOUN
admet-328	105	1	[	[	X
admet-328	105	2	22	22	NUM
admet-328	105	3	]	]	PUNCT
admet-328	105	4	.	.	PUNCT
admet-328	106	1	results	result	VERB
admet-328	106	2	lc	lc	PROPN
admet-328	106	3	-	-	PUNCT
admet-328	106	4	ms	ms	PROPN
admet-328	106	5	/	/	SYM
admet-328	106	6	ms	ms	PROPN
admet-328	106	7	analytical	analytical	ADJ
admet-328	106	8	method	method	NOUN
admet-328	106	9	validation	validation	NOUN
admet-328	106	10	the	the	DET
admet-328	106	11	analysis	analysis	NOUN
admet-328	106	12	of	of	ADP
admet-328	106	13	plasma	plasma	NOUN
admet-328	106	14	samples	sample	NOUN
admet-328	106	15	was	be	AUX
admet-328	106	16	completed	complete	VERB
admet-328	106	17	after	after	ADP
admet-328	106	18	thorough	thorough	ADJ
admet-328	106	19	validation	validation	NOUN
admet-328	106	20	of	of	ADP
admet-328	106	21	lc	lc	PROPN
admet-328	106	22	-	-	PUNCT
admet-328	106	23	ms	ms	PROPN
admet-328	106	24	/	/	SYM
admet-328	106	25	ms	ms	PROPN
admet-328	106	26	method	method	NOUN
admet-328	106	27	.	.	PUNCT
admet-328	107	1	no	no	DET
admet-328	107	2	interfering	interfere	VERB
admet-328	107	3	peaks	peak	NOUN
admet-328	107	4	were	be	AUX
admet-328	107	5	observed	observe	VERB
admet-328	107	6	in	in	ADP
admet-328	107	7	blank	blank	ADJ
admet-328	107	8	plasma	plasma	NOUN
admet-328	107	9	chromatograms	chromatogram	NOUN
admet-328	107	10	at	at	ADP
admet-328	107	11	atazanavir	atazanavir	PROPN
admet-328	107	12	and	and	CCONJ
admet-328	107	13	repaglinide	repaglinide	PROPN
admet-328	107	14	retention	retention	NOUN
admet-328	107	15	time	time	NOUN
admet-328	107	16	indicating	indicate	VERB
admet-328	107	17	the	the	DET
admet-328	107	18	selectivity	selectivity	NOUN
admet-328	107	19	of	of	ADP
admet-328	107	20	the	the	DET
admet-328	107	21	present	present	ADJ
admet-328	107	22	method	method	NOUN
admet-328	107	23	.	.	PUNCT
admet-328	108	1	the	the	DET
admet-328	108	2	calibration	calibration	NOUN
admet-328	108	3	curves	curve	NOUN
admet-328	108	4	and	and	CCONJ
admet-328	108	5	linearity	linearity	NOUN
admet-328	108	6	of	of	ADP
admet-328	108	7	repaglinide	repaglinide	NOUN
admet-328	108	8	(	(	PUNCT
admet-328	108	9	19.5	19.5	NUM
admet-328	108	10	-	-	SYM
admet-328	108	11	20000	20000	NUM
admet-328	108	12	ng	ng	PROPN
admet-328	108	13	/	/	SYM
admet-328	108	14	ml	ml	PROPN
admet-328	108	15	)	)	PUNCT
admet-328	108	16	and	and	CCONJ
admet-328	108	17	atazanavir	atazanavir	PROPN
admet-328	108	18	(	(	PUNCT
admet-328	108	19	19	19	NUM
admet-328	108	20	-	-	SYM
admet-328	108	21	20000	20000	NUM
admet-328	108	22	ng	ng	PROPN
admet-328	108	23	/	/	SYM
admet-328	108	24	ml	ml	NOUN
admet-328	108	25	)	)	PUNCT
admet-328	108	26	samples	sample	NOUN
admet-328	108	27	was	be	AUX
admet-328	108	28	determined	determine	VERB
admet-328	108	29	using	use	VERB
admet-328	108	30	weighted	weight	VERB
admet-328	108	31	(	(	PUNCT
admet-328	108	32	1	1	NUM
admet-328	108	33	/	/	SYM
admet-328	108	34	x2	x2	ADJ
admet-328	108	35	)	)	PUNCT
admet-328	108	36	linear	linear	ADJ
admet-328	108	37	regression	regression	NOUN
admet-328	108	38	analysis	analysis	NOUN
admet-328	108	39	.	.	PUNCT
admet-328	109	1	the	the	DET
admet-328	109	2	correlation	correlation	NOUN
admet-328	109	3	coefficients	coefficient	NOUN
admet-328	109	4	were	be	AUX
admet-328	109	5	0.994	0.994	NUM
admet-328	109	6	for	for	ADP
admet-328	109	7	calibration	calibration	NOUN
admet-328	109	8	curves	curve	NOUN
admet-328	109	9	.	.	PUNCT
admet-328	110	1	the	the	DET
admet-328	110	2	retention	retention	NOUN
admet-328	110	3	times	time	NOUN
admet-328	110	4	for	for	ADP
admet-328	110	5	atazanavir	atazanavir	PROPN
admet-328	110	6	,	,	PUNCT
admet-328	110	7	repaglinide	repaglinide	NOUN
admet-328	110	8	and	and	CCONJ
admet-328	110	9	internal	internal	ADJ
admet-328	110	10	standard	standard	NOUN
admet-328	110	11	were	be	AUX
admet-328	110	12	3.0	3.0	NUM
admet-328	110	13	,	,	PUNCT
admet-328	110	14	3.5	3.5	NUM
admet-328	110	15	and	and	CCONJ
admet-328	110	16	3.3	3.3	NUM
admet-328	110	17	min	min	NOUN
admet-328	110	18	,	,	PUNCT
admet-328	110	19	respectively	respectively	ADV
admet-328	110	20	.	.	PUNCT
admet-328	111	1	quality	quality	NOUN
admet-328	111	2	control	control	PROPN
admet-328	111	3	(	(	PUNCT
admet-328	111	4	qc	qc	PROPN
admet-328	111	5	)	)	PUNCT
admet-328	111	6	samples	sample	NOUN
admet-328	111	7	were	be	AUX
admet-328	111	8	prepared	prepare	VERB
admet-328	111	9	at	at	ADP
admet-328	111	10	low	low	ADJ
admet-328	111	11	,	,	PUNCT
admet-328	111	12	medium	medium	ADJ
admet-328	111	13	,	,	PUNCT
admet-328	111	14	and	and	CCONJ
admet-328	111	15	high	high	ADJ
admet-328	111	16	concentrations	concentration	NOUN
admet-328	111	17	to	to	PART
admet-328	111	18	assess	assess	VERB
admet-328	111	19	accuracy	accuracy	NOUN
admet-328	111	20	,	,	PUNCT
admet-328	111	21	precision	precision	NOUN
admet-328	111	22	and	and	CCONJ
admet-328	111	23	recovery	recovery	NOUN
admet-328	111	24	.	.	PUNCT
admet-328	112	1	intraday	intraday	NOUN
admet-328	112	2	precision	precision	NOUN
admet-328	112	3	from	from	ADP
admet-328	112	4	a	a	DET
admet-328	112	5	measurement	measurement	NOUN
admet-328	112	6	of	of	ADP
admet-328	112	7	a	a	DET
admet-328	112	8	minimum	minimum	NOUN
admet-328	112	9	of	of	ADP
admet-328	112	10	six	six	NUM
admet-328	112	11	replicates	replicate	NOUN
admet-328	112	12	was	be	AUX
admet-328	112	13	<	<	X
admet-328	112	14	7.1	7.1	NUM
admet-328	112	15	%	%	NOUN
admet-328	112	16	in	in	ADP
admet-328	112	17	rat	rat	NOUN
admet-328	112	18	plasma	plasma	NOUN
admet-328	112	19	.	.	PUNCT
admet-328	113	1	the	the	DET
admet-328	113	2	inter	inter	ADJ
admet-328	113	3	-	-	ADJ
admet-328	113	4	day	day	ADJ
admet-328	113	5	precision	precision	NOUN
admet-328	113	6	was	be	AUX
admet-328	113	7	determined	determine	VERB
admet-328	113	8	from	from	ADP
admet-328	113	9	analysis	analysis	NOUN
admet-328	113	10	of	of	ADP
admet-328	113	11	standard	standard	ADJ
admet-328	113	12	samples	sample	NOUN
admet-328	113	13	on	on	ADP
admet-328	113	14	three	three	NUM
admet-328	113	15	consecutive	consecutive	ADJ
admet-328	113	16	days	day	NOUN
admet-328	113	17	and	and	CCONJ
admet-328	113	18	the	the	DET
admet-328	113	19	relative	relative	ADJ
admet-328	113	20	standard	standard	ADJ
admet-328	113	21	deviation	deviation	NOUN
admet-328	113	22	was	be	AUX
admet-328	113	23	found	find	VERB
admet-328	113	24	to	to	PART
admet-328	113	25	be	be	AUX
admet-328	113	26	<	<	X
admet-328	113	27	6.9	6.9	NUM
admet-328	113	28	%	%	NOUN
admet-328	113	29	and	and	CCONJ
admet-328	113	30	<	<	X
admet-328	113	31	9	9	NUM
admet-328	113	32	%	%	NOUN
admet-328	113	33	for	for	ADP
admet-328	113	34	atazanavir	atazanavir	PROPN
admet-328	113	35	and	and	CCONJ
admet-328	113	36	repaglinide	repaglinide	NOUN
admet-328	113	37	,	,	PUNCT
admet-328	113	38	respectively	respectively	ADV
admet-328	113	39	.	.	PUNCT
admet-328	114	1	the	the	DET
admet-328	114	2	overall	overall	ADJ
admet-328	114	3	accuracy	accuracy	NOUN
admet-328	114	4	of	of	ADP
admet-328	114	5	qc	qc	PROPN
admet-328	114	6	samples	sample	NOUN
admet-328	114	7	was	be	AUX
admet-328	114	8	in	in	ADP
admet-328	114	9	the	the	DET
admet-328	114	10	range	range	NOUN
admet-328	114	11	of	of	ADP
admet-328	114	12	90	90	NUM
admet-328	114	13	-	-	SYM
admet-328	114	14	110	110	NUM
admet-328	114	15	%	%	NOUN
admet-328	114	16	.	.	PUNCT
admet-328	115	1	percentage	percentage	NOUN
admet-328	115	2	recovery	recovery	NOUN
admet-328	115	3	was	be	AUX
admet-328	115	4	calculated	calculate	VERB
admet-328	115	5	as	as	ADP
admet-328	115	6	a	a	DET
admet-328	115	7	ratio	ratio	NOUN
admet-328	115	8	of	of	ADP
admet-328	115	9	the	the	DET
admet-328	115	10	peak	peak	NOUN
admet-328	115	11	areas	area	NOUN
admet-328	115	12	of	of	ADP
admet-328	115	13	drug	drug	NOUN
admet-328	115	14	in	in	ADP
admet-328	115	15	the	the	DET
admet-328	115	16	matrix	matrix	NOUN
admet-328	115	17	and	and	CCONJ
admet-328	115	18	the	the	DET
admet-328	115	19	corresponding	correspond	VERB
admet-328	115	20	peak	peak	NOUN
admet-328	115	21	area	area	NOUN
admet-328	115	22	of	of	ADP
admet-328	115	23	drug	drug	NOUN
admet-328	115	24	in	in	ADP
admet-328	115	25	acetonitrile	acetonitrile	NOUN
admet-328	115	26	.	.	PUNCT
admet-328	116	1	in	in	ADP
admet-328	116	2	plasma	plasma	NOUN
admet-328	116	3	samples	sample	NOUN
admet-328	116	4	,	,	PUNCT
admet-328	116	5	greater	great	ADJ
admet-328	116	6	than	than	ADP
admet-328	116	7	85	85	NUM
admet-328	116	8	%	%	NOUN
admet-328	116	9	drug	drug	NOUN
admet-328	116	10	recovery	recovery	NOUN
admet-328	116	11	was	be	AUX
admet-328	116	12	accomplished	accomplish	VERB
admet-328	116	13	for	for	ADP
admet-328	116	14	both	both	CCONJ
admet-328	116	15	atazanavir	atazanavir	PROPN
admet-328	116	16	and	and	CCONJ
admet-328	116	17	repaglinide	repaglinide	NOUN
admet-328	116	18	.	.	PUNCT
admet-328	117	1	the	the	DET
admet-328	117	2	lower	low	ADJ
admet-328	117	3	limit	limit	NOUN
admet-328	117	4	of	of	ADP
admet-328	117	5	quantification	quantification	NOUN
admet-328	117	6	(	(	PUNCT
admet-328	117	7	loq	loq	PROPN
admet-328	117	8	)	)	PUNCT
admet-328	117	9	was	be	AUX
admet-328	117	10	determined	determine	VERB
admet-328	117	11	based	base	VERB
admet-328	117	12	on	on	ADP
admet-328	117	13	intra	intra	ADJ
admet-328	117	14	-	-	ADJ
admet-328	117	15	run	run	ADJ
admet-328	117	16	accuracy	accuracy	NOUN
admet-328	117	17	of	of	ADP
admet-328	117	18	loq	loq	PROPN
admet-328	117	19	replicates	replicate	NOUN
admet-328	117	20	.	.	PUNCT
admet-328	118	1	the	the	DET
admet-328	118	2	tested	test	VERB
admet-328	118	3	loq	loq	PROPN
admet-328	118	4	values	value	NOUN
admet-328	118	5	were	be	AUX
admet-328	118	6	9	9	NUM
admet-328	118	7	ng	ng	NOUN
admet-328	118	8	/	/	SYM
admet-328	118	9	ml	ml	PROPN
admet-328	118	10	and	and	CCONJ
admet-328	118	11	19.5	19.5	NUM
admet-328	118	12	ng	ng	NOUN
admet-328	118	13	/	/	SYM
admet-328	118	14	ml	ml	X
admet-328	118	15	for	for	ADP
admet-328	118	16	repaglinide	repaglinide	NOUN
admet-328	118	17	and	and	CCONJ
admet-328	118	18	atazanavir	atazanavir	PROPN
admet-328	118	19	,	,	PUNCT
admet-328	118	20	respectively	respectively	ADV
admet-328	118	21	,	,	PUNCT
admet-328	118	22	in	in	ADP
admet-328	118	23	rat	rat	NOUN
admet-328	118	24	plasma	plasma	NOUN
admet-328	118	25	.	.	PUNCT
admet-328	119	1	thirumaleswara	thirumaleswara	PROPN
admet-328	119	2	goud	goud	PROPN
admet-328	119	3	et	et	PROPN
admet-328	119	4	al	al	PROPN
admet-328	119	5	.	.	PROPN
admet-328	119	6	admet	admet	PROPN
admet-328	119	7	&	&	CCONJ
admet-328	119	8	dmpk	dmpk	PROPN
admet-328	119	9	4(3	4(3	NUM
admet-328	119	10	)	)	PUNCT
admet-328	119	11	(	(	PUNCT
admet-328	119	12	2016	2016	NUM
admet-328	119	13	)	)	PUNCT
admet-328	119	14	269	269	NUM
admet-328	119	15	-	-	SYM
admet-328	119	16	279	279	NUM
admet-328	119	17	274	274	NUM
admet-328	119	18	effect	effect	NOUN
admet-328	119	19	of	of	ADP
admet-328	119	20	atazanavir	atazanavir	PROPN
admet-328	119	21	on	on	ADP
admet-328	119	22	the	the	DET
admet-328	119	23	pharmacokinetics	pharmacokinetic	NOUN
admet-328	119	24	and	and	CCONJ
admet-328	119	25	pharmacodynamics	pharmacodynamic	NOUN
admet-328	119	26	of	of	ADP
admet-328	119	27	repaglinide	repaglinide	NOUN
admet-328	119	28	in	in	ADP
admet-328	119	29	normal	normal	ADJ
admet-328	119	30	rat	rat	NOUN
admet-328	119	31	mean	mean	ADJ
admet-328	119	32	plasma	plasma	NOUN
admet-328	119	33	concentration	concentration	NOUN
admet-328	119	34	of	of	ADP
admet-328	119	35	repaglinide	repaglinide	NOUN
admet-328	119	36	in	in	ADP
admet-328	119	37	the	the	DET
admet-328	119	38	absence	absence	NOUN
admet-328	119	39	and	and	CCONJ
admet-328	119	40	presence	presence	NOUN
admet-328	119	41	of	of	ADP
admet-328	119	42	atazanavir	atazanavir	PROPN
admet-328	119	43	in	in	ADP
admet-328	119	44	normal	normal	ADJ
admet-328	119	45	rats	rat	NOUN
admet-328	119	46	is	be	AUX
admet-328	119	47	shown	show	VERB
admet-328	119	48	in	in	ADP
admet-328	119	49	figure	figure	NOUN
admet-328	119	50	1	1	NUM
admet-328	119	51	.	.	PUNCT
admet-328	120	1	mean	mean	VERB
admet-328	120	2	pharmacokinetic	pharmacokinetic	ADJ
admet-328	120	3	parameters	parameter	NOUN
admet-328	120	4	of	of	ADP
admet-328	120	5	repaglinide	repaglinide	NOUN
admet-328	120	6	alone	alone	ADV
admet-328	120	7	and	and	CCONJ
admet-328	120	8	in	in	ADP
admet-328	120	9	the	the	DET
admet-328	120	10	presence	presence	NOUN
admet-328	120	11	of	of	ADP
admet-328	120	12	atazanavir	atazanavir	PROPN
admet-328	120	13	in	in	ADP
admet-328	120	14	normal	normal	ADJ
admet-328	120	15	rats	rat	NOUN
admet-328	120	16	were	be	AUX
admet-328	120	17	shown	show	VERB
admet-328	120	18	in	in	ADP
admet-328	120	19	table	table	NOUN
admet-328	120	20	1	1	NUM
admet-328	120	21	(	(	PUNCT
admet-328	120	22	column	column	NOUN
admet-328	120	23	i	i	PROPN
admet-328	120	24	and	and	CCONJ
admet-328	120	25	ii	ii	NUM
admet-328	120	26	)	)	PUNCT
admet-328	120	27	.	.	PUNCT
admet-328	121	1	the	the	DET
admet-328	121	2	pharmacokinetic	pharmacokinetic	ADJ
admet-328	121	3	parameters	parameter	NOUN
admet-328	121	4	of	of	ADP
admet-328	121	5	repaglinide	repaglinide	NOUN
admet-328	121	6	like	like	ADP
admet-328	121	7	auc	auc	NOUN
admet-328	121	8	,	,	PUNCT
admet-328	121	9	cmax	cmax	NOUN
admet-328	121	10	,	,	PUNCT
admet-328	121	11	and	and	CCONJ
admet-328	121	12	clearance	clearance	NOUN
admet-328	121	13	were	be	AUX
admet-328	121	14	altered	alter	VERB
admet-328	121	15	significantly	significantly	ADV
admet-328	121	16	with	with	ADP
admet-328	121	17	single	single	ADJ
admet-328	121	18	dose	dose	NOUN
admet-328	121	19	treatment	treatment	NOUN
admet-328	121	20	of	of	ADP
admet-328	121	21	atazanavir	atazanavir	PROPN
admet-328	121	22	in	in	ADP
admet-328	121	23	normal	normal	ADJ
admet-328	121	24	rats	rat	NOUN
admet-328	121	25	when	when	SCONJ
admet-328	121	26	compared	compare	VERB
admet-328	121	27	to	to	PART
admet-328	121	28	repaglinide	repaglinide	NOUN
admet-328	121	29	treated	treat	VERB
admet-328	121	30	group	group	NOUN
admet-328	121	31	.	.	PUNCT
admet-328	122	1	compared	compare	VERB
admet-328	122	2	to	to	ADP
admet-328	122	3	the	the	DET
admet-328	122	4	repaglinide	repaglinide	PROPN
admet-328	122	5	control	control	PROPN
admet-328	122	6	group	group	PROPN
admet-328	122	7	(	(	PUNCT
admet-328	122	8	repaglinide	repaglinide	NOUN
admet-328	122	9	alone	alone	ADV
admet-328	122	10	)	)	PUNCT
admet-328	122	11	atazanavir	atazanavir	PROPN
admet-328	122	12	increased	increase	VERB
admet-328	122	13	2	2	NUM
admet-328	122	14	-	-	ADJ
admet-328	122	15	fold	fold	ADJ
admet-328	122	16	peak	peak	NOUN
admet-328	122	17	plasma	plasma	NOUN
admet-328	122	18	concentration	concentration	NOUN
admet-328	122	19	(	(	PUNCT
admet-328	122	20	cmax	cmax	NOUN
admet-328	122	21	)	)	PUNCT
admet-328	122	22	,	,	PUNCT
admet-328	122	23	11	11	NUM
admet-328	122	24	-	-	ADJ
admet-328	122	25	fold	fold	ADJ
admet-328	122	26	area	area	NOUN
admet-328	122	27	under	under	ADP
admet-328	122	28	the	the	DET
admet-328	122	29	plasma	plasma	NOUN
admet-328	122	30	concentration	concentration	NOUN
admet-328	122	31	time	time	NOUN
admet-328	122	32	curve	curve	NOUN
admet-328	122	33	(	(	PUNCT
admet-328	122	34	auc0	auc0	PROPN
admet-328	122	35	-	-	PUNCT
admet-328	122	36	t	t	PROPN
admet-328	122	37	and	and	CCONJ
admet-328	122	38	auc0-∞	auc0-∞	NUM
admet-328	122	39	)	)	PUNCT
admet-328	122	40	of	of	ADP
admet-328	122	41	repaglinide	repaglinide	NOUN
admet-328	122	42	and	and	CCONJ
admet-328	122	43	atazanavir	atazanavir	PROPN
admet-328	122	44	relative	relative	ADJ
admet-328	122	45	decrease	decrease	NOUN
admet-328	122	46	in	in	ADP
admet-328	122	47	the	the	DET
admet-328	122	48	total	total	ADJ
admet-328	122	49	body	body	NOUN
admet-328	122	50	clearance	clearance	NOUN
admet-328	122	51	by	by	ADP
admet-328	122	52	6	6	NUM
admet-328	122	53	folds	fold	NOUN
admet-328	122	54	.	.	PUNCT
admet-328	123	1	repaglinide	repaglinide	PROPN
admet-328	123	2	produced	produce	VERB
admet-328	123	3	a	a	DET
admet-328	123	4	hypoglycemic	hypoglycemic	ADJ
admet-328	123	5	effect	effect	NOUN
admet-328	123	6	which	which	PRON
admet-328	123	7	was	be	AUX
admet-328	123	8	indicated	indicate	VERB
admet-328	123	9	by	by	ADP
admet-328	123	10	percentage	percentage	NOUN
admet-328	123	11	reduction	reduction	NOUN
admet-328	123	12	levels	level	NOUN
admet-328	123	13	in	in	ADP
admet-328	123	14	normal	normal	ADJ
admet-328	123	15	rats	rat	NOUN
admet-328	123	16	.	.	PUNCT
admet-328	124	1	the	the	DET
admet-328	124	2	hypoglycemic	hypoglycemic	ADJ
admet-328	124	3	effect	effect	NOUN
admet-328	124	4	of	of	ADP
admet-328	124	5	repaglinide	repaglinide	NOUN
admet-328	124	6	enhanced	enhance	VERB
admet-328	124	7	when	when	SCONJ
admet-328	124	8	given	give	VERB
admet-328	124	9	in	in	ADP
admet-328	124	10	combination	combination	NOUN
admet-328	124	11	with	with	ADP
admet-328	124	12	atazanavir	atazanavir	PROPN
admet-328	124	13	.	.	PUNCT
admet-328	125	1	it	it	PRON
admet-328	125	2	was	be	AUX
admet-328	125	3	indicated	indicate	VERB
admet-328	125	4	by	by	ADP
admet-328	125	5	a	a	DET
admet-328	125	6	significant	significant	ADJ
admet-328	125	7	increase	increase	NOUN
admet-328	125	8	in	in	ADP
admet-328	125	9	percentage	percentage	NOUN
admet-328	125	10	glucose	glucose	NOUN
admet-328	125	11	reduction	reduction	NOUN
admet-328	125	12	in	in	ADP
admet-328	125	13	comparison	comparison	NOUN
admet-328	125	14	to	to	PART
admet-328	125	15	repaglinide	repaglinide	VERB
admet-328	125	16	alone	alone	ADV
admet-328	125	17	treated	treat	VERB
admet-328	125	18	group	group	NOUN
admet-328	125	19	in	in	ADP
admet-328	125	20	normal	normal	ADJ
admet-328	125	21	rats	rat	NOUN
admet-328	125	22	were	be	AUX
admet-328	125	23	shown	show	VERB
admet-328	125	24	in	in	ADP
admet-328	125	25	table	table	NOUN
admet-328	125	26	2	2	NUM
admet-328	125	27	and	and	CCONJ
admet-328	125	28	figure	figure	VERB
admet-328	125	29	4	4	NUM
admet-328	125	30	.	.	PUNCT
admet-328	125	31	figure	figure	NOUN
admet-328	125	32	1	1	NUM
admet-328	125	33	.	.	PUNCT
admet-328	126	1	plasma	plasma	NOUN
admet-328	126	2	concentration	concentration	NOUN
admet-328	126	3	-	-	PUNCT
admet-328	126	4	time	time	NOUN
admet-328	126	5	curves	curve	NOUN
admet-328	126	6	of	of	ADP
admet-328	126	7	repaglinide	repaglinide	NOUN
admet-328	126	8	following	follow	VERB
admet-328	126	9	its	its	PRON
admet-328	126	10	oral	oral	ADJ
admet-328	126	11	administration	administration	NOUN
admet-328	126	12	(	(	PUNCT
admet-328	126	13	0.5	0.5	NUM
admet-328	126	14	mg	mg	PROPN
admet-328	126	15	/	/	SYM
admet-328	126	16	kg	kg	NOUN
admet-328	126	17	)	)	PUNCT
admet-328	126	18	in	in	ADP
admet-328	126	19	control	control	NOUN
admet-328	126	20	and	and	CCONJ
admet-328	126	21	atazanavir	atazanavir	PROPN
admet-328	126	22	(	(	PUNCT
admet-328	126	23	36	36	NUM
admet-328	126	24	mg	mg	PROPN
admet-328	126	25	/	/	SYM
admet-328	126	26	kg	kg	NOUN
admet-328	126	27	)	)	PUNCT
admet-328	126	28	pretreated	pretreate	VERB
admet-328	126	29	normal	normal	ADJ
admet-328	126	30	rats	rat	NOUN
admet-328	126	31	.	.	PUNCT
admet-328	127	1	data	datum	NOUN
admet-328	127	2	are	be	AUX
admet-328	127	3	expressed	express	VERB
admet-328	127	4	as	as	ADP
admet-328	127	5	mean	mean	ADJ
admet-328	127	6	±sd	±sd	NOUN
admet-328	127	7	in	in	ADP
admet-328	127	8	six	six	NUM
admet-328	127	9	rats	rat	NOUN
admet-328	127	10	.	.	PUNCT
admet-328	128	1	table	table	NOUN
admet-328	128	2	1	1	NUM
admet-328	128	3	.	.	PUNCT
admet-328	129	1	plasma	plasma	NOUN
admet-328	129	2	concentration	concentration	NOUN
admet-328	129	3	time	time	NOUN
admet-328	129	4	profiles	profile	NOUN
admet-328	129	5	of	of	ADP
admet-328	129	6	repaglinide	repaglinide	NOUN
admet-328	129	7	following	follow	VERB
admet-328	129	8	its	its	PRON
admet-328	129	9	oral	oral	ADJ
admet-328	129	10	administration	administration	NOUN
admet-328	129	11	at	at	ADP
admet-328	129	12	0.5	0.5	NUM
admet-328	129	13	mg	mg	PROPN
admet-328	129	14	/	/	SYM
admet-328	129	15	kg	kg	PROPN
admet-328	129	16	in	in	ADP
admet-328	129	17	control	control	NOUN
admet-328	129	18	and	and	CCONJ
admet-328	129	19	atazanavir	atazanavir	PROPN
admet-328	129	20	(	(	PUNCT
admet-328	129	21	36	36	NUM
admet-328	129	22	mg	mg	PROPN
admet-328	129	23	/	/	SYM
admet-328	129	24	kg	kg	NOUN
admet-328	129	25	)	)	PUNCT
admet-328	129	26	pretreated	pretreate	VERB
admet-328	129	27	normal	normal	ADJ
admet-328	129	28	,	,	PUNCT
admet-328	129	29	diabetic	diabetic	ADJ
admet-328	129	30	and	and	CCONJ
admet-328	129	31	hepatic	hepatic	ADJ
admet-328	129	32	impaired	impaired	ADJ
admet-328	129	33	rats	rat	NOUN
admet-328	129	34	.	.	PUNCT
admet-328	130	1	data	datum	NOUN
admet-328	130	2	are	be	AUX
admet-328	130	3	expressed	express	VERB
admet-328	130	4	as	as	ADP
admet-328	130	5	mean	mean	PROPN
admet-328	130	6	±s.d	±s.d	PROPN
admet-328	130	7	.	.	PUNCT
admet-328	131	1	in	in	ADP
admet-328	131	2	(	(	PUNCT
admet-328	131	3	n=6	n=6	NOUN
admet-328	131	4	)	)	PUNCT
admet-328	131	5	rats	rat	NOUN
admet-328	131	6	.	.	PUNCT
admet-328	132	1	pharmacokinetic	pharmacokinetic	ADJ
admet-328	132	2	parameters	parameter	NOUN
admet-328	132	3	repaglinide	repaglinide	VERB
admet-328	132	4	alone	alone	ADV
admet-328	132	5	(	(	PUNCT
admet-328	132	6	control	control	NOUN
admet-328	132	7	)	)	PUNCT
admet-328	132	8	repaglinide	repaglinide	NOUN
admet-328	132	9	in	in	ADP
admet-328	132	10	the	the	DET
admet-328	132	11	presence	presence	NOUN
admet-328	132	12	of	of	ADP
admet-328	132	13	atazanavir	atazanavir	PROPN
admet-328	132	14	in	in	ADP
admet-328	132	15	normal	normal	ADJ
admet-328	132	16	rats	rat	NOUN
admet-328	132	17	repaglinide	repaglinide	ADV
admet-328	132	18	in	in	ADP
admet-328	132	19	the	the	DET
admet-328	132	20	presence	presence	NOUN
admet-328	132	21	of	of	ADP
admet-328	132	22	atazanavir	atazanavir	PROPN
admet-328	132	23	in	in	ADP
admet-328	132	24	diabetic	diabetic	ADJ
admet-328	132	25	rats	rat	NOUN
admet-328	132	26	repaglinide	repaglinide	ADV
admet-328	132	27	in	in	ADP
admet-328	132	28	the	the	DET
admet-328	132	29	presence	presence	NOUN
admet-328	132	30	of	of	ADP
admet-328	132	31	atazanavir	atazanavir	PROPN
admet-328	132	32	in	in	ADP
admet-328	132	33	hepatic	hepatic	ADJ
admet-328	132	34	impaired	impaired	ADJ
admet-328	132	35	rats	rat	NOUN
admet-328	132	36	cmax	cmax	NOUN
admet-328	132	37	(	(	PUNCT
admet-328	132	38	ng	ng	NOUN
admet-328	132	39	/	/	SYM
admet-328	132	40	ml	ml	PROPN
admet-328	132	41	)	)	PUNCT
admet-328	132	42	536	536	NUM
admet-328	132	43	±	±	NUM
admet-328	132	44	30	30	NUM
admet-328	132	45	1089	1089	NUM
admet-328	132	46	±	±	NUM
admet-328	132	47	123	123	NUM
admet-328	132	48	*	*	PUNCT
admet-328	132	49	*	*	PUNCT
admet-328	132	50	*	*	X
admet-328	132	51	2753	2753	NUM
admet-328	132	52	±	±	NUM
admet-328	132	53	7	7	NUM
admet-328	132	54	*	*	PUNCT
admet-328	132	55	*	*	PUNCT
admet-328	132	56	*	*	SYM
admet-328	132	57	3410	3410	NUM
admet-328	132	58	±	±	NUM
admet-328	132	59	64	64	NUM
admet-328	132	60	*	*	PUNCT
admet-328	132	61	*	*	PUNCT
admet-328	132	62	*	*	PUNCT
admet-328	132	63	tmax	tmax	X
admet-328	132	64	(	(	PUNCT
admet-328	132	65	h	h	NOUN
admet-328	132	66	)	)	PUNCT
admet-328	132	67	0.25	0.25	NUM
admet-328	132	68	±	±	NUM
admet-328	132	69	0.00	0.00	NUM
admet-328	132	70	4.0	4.0	NUM
admet-328	132	71	±	±	NOUN
admet-328	132	72	0.0	0.0	NUM
admet-328	132	73	*	*	PUNCT
admet-328	132	74	*	*	PUNCT
admet-328	132	75	4.0	4.0	NUM
admet-328	132	76	±	±	NOUN
admet-328	132	77	0.0	0.0	NUM
admet-328	132	78	*	*	PUNCT
admet-328	132	79	*	*	SYM
admet-328	132	80	0.5	0.5	NUM
admet-328	132	81	±	±	NUM
admet-328	132	82	0.0	0.0	NUM
admet-328	132	83	auc0	auc0	PROPN
admet-328	132	84	-	-	PUNCT
admet-328	132	85	t	t	PROPN
admet-328	132	86	(	(	PUNCT
admet-328	132	87	ng	ng	PROPN
admet-328	132	88	/	/	SYM
admet-328	132	89	ml.h	ml.h	NOUN
admet-328	132	90	)	)	PUNCT
admet-328	132	91	678	678	NUM
admet-328	132	92	±	±	NUM
admet-328	132	93	51	51	NUM
admet-328	132	94	8031	8031	NUM
admet-328	132	95	±	±	NUM
admet-328	132	96	274	274	NUM
admet-328	132	97	*	*	PUNCT
admet-328	132	98	*	*	PUNCT
admet-328	132	99	*	*	X
admet-328	132	100	12602	12602	NUM
admet-328	132	101	±	±	NUM
admet-328	132	102	227	227	NUM
admet-328	132	103	*	*	PUNCT
admet-328	132	104	*	*	PUNCT
admet-328	132	105	*	*	X
admet-328	132	106	18301	18301	NUM
admet-328	132	107	±	±	NUM
admet-328	132	108	151	151	NUM
admet-328	132	109	*	*	PUNCT
admet-328	132	110	*	*	PUNCT
admet-328	132	111	*	*	PUNCT
admet-328	132	112	auctotal(ng	auctotal(ng	PROPN
admet-328	132	113	/	/	SYM
admet-328	132	114	ml.h	ml.h	NOUN
admet-328	132	115	)	)	PUNCT
admet-328	132	116	726	726	NUM
admet-328	132	117	±	±	NUM
admet-328	132	118	55	55	NUM
admet-328	132	119	8044	8044	NUM
admet-328	132	120	±	±	NUM
admet-328	132	121	265	265	NUM
admet-328	132	122	*	*	PUNCT
admet-328	132	123	*	*	PUNCT
admet-328	132	124	*	*	X
admet-328	132	125	12722	12722	NUM
admet-328	132	126	±	±	NUM
admet-328	133	1	209	209	NUM
admet-328	133	2	*	*	PUNCT
admet-328	133	3	*	*	PUNCT
admet-328	133	4	*	*	X
admet-328	133	5	19101	19101	NUM
admet-328	133	6	±	±	NOUN
admet-328	133	7	184	184	NUM
admet-328	133	8	*	*	PUNCT
admet-328	133	9	*	*	PUNCT
admet-328	133	10	*	*	PUNCT
admet-328	133	11	oral	oral	ADJ
admet-328	133	12	t1/2	t1/2	NOUN
admet-328	133	13	(	(	PUNCT
admet-328	133	14	h	h	NOUN
admet-328	133	15	)	)	PUNCT
admet-328	133	16	3.0	3.0	NUM
admet-328	133	17	±	±	NUM
admet-328	133	18	0.1	0.1	NUM
admet-328	133	19	2.6	2.6	NUM
admet-328	133	20	±	±	NUM
admet-328	133	21	0.1	0.1	NUM
admet-328	133	22	3.5±	3.5±	NUM
admet-328	133	23	0.1	0.1	NUM
admet-328	133	24	6.2	6.2	NUM
admet-328	133	25	±	±	NOUN
admet-328	133	26	0.3	0.3	NUM
admet-328	133	27	*	*	PUNCT
admet-328	133	28	*	*	PUNCT
admet-328	133	29	oral	oral	ADJ
admet-328	133	30	cl	cl	NOUN
admet-328	133	31	(	(	PUNCT
admet-328	133	32	ml	ml	NOUN
admet-328	133	33	/	/	SYM
admet-328	133	34	min	min	NOUN
admet-328	133	35	/	/	SYM
admet-328	133	36	kg	kg	NOUN
admet-328	133	37	)	)	PUNCT
admet-328	133	38	11	11	NUM
admet-328	133	39	±	±	NUM
admet-328	133	40	1	1	NUM
admet-328	133	41	1.03	1.03	NUM
admet-328	133	42	±	±	NUM
admet-328	133	43	0.03	0.03	NUM
admet-328	133	44	*	*	PUNCT
admet-328	133	45	*	*	PUNCT
admet-328	133	46	*	*	PUNCT
admet-328	133	47	0.44	0.44	NUM
admet-328	133	48	±	±	NUM
admet-328	133	49	0.01	0.01	NUM
admet-328	133	50	*	*	PUNCT
admet-328	133	51	*	*	PUNCT
admet-328	133	52	*	*	PUNCT
admet-328	133	53	0.65	0.65	NUM
admet-328	133	54	±	±	NUM
admet-328	133	55	0.01	0.01	NUM
admet-328	133	56	*	*	PUNCT
admet-328	133	57	*	*	PUNCT
admet-328	133	58	*	*	PUNCT
admet-328	134	1	*	*	PUNCT
admet-328	134	2	*	*	PUNCT
admet-328	134	3	*	*	PUNCT
admet-328	134	4	significant	significant	ADJ
admet-328	134	5	at	at	ADP
admet-328	134	6	p<0.0001	p<0.0001	NOUN
admet-328	134	7	compared	compare	VERB
admet-328	134	8	to	to	ADP
admet-328	134	9	repaglinide	repaglinide	NOUN
admet-328	134	10	control	control	NOUN
admet-328	134	11	(	(	PUNCT
admet-328	134	12	alone	alone	ADV
admet-328	134	13	)	)	PUNCT
admet-328	134	14	group	group	NOUN
admet-328	134	15	.	.	PUNCT
admet-328	135	1	*	*	PUNCT
admet-328	135	2	*	*	PUNCT
admet-328	135	3	significant	significant	ADJ
admet-328	135	4	at	at	ADP
admet-328	135	5	p<0.0001	p<0.0001	NOUN
admet-328	135	6	compared	compare	VERB
admet-328	135	7	to	to	ADP
admet-328	135	8	repaglinide	repaglinide	NOUN
admet-328	135	9	control	control	NOUN
admet-328	135	10	(	(	PUNCT
admet-328	135	11	alone	alone	ADV
admet-328	135	12	)	)	PUNCT
admet-328	135	13	group	group	NOUN
admet-328	135	14	admet	admet	PROPN
admet-328	135	15	&	&	CCONJ
admet-328	135	16	dmpk	dmpk	PROPN
admet-328	135	17	4(3	4(3	NUM
admet-328	135	18	)	)	PUNCT
admet-328	135	19	(	(	PUNCT
admet-328	135	20	2016	2016	NUM
admet-328	135	21	)	)	PUNCT
admet-328	135	22	269	269	NUM
admet-328	135	23	-	-	SYM
admet-328	135	24	279	279	NUM
admet-328	135	25	pk	pk	NOUN
admet-328	135	26	and	and	CCONJ
admet-328	135	27	pd	pd	NOUN
admet-328	135	28	interaction	interaction	NOUN
admet-328	135	29	between	between	ADP
admet-328	135	30	repaglinide	repaglinide	NOUN
admet-328	135	31	and	and	CCONJ
admet-328	135	32	atazanavir	atazanavir	PROPN
admet-328	135	33	doi	doi	PROPN
admet-328	135	34	:	:	PUNCT
admet-328	135	35	10.5599	10.5599	NUM
admet-328	135	36	/	/	SYM
admet-328	135	37	admet.4.3.328	admet.4.3.328	NUM
admet-328	135	38	275	275	NUM
admet-328	135	39	effect	effect	NOUN
admet-328	135	40	of	of	ADP
admet-328	135	41	atazanavir	atazanavir	PROPN
admet-328	135	42	on	on	ADP
admet-328	135	43	the	the	DET
admet-328	135	44	pharmacokinetics	pharmacokinetic	NOUN
admet-328	135	45	and	and	CCONJ
admet-328	135	46	pharmacodynamics	pharmacodynamic	NOUN
admet-328	135	47	of	of	ADP
admet-328	135	48	repaglinide	repaglinide	NOUN
admet-328	135	49	in	in	ADP
admet-328	135	50	diabetic	diabetic	ADJ
admet-328	135	51	rats	rat	NOUN
admet-328	135	52	mean	mean	VERB
admet-328	135	53	plasma	plasma	NOUN
admet-328	135	54	concentration	concentration	NOUN
admet-328	135	55	of	of	ADP
admet-328	135	56	repaglinide	repaglinide	NOUN
admet-328	135	57	in	in	ADP
admet-328	135	58	the	the	DET
admet-328	135	59	absence	absence	NOUN
admet-328	135	60	and	and	CCONJ
admet-328	135	61	presence	presence	NOUN
admet-328	135	62	of	of	ADP
admet-328	135	63	atazanavir	atazanavir	PROPN
admet-328	135	64	in	in	ADP
admet-328	135	65	diabetic	diabetic	ADJ
admet-328	135	66	rats	rat	NOUN
admet-328	135	67	is	be	AUX
admet-328	135	68	shown	show	VERB
admet-328	135	69	in	in	ADP
admet-328	135	70	figures	figure	NOUN
admet-328	135	71	2	2	NUM
admet-328	135	72	&	&	CCONJ
admet-328	135	73	3	3	NUM
admet-328	135	74	.	.	PUNCT
admet-328	136	1	mean	mean	VERB
admet-328	136	2	pharmacokinetic	pharmacokinetic	ADJ
admet-328	136	3	parameters	parameter	NOUN
admet-328	136	4	of	of	ADP
admet-328	136	5	repaglinide	repaglinide	NOUN
admet-328	136	6	and	and	CCONJ
admet-328	136	7	atazanavir	atazanavir	PROPN
admet-328	136	8	in	in	ADP
admet-328	136	9	diabetic	diabetic	ADJ
admet-328	136	10	rats	rat	NOUN
admet-328	136	11	are	be	AUX
admet-328	136	12	shown	show	VERB
admet-328	136	13	in	in	ADP
admet-328	136	14	table	table	NOUN
admet-328	136	15	1	1	NUM
admet-328	136	16	(	(	PUNCT
admet-328	136	17	column	column	NOUN
admet-328	136	18	i	i	PROPN
admet-328	136	19	and	and	CCONJ
admet-328	136	20	iii	iii	NUM
admet-328	136	21	)	)	PUNCT
admet-328	136	22	.	.	PUNCT
admet-328	137	1	the	the	DET
admet-328	137	2	pharmacokinetic	pharmacokinetic	ADJ
admet-328	137	3	parameters	parameter	NOUN
admet-328	137	4	of	of	ADP
admet-328	137	5	repaglinide	repaglinide	NOUN
admet-328	137	6	like	like	ADP
admet-328	137	7	auc	auc	NOUN
admet-328	137	8	,	,	PUNCT
admet-328	137	9	cmax	cmax	NOUN
admet-328	137	10	,	,	PUNCT
admet-328	137	11	and	and	CCONJ
admet-328	137	12	clearance	clearance	NOUN
admet-328	137	13	were	be	AUX
admet-328	137	14	altered	alter	VERB
admet-328	137	15	significantly	significantly	ADV
admet-328	137	16	with	with	ADP
admet-328	137	17	single	single	ADJ
admet-328	137	18	dose	dose	NOUN
admet-328	137	19	treatment	treatment	NOUN
admet-328	137	20	of	of	ADP
admet-328	137	21	atazanavir	atazanavir	PROPN
admet-328	137	22	in	in	ADP
admet-328	137	23	diabetic	diabetic	ADJ
admet-328	137	24	rats	rat	NOUN
admet-328	137	25	when	when	SCONJ
admet-328	137	26	compared	compare	VERB
admet-328	137	27	to	to	PART
admet-328	137	28	repaglinide	repaglinide	NOUN
admet-328	137	29	treated	treat	VERB
admet-328	137	30	group	group	NOUN
admet-328	137	31	.	.	PUNCT
admet-328	138	1	compared	compare	VERB
admet-328	138	2	to	to	ADP
admet-328	138	3	the	the	DET
admet-328	138	4	repaglinide	repaglinide	PROPN
admet-328	138	5	control	control	PROPN
admet-328	138	6	group	group	PROPN
admet-328	138	7	(	(	PUNCT
admet-328	138	8	repaglinide	repaglinide	NOUN
admet-328	138	9	alone	alone	ADV
admet-328	138	10	)	)	PUNCT
admet-328	138	11	atazanavir	atazanavir	PROPN
admet-328	138	12	increased	increase	VERB
admet-328	138	13	5	5	NUM
admet-328	138	14	-	-	ADJ
admet-328	138	15	fold	fold	ADJ
admet-328	138	16	peak	peak	NOUN
admet-328	138	17	plasma	plasma	NOUN
admet-328	138	18	concentration	concentration	NOUN
admet-328	138	19	(	(	PUNCT
admet-328	138	20	cmax	cmax	NOUN
admet-328	138	21	)	)	PUNCT
admet-328	138	22	,	,	PUNCT
admet-328	138	23	18	18	NUM
admet-328	138	24	-	-	ADJ
admet-328	138	25	fold	fold	ADJ
admet-328	138	26	area	area	NOUN
admet-328	138	27	under	under	ADP
admet-328	138	28	the	the	DET
admet-328	138	29	plasma	plasma	NOUN
admet-328	138	30	concentration	concentration	NOUN
admet-328	138	31	time	time	NOUN
admet-328	138	32	curve	curve	NOUN
admet-328	138	33	(	(	PUNCT
admet-328	138	34	auc0-∞	auc0-∞	NUM
admet-328	138	35	)	)	PUNCT
admet-328	138	36	of	of	ADP
admet-328	138	37	repaglinide	repaglinide	NOUN
admet-328	138	38	and	and	CCONJ
admet-328	138	39	atazanavir	atazanavir	PROPN
admet-328	138	40	relatively	relatively	ADV
admet-328	138	41	decreases	decrease	VERB
admet-328	138	42	in	in	ADP
admet-328	138	43	the	the	DET
admet-328	138	44	total	total	ADJ
admet-328	138	45	body	body	NOUN
admet-328	138	46	clearance	clearance	NOUN
admet-328	138	47	by	by	ADP
admet-328	138	48	25fold	25fold	PROPN
admet-328	138	49	.	.	PROPN
admet-328	139	1	repaglinide	repaglinide	PROPN
admet-328	139	2	produced	produce	VERB
admet-328	139	3	a	a	DET
admet-328	139	4	hypoglycemic	hypoglycemic	ADJ
admet-328	139	5	effect	effect	NOUN
admet-328	139	6	indicated	indicate	VERB
admet-328	139	7	by	by	ADP
admet-328	139	8	percentage	percentage	NOUN
admet-328	139	9	reduction	reduction	NOUN
admet-328	139	10	levels	level	NOUN
admet-328	139	11	in	in	ADP
admet-328	139	12	diabetic	diabetic	ADJ
admet-328	139	13	rats	rat	NOUN
admet-328	139	14	.	.	PUNCT
admet-328	140	1	the	the	DET
admet-328	140	2	hypoglycemic	hypoglycemic	ADJ
admet-328	140	3	effect	effect	NOUN
admet-328	140	4	of	of	ADP
admet-328	140	5	repaglinide	repaglinide	NOUN
admet-328	140	6	exaggerated	exaggerated	ADJ
admet-328	140	7	when	when	SCONJ
admet-328	140	8	given	give	VERB
admet-328	140	9	in	in	ADP
admet-328	140	10	combination	combination	NOUN
admet-328	140	11	with	with	ADP
admet-328	140	12	atazanavir	atazanavir	PROPN
admet-328	140	13	,	,	PUNCT
admet-328	140	14	it	it	PRON
admet-328	140	15	was	be	AUX
admet-328	140	16	indicated	indicate	VERB
admet-328	140	17	by	by	ADP
admet-328	140	18	a	a	DET
admet-328	140	19	significant	significant	ADJ
admet-328	140	20	increase	increase	NOUN
admet-328	140	21	in	in	ADP
admet-328	140	22	percentage	percentage	NOUN
admet-328	140	23	glucose	glucose	NOUN
admet-328	140	24	reduction	reduction	NOUN
admet-328	140	25	in	in	ADP
admet-328	140	26	comparison	comparison	NOUN
admet-328	140	27	to	to	PART
admet-328	140	28	repaglinide	repaglinide	VERB
admet-328	140	29	alone	alone	ADV
admet-328	140	30	treated	treat	VERB
admet-328	140	31	group	group	NOUN
admet-328	140	32	in	in	ADP
admet-328	140	33	normal	normal	ADJ
admet-328	140	34	rats	rat	NOUN
admet-328	140	35	were	be	AUX
admet-328	140	36	shown	show	VERB
admet-328	140	37	in	in	ADP
admet-328	140	38	table	table	NOUN
admet-328	140	39	2	2	NUM
admet-328	140	40	and	and	CCONJ
admet-328	140	41	figure	figure	VERB
admet-328	140	42	4	4	NUM
admet-328	140	43	.	.	PUNCT
admet-328	140	44	table	table	NOUN
admet-328	140	45	2	2	NUM
admet-328	140	46	.	.	PUNCT
admet-328	141	1	mean	mean	VERB
admet-328	141	2	percentage	percentage	NOUN
admet-328	141	3	blood	blood	NOUN
admet-328	141	4	glucose	glucose	NOUN
admet-328	141	5	reduction	reduction	NOUN
admet-328	141	6	of	of	ADP
admet-328	141	7	repaglinide	repaglinide	NOUN
admet-328	141	8	following	follow	VERB
admet-328	141	9	its	its	PRON
admet-328	141	10	oral	oral	ADJ
admet-328	141	11	administration	administration	NOUN
admet-328	141	12	at	at	ADP
admet-328	141	13	0.5mg	0.5mg	PROPN
admet-328	141	14	/	/	SYM
admet-328	141	15	kg	kg	PROPN
admet-328	141	16	in	in	ADP
admet-328	141	17	control	control	NOUN
admet-328	141	18	and	and	CCONJ
admet-328	141	19	atazanavir	atazanavir	PROPN
admet-328	141	20	(	(	PUNCT
admet-328	141	21	36	36	NUM
admet-328	141	22	mg	mg	PROPN
admet-328	141	23	/	/	SYM
admet-328	141	24	kg	kg	NOUN
admet-328	141	25	)	)	PUNCT
admet-328	141	26	pretreated	pretreate	VERB
admet-328	141	27	normal	normal	ADJ
admet-328	141	28	,	,	PUNCT
admet-328	141	29	diabetic	diabetic	ADJ
admet-328	141	30	and	and	CCONJ
admet-328	141	31	hepatic	hepatic	ADJ
admet-328	141	32	impaired	impaired	ADJ
admet-328	141	33	rats	rat	NOUN
admet-328	141	34	.	.	PUNCT
admet-328	142	1	data	datum	NOUN
admet-328	142	2	are	be	AUX
admet-328	142	3	expressed	express	VERB
admet-328	142	4	as	as	ADP
admet-328	142	5	mean	mean	PROPN
admet-328	142	6	±s.d	±s.d	PROPN
admet-328	142	7	.	.	PUNCT
admet-328	143	1	in	in	ADP
admet-328	143	2	(	(	PUNCT
admet-328	143	3	n=6	n=6	NOUN
admet-328	143	4	)	)	PUNCT
admet-328	143	5	rats	rat	NOUN
admet-328	143	6	.	.	PUNCT
admet-328	144	1	repaglinide	repaglinide	NOUN
admet-328	144	2	alone	alone	ADV
admet-328	144	3	(	(	PUNCT
admet-328	144	4	control	control	NOUN
admet-328	144	5	)	)	PUNCT
admet-328	144	6	repaglinide	repaglinide	NOUN
admet-328	144	7	in	in	ADP
admet-328	144	8	the	the	DET
admet-328	144	9	presence	presence	NOUN
admet-328	144	10	of	of	ADP
admet-328	144	11	atazanavir	atazanavir	PROPN
admet-328	144	12	in	in	ADP
admet-328	144	13	normal	normal	ADJ
admet-328	144	14	rats	rat	NOUN
admet-328	144	15	repaglinide	repaglinide	ADV
admet-328	144	16	in	in	ADP
admet-328	144	17	the	the	DET
admet-328	144	18	presence	presence	NOUN
admet-328	144	19	of	of	ADP
admet-328	144	20	atazanavir	atazanavir	PROPN
admet-328	144	21	in	in	ADP
admet-328	144	22	diabetic	diabetic	ADJ
admet-328	144	23	rats	rat	NOUN
admet-328	144	24	repaglinide	repaglinide	ADV
admet-328	144	25	in	in	ADP
admet-328	144	26	the	the	DET
admet-328	144	27	presence	presence	NOUN
admet-328	144	28	of	of	ADP
admet-328	144	29	atazanavir	atazanavir	PROPN
admet-328	144	30	in	in	ADP
admet-328	144	31	hepatic	hepatic	ADJ
admet-328	144	32	impaired	impair	VERB
admet-328	144	33	rats	rat	NOUN
admet-328	144	34	time	time	NOUN
admet-328	144	35	,	,	PUNCT
admet-328	145	1	h	h	PROPN
admet-328	145	2	mean±sd	mean±sd	ADP
admet-328	145	3	mean±sd	mean±sd	PROPN
admet-328	145	4	mean±sd	mean±sd	PROPN
admet-328	145	5	mean±sd	mean±sd	ADP
admet-328	145	6	0.25	0.25	NUM
admet-328	145	7	37.07±3.80	37.07±3.80	NUM
admet-328	145	8	17.70±5.91	17.70±5.91	NUM
admet-328	145	9	15.76±4.77	15.76±4.77	X
admet-328	145	10	*	*	PUNCT
admet-328	145	11	*	*	PUNCT
admet-328	145	12	*	*	PUNCT
admet-328	146	1	43.95±2.32	43.95±2.32	NUM
admet-328	146	2	*	*	PUNCT
admet-328	146	3	*	*	PUNCT
admet-328	146	4	*	*	X
admet-328	146	5	0.50	0.50	NUM
admet-328	146	6	25.12±5.84	25.12±5.84	NUM
admet-328	146	7	37.21±22.51	37.21±22.51	NUM
admet-328	146	8	*	*	PUNCT
admet-328	147	1	33.27±24.79	33.27±24.79	NOUN
admet-328	147	2	*	*	NOUN
admet-328	147	3	*	*	PUNCT
admet-328	147	4	*	*	PUNCT
admet-328	147	5	64.62±3.31	64.62±3.31	NOUN
admet-328	147	6	*	*	PUNCT
admet-328	147	7	*	*	PUNCT
admet-328	147	8	*	*	PUNCT
admet-328	147	9	1	1	NUM
admet-328	147	10	19.76±5.99	19.76±5.99	NUM
admet-328	147	11	43.12±15.56	43.12±15.56	NUM
admet-328	147	12	*	*	PUNCT
admet-328	147	13	*	*	PUNCT
admet-328	147	14	28.25±2.38	28.25±2.38	NUM
admet-328	147	15	*	*	PUNCT
admet-328	147	16	*	*	PUNCT
admet-328	147	17	*	*	PUNCT
admet-328	147	18	57.15±2.04	57.15±2.04	NUM
admet-328	147	19	*	*	PUNCT
admet-328	147	20	*	*	PUNCT
admet-328	147	21	*	*	PUNCT
admet-328	147	22	2	2	NUM
admet-328	147	23	7.03±5.02	7.03±5.02	NUM
admet-328	147	24	44.50±6.84	44.50±6.84	NUM
admet-328	147	25	*	*	PUNCT
admet-328	147	26	*	*	PUNCT
admet-328	147	27	53.88±2.93	53.88±2.93	NUM
admet-328	147	28	*	*	PUNCT
admet-328	147	29	*	*	PUNCT
admet-328	147	30	*	*	PUNCT
admet-328	147	31	46.54±1.72	46.54±1.72	PUNCT
admet-328	147	32	*	*	PUNCT
admet-328	147	33	*	*	PUNCT
admet-328	147	34	*	*	PROPN
admet-328	147	35	4	4	NUM
admet-328	147	36	9.63±3.65	9.63±3.65	NUM
admet-328	147	37	59.22±7.72	59.22±7.72	NUM
admet-328	147	38	*	*	SYM
admet-328	147	39	*	*	PROPN
admet-328	147	40	65.89±1.27	65.89±1.27	NUM
admet-328	147	41	*	*	PUNCT
admet-328	147	42	*	*	PUNCT
admet-328	147	43	*	*	PUNCT
admet-328	147	44	38.45±5.03	38.45±5.03	NUM
admet-328	147	45	*	*	PUNCT
admet-328	147	46	*	*	PUNCT
admet-328	147	47	*	*	PROPN
admet-328	147	48	6	6	NUM
admet-328	147	49	12.57±5.11	12.57±5.11	NUM
admet-328	147	50	47.72±5.50	47.72±5.50	NUM
admet-328	147	51	*	*	PUNCT
admet-328	147	52	*	*	PUNCT
admet-328	148	1	31.13±3.25	31.13±3.25	NUM
admet-328	148	2	*	*	PUNCT
admet-328	148	3	*	*	PUNCT
admet-328	148	4	*	*	PUNCT
admet-328	148	5	23.54±4.18	23.54±4.18	X
admet-328	148	6	*	*	PUNCT
admet-328	148	7	*	*	PUNCT
admet-328	148	8	*	*	PUNCT
admet-328	148	9	8	8	NUM
admet-328	148	10	3.47±3.67	3.47±3.67	NUM
admet-328	148	11	38.38±3.03	38.38±3.03	NUM
admet-328	148	12	*	*	SYM
admet-328	148	13	*	*	NOUN
admet-328	148	14	16.86±2.29	16.86±2.29	NUM
admet-328	148	15	*	*	PUNCT
admet-328	148	16	*	*	PUNCT
admet-328	148	17	*	*	PUNCT
admet-328	148	18	14.47±15.70	14.47±15.70	NUM
admet-328	148	19	*	*	PUNCT
admet-328	148	20	*	*	PUNCT
admet-328	148	21	*	*	PROPN
admet-328	148	22	12	12	NUM
admet-328	148	23	2.28±6.66	2.28±6.66	NUM
admet-328	148	24	27.75±6.10	27.75±6.10	NUM
admet-328	148	25	*	*	X
admet-328	148	26	*	*	PROPN
admet-328	149	1	10.69±3.81	10.69±3.81	NUM
admet-328	149	2	*	*	PUNCT
admet-328	149	3	*	*	PUNCT
admet-328	149	4	*	*	PUNCT
admet-328	149	5	9.14±10.03	9.14±10.03	NUM
admet-328	149	6	*	*	PUNCT
admet-328	149	7	*	*	PUNCT
admet-328	149	8	*	*	PUNCT
admet-328	149	9	24	24	NUM
admet-328	149	10	0.34±5.34	0.34±5.34	NUM
admet-328	149	11	12.24±3.84	12.24±3.84	NUM
admet-328	149	12	*	*	X
admet-328	149	13	4.82±3.24	4.82±3.24	NOUN
admet-328	149	14	*	*	PUNCT
admet-328	149	15	*	*	PUNCT
admet-328	149	16	*	*	PUNCT
admet-328	150	1	3.71±11.59	3.71±11.59	NUM
admet-328	150	2	*	*	NOUN
admet-328	150	3	*	*	PUNCT
admet-328	150	4	*	*	PUNCT
admet-328	151	1	*	*	PUNCT
admet-328	151	2	*	*	PUNCT
admet-328	151	3	*	*	PUNCT
admet-328	151	4	significant	significant	ADJ
admet-328	151	5	at	at	ADP
admet-328	151	6	p<0.0001	p<0.0001	NOUN
admet-328	151	7	compared	compare	VERB
admet-328	151	8	to	to	ADP
admet-328	151	9	repaglinide	repaglinide	NOUN
admet-328	151	10	control	control	NOUN
admet-328	151	11	(	(	PUNCT
admet-328	151	12	alone	alone	ADV
admet-328	151	13	)	)	PUNCT
admet-328	151	14	group	group	NOUN
admet-328	151	15	.	.	PUNCT
admet-328	152	1	*	*	PUNCT
admet-328	152	2	*	*	PUNCT
admet-328	152	3	significant	significant	ADJ
admet-328	152	4	at	at	ADP
admet-328	152	5	p<0.005	p<0.005	NOUN
admet-328	152	6	compared	compare	VERB
admet-328	152	7	to	to	ADP
admet-328	152	8	repaglinide	repaglinide	NOUN
admet-328	152	9	(	(	PUNCT
admet-328	152	10	alone	alone	ADV
admet-328	152	11	)	)	PUNCT
admet-328	152	12	control	control	NOUN
admet-328	152	13	group	group	NOUN
admet-328	152	14	.	.	PUNCT
admet-328	153	1	effect	effect	NOUN
admet-328	153	2	of	of	ADP
admet-328	153	3	atazanavir	atazanavir	PROPN
admet-328	153	4	on	on	ADP
admet-328	153	5	the	the	DET
admet-328	153	6	pharmacokinetics	pharmacokinetic	NOUN
admet-328	153	7	and	and	CCONJ
admet-328	153	8	pharmacodynamics	pharmacodynamic	NOUN
admet-328	153	9	of	of	ADP
admet-328	153	10	repaglinide	repaglinide	NOUN
admet-328	153	11	in	in	ADP
admet-328	153	12	hepatic	hepatic	ADJ
admet-328	153	13	rats	rat	NOUN
admet-328	153	14	mean	mean	VERB
admet-328	153	15	plasma	plasma	NOUN
admet-328	153	16	concentration	concentration	NOUN
admet-328	153	17	of	of	ADP
admet-328	153	18	repaglinide	repaglinide	NOUN
admet-328	153	19	in	in	ADP
admet-328	153	20	the	the	DET
admet-328	153	21	absence	absence	NOUN
admet-328	153	22	and	and	CCONJ
admet-328	153	23	presence	presence	NOUN
admet-328	153	24	of	of	ADP
admet-328	153	25	atazanavir	atazanavir	PROPN
admet-328	153	26	in	in	ADP
admet-328	153	27	hepatic	hepatic	ADJ
admet-328	153	28	impaired	impaired	ADJ
admet-328	153	29	rats	rat	NOUN
admet-328	153	30	has	have	AUX
admet-328	153	31	shown	show	VERB
admet-328	153	32	in	in	ADP
admet-328	153	33	figures	figure	NOUN
admet-328	153	34	2	2	NUM
admet-328	153	35	&	&	CCONJ
admet-328	153	36	3	3	NUM
admet-328	153	37	.	.	PUNCT
admet-328	154	1	mean	mean	VERB
admet-328	154	2	pharmacokinetic	pharmacokinetic	ADJ
admet-328	154	3	parameters	parameter	NOUN
admet-328	154	4	of	of	ADP
admet-328	154	5	repaglinide	repaglinide	NOUN
admet-328	154	6	in	in	ADP
admet-328	154	7	the	the	DET
admet-328	154	8	presence	presence	NOUN
admet-328	154	9	of	of	ADP
admet-328	154	10	atazanavir	atazanavir	PROPN
admet-328	154	11	in	in	ADP
admet-328	154	12	hepatic	hepatic	ADJ
admet-328	154	13	impaired	impaired	ADJ
admet-328	154	14	rats	rat	NOUN
admet-328	154	15	were	be	AUX
admet-328	154	16	shown	show	VERB
admet-328	154	17	in	in	ADP
admet-328	154	18	table	table	NOUN
admet-328	154	19	1	1	NUM
admet-328	154	20	(	(	PUNCT
admet-328	154	21	column	column	NOUN
admet-328	154	22	i	i	PROPN
admet-328	154	23	and	and	CCONJ
admet-328	154	24	iv	iv	NUM
admet-328	154	25	)	)	PUNCT
admet-328	154	26	.	.	PUNCT
admet-328	155	1	the	the	DET
admet-328	155	2	pharmacokinetic	pharmacokinetic	ADJ
admet-328	155	3	parameters	parameter	NOUN
admet-328	155	4	of	of	ADP
admet-328	155	5	repaglinide	repaglinide	NOUN
admet-328	155	6	like	like	ADP
admet-328	155	7	auc	auc	NOUN
admet-328	155	8	,	,	PUNCT
admet-328	155	9	cmax	cmax	NOUN
admet-328	155	10	,	,	PUNCT
admet-328	155	11	t1/2	t1/2	NOUN
admet-328	155	12	,	,	PUNCT
admet-328	155	13	clearance	clearance	NOUN
admet-328	155	14	were	be	AUX
admet-328	155	15	altered	alter	VERB
admet-328	155	16	significantly	significantly	ADV
admet-328	155	17	by	by	ADP
admet-328	155	18	a	a	DET
admet-328	155	19	single	single	ADJ
admet-328	155	20	treatment	treatment	NOUN
admet-328	155	21	of	of	ADP
admet-328	155	22	atazanavir	atazanavir	PROPN
admet-328	155	23	in	in	ADP
admet-328	155	24	normal	normal	ADJ
admet-328	155	25	rats	rat	NOUN
admet-328	155	26	when	when	SCONJ
admet-328	155	27	compared	compare	VERB
admet-328	155	28	to	to	PART
admet-328	155	29	repaglinide	repaglinide	NOUN
admet-328	155	30	treated	treat	VERB
admet-328	155	31	group	group	NOUN
admet-328	155	32	.	.	PUNCT
admet-328	156	1	in	in	ADP
admet-328	156	2	a	a	DET
admet-328	156	3	single	single	ADJ
admet-328	156	4	dose	dose	NOUN
admet-328	156	5	study	study	NOUN
admet-328	156	6	with	with	ADP
admet-328	156	7	atazanavir	atazanavir	PROPN
admet-328	156	8	,	,	PUNCT
admet-328	156	9	increases	increase	NOUN
admet-328	156	10	in	in	ADP
admet-328	156	11	pharmacokinetic	pharmacokinetic	ADJ
admet-328	156	12	parameters	parameter	NOUN
admet-328	156	13	of	of	ADP
admet-328	156	14	repaglinide	repaglinide	NOUN
admet-328	156	15	are	be	AUX
admet-328	156	16	as	as	SCONJ
admet-328	156	17	follows	follow	VERB
admet-328	156	18	:	:	PUNCT
admet-328	156	19	auc	auc	NOUN
admet-328	156	20	(	(	PUNCT
admet-328	156	21	26	26	NUM
admet-328	156	22	-	-	ADJ
admet-328	156	23	fold	fold	ADJ
admet-328	156	24	)	)	PUNCT
admet-328	156	25	,	,	PUNCT
admet-328	156	26	cmax	cmax	NOUN
admet-328	156	27	(	(	PUNCT
admet-328	157	1	6	6	NUM
admet-328	157	2	thirumaleswara	thirumaleswara	NOUN
admet-328	157	3	goud	goud	PROPN
admet-328	157	4	et	et	PROPN
admet-328	157	5	al	al	PROPN
admet-328	157	6	.	.	PROPN
admet-328	157	7	admet	admet	PROPN
admet-328	157	8	&	&	CCONJ
admet-328	157	9	dmpk	dmpk	PROPN
admet-328	157	10	4(3	4(3	NUM
admet-328	157	11	)	)	PUNCT
admet-328	157	12	(	(	PUNCT
admet-328	157	13	2016	2016	NUM
admet-328	157	14	)	)	PUNCT
admet-328	157	15	269	269	NUM
admet-328	157	16	-	-	SYM
admet-328	157	17	279	279	NUM
admet-328	157	18	276	276	NUM
admet-328	157	19	fold	fold	NOUN
admet-328	157	20	)	)	PUNCT
admet-328	157	21	with	with	ADP
admet-328	157	22	a	a	DET
admet-328	157	23	relative	relative	ADJ
admet-328	157	24	decrease	decrease	NOUN
admet-328	157	25	in	in	ADP
admet-328	157	26	total	total	ADJ
admet-328	157	27	body	body	NOUN
admet-328	157	28	clearance	clearance	NOUN
admet-328	157	29	of	of	ADP
admet-328	157	30	16	16	NUM
admet-328	157	31	-	-	NOUN
admet-328	157	32	fold	fold	ADV
admet-328	157	33	.	.	PUNCT
admet-328	158	1	the	the	DET
admet-328	158	2	hypoglycemic	hypoglycemic	ADJ
admet-328	158	3	effect	effect	NOUN
admet-328	158	4	of	of	ADP
admet-328	158	5	repaglinide	repaglinide	NOUN
admet-328	158	6	enhanced	enhance	VERB
admet-328	158	7	when	when	SCONJ
admet-328	158	8	given	give	VERB
admet-328	158	9	in	in	ADP
admet-328	158	10	combination	combination	NOUN
admet-328	158	11	with	with	ADP
admet-328	158	12	atazanavir	atazanavir	PROPN
admet-328	158	13	,	,	PUNCT
admet-328	158	14	it	it	PRON
admet-328	158	15	was	be	AUX
admet-328	158	16	indicated	indicate	VERB
admet-328	158	17	by	by	ADP
admet-328	158	18	a	a	DET
admet-328	158	19	significant	significant	ADJ
admet-328	158	20	increase	increase	NOUN
admet-328	158	21	in	in	ADP
admet-328	158	22	percentage	percentage	NOUN
admet-328	158	23	glucose	glucose	NOUN
admet-328	158	24	reduction	reduction	NOUN
admet-328	158	25	in	in	ADP
admet-328	158	26	comparison	comparison	NOUN
admet-328	158	27	to	to	PART
admet-328	158	28	repaglinide	repaglinide	VERB
admet-328	158	29	alone	alone	ADV
admet-328	158	30	treated	treat	VERB
admet-328	158	31	group	group	NOUN
admet-328	158	32	in	in	ADP
admet-328	158	33	normal	normal	ADJ
admet-328	158	34	rats	rat	NOUN
admet-328	158	35	(	(	PUNCT
admet-328	158	36	see	see	VERB
admet-328	158	37	table	table	NOUN
admet-328	158	38	2	2	NUM
admet-328	158	39	and	and	CCONJ
admet-328	158	40	figure	figure	VERB
admet-328	158	41	4	4	NUM
admet-328	158	42	)	)	PUNCT
admet-328	158	43	.	.	PUNCT
admet-328	159	1	figure	figure	NOUN
admet-328	159	2	2	2	NUM
admet-328	159	3	.	.	PUNCT
admet-328	159	4	plasma	plasma	NOUN
admet-328	159	5	concentration	concentration	NOUN
admet-328	159	6	time	time	NOUN
admet-328	159	7	curves	curve	NOUN
admet-328	159	8	of	of	ADP
admet-328	159	9	repaglinide	repaglinide	NOUN
admet-328	159	10	following	follow	VERB
admet-328	159	11	its	its	PRON
admet-328	159	12	oral	oral	ADJ
admet-328	159	13	administration	administration	NOUN
admet-328	159	14	at	at	ADP
admet-328	159	15	0.5	0.5	NUM
admet-328	159	16	mg	mg	PROPN
admet-328	159	17	/	/	SYM
admet-328	159	18	kg	kg	PROPN
admet-328	159	19	in	in	ADP
admet-328	159	20	control	control	NOUN
admet-328	159	21	and	and	CCONJ
admet-328	159	22	atazanavir	atazanavir	PROPN
admet-328	159	23	(	(	PUNCT
admet-328	159	24	36	36	NUM
admet-328	159	25	mg	mg	PROPN
admet-328	159	26	/	/	SYM
admet-328	159	27	kg	kg	NOUN
admet-328	159	28	)	)	PUNCT
admet-328	159	29	pretreated	pretreate	VERB
admet-328	159	30	a	a	DET
admet-328	159	31	)	)	PUNCT
admet-328	159	32	diabetic	diabetic	NOUN
admet-328	159	33	and	and	CCONJ
admet-328	159	34	b	b	NOUN
admet-328	159	35	)	)	PUNCT
admet-328	159	36	hepatic	hepatic	ADJ
admet-328	159	37	impaired	impaired	ADJ
admet-328	159	38	rats	rat	NOUN
admet-328	159	39	.	.	PUNCT
admet-328	160	1	data	datum	NOUN
admet-328	160	2	are	be	AUX
admet-328	160	3	expressed	express	VERB
admet-328	160	4	as	as	ADP
admet-328	160	5	mean	mean	PROPN
admet-328	160	6	±s.d	±s.d	PROPN
admet-328	160	7	.	.	PUNCT
admet-328	161	1	in	in	ADP
admet-328	161	2	(	(	PUNCT
admet-328	161	3	n=6	n=6	NOUN
admet-328	161	4	)	)	PUNCT
admet-328	161	5	rats	rat	NOUN
admet-328	161	6	.	.	PUNCT
admet-328	162	1	figure	figure	VERB
admet-328	162	2	3	3	NUM
admet-328	162	3	.	.	PUNCT
admet-328	162	4	plasma	plasma	NOUN
admet-328	162	5	concentration	concentration	NOUN
admet-328	162	6	time	time	NOUN
admet-328	162	7	curves	curve	NOUN
admet-328	162	8	of	of	ADP
admet-328	162	9	repaglinide	repaglinide	NOUN
admet-328	162	10	following	follow	VERB
admet-328	162	11	its	its	PRON
admet-328	162	12	oral	oral	ADJ
admet-328	162	13	administration	administration	NOUN
admet-328	162	14	at	at	ADP
admet-328	162	15	0.5	0.5	NUM
admet-328	162	16	mg	mg	PROPN
admet-328	162	17	/	/	SYM
admet-328	162	18	kg	kg	PROPN
admet-328	162	19	in	in	ADP
admet-328	162	20	control	control	NOUN
admet-328	162	21	and	and	CCONJ
admet-328	162	22	atazanavir	atazanavir	PROPN
admet-328	162	23	(	(	PUNCT
admet-328	162	24	36	36	NUM
admet-328	162	25	mg	mg	PROPN
admet-328	162	26	/	/	SYM
admet-328	162	27	kg	kg	NOUN
admet-328	162	28	)	)	PUNCT
admet-328	162	29	pretreated	pretreate	VERB
admet-328	162	30	normal	normal	ADJ
admet-328	162	31	,	,	PUNCT
admet-328	162	32	diabetic	diabetic	ADJ
admet-328	162	33	and	and	CCONJ
admet-328	162	34	hepatic	hepatic	ADJ
admet-328	162	35	impaired	impaired	ADJ
admet-328	162	36	rats	rat	NOUN
admet-328	162	37	.	.	PUNCT
admet-328	163	1	data	datum	NOUN
admet-328	163	2	are	be	AUX
admet-328	163	3	expressed	express	VERB
admet-328	163	4	as	as	ADP
admet-328	163	5	mean	mean	PROPN
admet-328	163	6	±s.d	±s.d	PROPN
admet-328	163	7	.	.	PUNCT
admet-328	164	1	in	in	ADP
admet-328	164	2	(	(	PUNCT
admet-328	164	3	n=6	n=6	NOUN
admet-328	164	4	)	)	PUNCT
admet-328	164	5	rats	rat	NOUN
admet-328	164	6	.	.	PUNCT
admet-328	165	1	discussion	discussion	NOUN
admet-328	165	2	the	the	DET
admet-328	165	3	most	most	ADV
admet-328	165	4	challenging	challenging	ADJ
admet-328	165	5	aspect	aspect	NOUN
admet-328	165	6	in	in	ADP
admet-328	165	7	treating	treat	VERB
admet-328	165	8	hiv	hiv	PROPN
admet-328	165	9	patients	patient	NOUN
admet-328	165	10	are	be	AUX
admet-328	165	11	to	to	PART
admet-328	165	12	give	give	VERB
admet-328	165	13	the	the	DET
admet-328	165	14	safe	safe	ADJ
admet-328	165	15	combination	combination	NOUN
admet-328	165	16	of	of	ADP
admet-328	165	17	drugs	drug	NOUN
admet-328	165	18	during	during	ADP
admet-328	165	19	the	the	DET
admet-328	165	20	therapy	therapy	NOUN
admet-328	165	21	because	because	SCONJ
admet-328	165	22	the	the	DET
admet-328	165	23	hiv	hiv	PROPN
admet-328	165	24	therapy	therapy	NOUN
admet-328	165	25	regimen	regimen	NOUN
admet-328	165	26	contains	contain	VERB
admet-328	165	27	one	one	NUM
admet-328	165	28	nucleoside	nucleoside	ADV
admet-328	165	29	reverse	reverse	ADJ
admet-328	165	30	transcriptase	transcriptase	NOUN
admet-328	165	31	inhibitor	inhibitor	NOUN
admet-328	165	32	,	,	PUNCT
admet-328	165	33	one	one	NUM
admet-328	165	34	non	non	ADJ
admet-328	165	35	-	-	ADJ
admet-328	165	36	nucleoside	nucleoside	ADJ
admet-328	165	37	reverse	reverse	ADJ
admet-328	165	38	transcriptase	transcriptase	NOUN
admet-328	165	39	inhibitor	inhibitor	NOUN
admet-328	165	40	and	and	CCONJ
admet-328	165	41	two	two	NUM
admet-328	165	42	protease	protease	NOUN
admet-328	165	43	inhibitors	inhibitor	NOUN
admet-328	165	44	to	to	PART
admet-328	165	45	reduce	reduce	VERB
admet-328	165	46	the	the	DET
admet-328	165	47	viral	viral	ADJ
admet-328	165	48	load	load	NOUN
admet-328	165	49	in	in	ADP
admet-328	165	50	the	the	DET
admet-328	165	51	patients	patient	NOUN
admet-328	165	52	.	.	PUNCT
admet-328	166	1	the	the	DET
admet-328	166	2	hiv	hiv	PROPN
admet-328	166	3	patients	patient	NOUN
admet-328	166	4	will	will	AUX
admet-328	166	5	also	also	ADV
admet-328	166	6	have	have	VERB
admet-328	166	7	several	several	ADJ
admet-328	166	8	other	other	ADJ
admet-328	166	9	co	co	ADJ
admet-328	166	10	-	-	ADJ
admet-328	166	11	morbid	morbid	ADJ
admet-328	166	12	conditions	condition	NOUN
admet-328	166	13	like	like	ADP
admet-328	166	14	kaposi	kaposi	PROPN
admet-328	166	15	’s	’s	PART
admet-328	166	16	sarcoma	sarcoma	NOUN
admet-328	166	17	,	,	PUNCT
admet-328	166	18	lymphoma	lymphoma	NOUN
admet-328	166	19	,	,	PUNCT
admet-328	166	20	and	and	CCONJ
admet-328	166	21	tuberculosis	tuberculosis	NOUN
admet-328	166	22	.	.	PUNCT
admet-328	167	1	apart	apart	ADV
admet-328	167	2	from	from	ADP
admet-328	167	3	this	this	PRON
admet-328	167	4	the	the	DET
admet-328	167	5	highly	highly	ADV
admet-328	167	6	active	active	ADJ
admet-328	167	7	antiretroviral	antiretroviral	ADJ
admet-328	167	8	is	be	AUX
admet-328	167	9	encountered	encounter	VERB
admet-328	167	10	with	with	ADP
admet-328	167	11	the	the	DET
admet-328	167	12	admet	admet	PROPN
admet-328	167	13	&	&	CCONJ
admet-328	167	14	dmpk	dmpk	PROPN
admet-328	167	15	4(3	4(3	NUM
admet-328	167	16	)	)	PUNCT
admet-328	167	17	(	(	PUNCT
admet-328	167	18	2016	2016	NUM
admet-328	167	19	)	)	PUNCT
admet-328	167	20	269	269	NUM
admet-328	167	21	-	-	SYM
admet-328	167	22	279	279	NUM
admet-328	167	23	pk	pk	NOUN
admet-328	167	24	and	and	CCONJ
admet-328	167	25	pd	pd	NOUN
admet-328	167	26	interaction	interaction	NOUN
admet-328	167	27	between	between	ADP
admet-328	167	28	repaglinide	repaglinide	NOUN
admet-328	167	29	and	and	CCONJ
admet-328	167	30	atazanavir	atazanavir	PROPN
admet-328	167	31	doi	doi	PROPN
admet-328	167	32	:	:	PUNCT
admet-328	167	33	10.5599	10.5599	NUM
admet-328	167	34	/	/	SYM
admet-328	167	35	admet.4.3.328	admet.4.3.328	NUM
admet-328	167	36	277	277	NUM
admet-328	167	37	increase	increase	NOUN
admet-328	167	38	in	in	ADP
admet-328	167	39	prevalence	prevalence	NOUN
admet-328	167	40	of	of	ADP
admet-328	167	41	diabetes	diabetes	NOUN
admet-328	167	42	mellitus	mellitus	NOUN
admet-328	167	43	includes	include	VERB
admet-328	167	44	insulin	insulin	NOUN
admet-328	167	45	resistance	resistance	NOUN
admet-328	167	46	and	and	CCONJ
admet-328	167	47	glucose	glucose	NOUN
admet-328	167	48	tolerance	tolerance	NOUN
admet-328	167	49	.	.	PUNCT
admet-328	168	1	the	the	DET
admet-328	168	2	development	development	NOUN
admet-328	168	3	of	of	ADP
admet-328	168	4	these	these	DET
admet-328	168	5	metabolic	metabolic	NOUN
admet-328	168	6	syndromes	syndrome	NOUN
admet-328	168	7	like	like	ADP
admet-328	168	8	glucose	glucose	NOUN
admet-328	168	9	and	and	CCONJ
admet-328	168	10	lipid	lipid	NOUN
admet-328	168	11	disturbances	disturbance	NOUN
admet-328	168	12	presents	present	VERB
admet-328	168	13	a	a	DET
admet-328	168	14	pharmacological	pharmacological	ADJ
admet-328	168	15	challenge	challenge	NOUN
admet-328	168	16	because	because	SCONJ
admet-328	168	17	of	of	ADP
admet-328	168	18	the	the	DET
admet-328	168	19	possible	possible	ADJ
admet-328	168	20	pharmacokinetic	pharmacokinetic	ADJ
admet-328	168	21	drug	drug	NOUN
admet-328	168	22	-	-	PUNCT
admet-328	168	23	drug	drug	NOUN
admet-328	168	24	interactions	interaction	NOUN
admet-328	168	25	associated	associate	VERB
admet-328	168	26	with	with	ADP
admet-328	168	27	oral	oral	ADJ
admet-328	168	28	hypoglycemics	hypoglycemic	NOUN
admet-328	168	29	and	and	CCONJ
admet-328	168	30	antiretroviral	antiretroviral	ADJ
admet-328	168	31	drugs	drug	NOUN
admet-328	168	32	.	.	PUNCT
admet-328	169	1	there	there	PRON
admet-328	169	2	are	be	VERB
admet-328	169	3	limited	limit	VERB
admet-328	169	4	published	publish	VERB
admet-328	169	5	data	datum	NOUN
admet-328	169	6	on	on	ADP
admet-328	169	7	drug	drug	NOUN
admet-328	169	8	interactions	interaction	NOUN
admet-328	169	9	between	between	ADP
admet-328	169	10	antidiabetic	antidiabetic	ADJ
admet-328	169	11	medications	medication	NOUN
admet-328	169	12	and	and	CCONJ
admet-328	169	13	antiretroviral	antiretroviral	ADJ
admet-328	169	14	agents	agent	NOUN
admet-328	169	15	.	.	PUNCT
admet-328	170	1	in	in	ADP
admet-328	170	2	this	this	DET
admet-328	170	3	investigation	investigation	NOUN
admet-328	170	4	we	we	PRON
admet-328	170	5	studied	study	VERB
admet-328	170	6	the	the	DET
admet-328	170	7	influence	influence	NOUN
admet-328	170	8	of	of	ADP
admet-328	170	9	atazanavir	atazanavir	PROPN
admet-328	170	10	on	on	ADP
admet-328	170	11	the	the	DET
admet-328	170	12	pharmacokinetics	pharmacokinetic	NOUN
admet-328	170	13	and	and	CCONJ
admet-328	170	14	pharmacodynamics	pharmacodynamic	NOUN
admet-328	170	15	of	of	ADP
admet-328	170	16	repaglinide	repaglinide	NOUN
admet-328	170	17	at	at	ADP
admet-328	170	18	therapeutic	therapeutic	ADJ
admet-328	170	19	doses	dose	NOUN
admet-328	170	20	in	in	ADP
admet-328	170	21	healthy	healthy	ADJ
admet-328	170	22	,	,	PUNCT
admet-328	170	23	diabetic	diabetic	ADJ
admet-328	170	24	and	and	CCONJ
admet-328	170	25	hepatic	hepatic	ADJ
admet-328	170	26	impaired	impaired	ADJ
admet-328	170	27	rats	rat	NOUN
admet-328	170	28	.	.	PUNCT
admet-328	171	1	the	the	DET
admet-328	171	2	healthy	healthy	ADJ
admet-328	171	3	rat	rat	NOUN
admet-328	171	4	model	model	NOUN
admet-328	171	5	served	serve	VERB
admet-328	171	6	to	to	PART
admet-328	171	7	quickly	quickly	ADV
admet-328	171	8	identify	identify	VERB
admet-328	171	9	the	the	DET
admet-328	171	10	interaction	interaction	NOUN
admet-328	171	11	and	and	CCONJ
admet-328	171	12	the	the	DET
admet-328	171	13	diabetic	diabetic	ADJ
admet-328	171	14	and	and	CCONJ
admet-328	171	15	hepatic	hepatic	ADJ
admet-328	171	16	impaired	impaired	ADJ
admet-328	171	17	model	model	NOUN
admet-328	171	18	to	to	PART
admet-328	171	19	validate	validate	VERB
admet-328	171	20	the	the	DET
admet-328	171	21	same	same	ADJ
admet-328	171	22	response	response	NOUN
admet-328	171	23	in	in	ADP
admet-328	171	24	the	the	DET
admet-328	171	25	disease	disease	NOUN
admet-328	171	26	condition	condition	NOUN
admet-328	171	27	.	.	PUNCT
admet-328	172	1	repaglinide	repaglinide	NOUN
admet-328	172	2	is	be	AUX
admet-328	172	3	extensively	extensively	ADV
admet-328	172	4	metabolized	metabolize	VERB
admet-328	172	5	by	by	ADP
admet-328	172	6	the	the	DET
admet-328	172	7	hepatic	hepatic	ADJ
admet-328	172	8	cytochrome	cytochrome	NOUN
admet-328	172	9	p450	p450	NUM
admet-328	172	10	enzyme	enzyme	NOUN
admet-328	172	11	system	system	NOUN
admet-328	172	12	,	,	PUNCT
admet-328	172	13	particularly	particularly	ADV
admet-328	172	14	with	with	ADP
admet-328	172	15	cyp3a4	cyp3a4	NOUN
admet-328	172	16	;	;	PUNCT
admet-328	172	17	cyp2c8	cyp2c8	ADV
admet-328	172	18	with	with	ADP
admet-328	172	19	less	less	ADJ
admet-328	172	20	than	than	ADP
admet-328	172	21	2	2	NUM
admet-328	172	22	%	%	NOUN
admet-328	172	23	of	of	ADP
admet-328	172	24	an	an	DET
admet-328	172	25	oral	oral	ADJ
admet-328	172	26	dose	dose	NOUN
admet-328	172	27	excreted	excrete	VERB
admet-328	172	28	unchanged	unchanged	ADJ
admet-328	172	29	in	in	ADP
admet-328	172	30	humans	human	NOUN
admet-328	172	31	.	.	PUNCT
admet-328	173	1	among	among	ADP
admet-328	173	2	this	this	DET
admet-328	173	3	cyp3a4	cyp3a4	NOUN
admet-328	173	4	has	have	AUX
admet-328	173	5	been	be	AUX
admet-328	173	6	identified	identify	VERB
admet-328	173	7	as	as	ADP
admet-328	173	8	an	an	DET
admet-328	173	9	important	important	ADJ
admet-328	173	10	enzyme	enzyme	NOUN
admet-328	173	11	in	in	ADP
admet-328	173	12	the	the	DET
admet-328	173	13	in	in	NOUN
admet-328	173	14	-	-	PUNCT
admet-328	173	15	vitro	vitro	X
admet-328	173	16	metabolism	metabolism	NOUN
admet-328	173	17	of	of	ADP
admet-328	173	18	repaglinide	repaglinide	NOUN
admet-328	173	19	[	[	X
admet-328	173	20	23	23	NUM
admet-328	173	21	]	]	PUNCT
admet-328	173	22	.	.	PUNCT
admet-328	174	1	the	the	DET
admet-328	174	2	repaglinide	repaglinide	NOUN
admet-328	174	3	pharmacokinetics	pharmacokinetic	NOUN
admet-328	174	4	was	be	AUX
admet-328	174	5	further	far	ADV
admet-328	174	6	complicated	complicated	ADJ
admet-328	174	7	because	because	SCONJ
admet-328	174	8	of	of	ADP
admet-328	174	9	active	active	ADJ
admet-328	174	10	hepatic	hepatic	ADJ
admet-328	174	11	uptake	uptake	NOUN
admet-328	174	12	of	of	ADP
admet-328	174	13	repaglinide	repaglinide	NOUN
admet-328	174	14	by	by	ADP
admet-328	174	15	oatp	oatp	ADJ
admet-328	174	16	uptake	uptake	ADJ
admet-328	174	17	transporter	transporter	NOUN
admet-328	174	18	and	and	CCONJ
admet-328	174	19	it	it	PRON
admet-328	174	20	is	be	AUX
admet-328	174	21	a	a	DET
admet-328	174	22	substrate	substrate	NOUN
admet-328	174	23	for	for	ADP
admet-328	174	24	the	the	DET
admet-328	174	25	oatp	oatp	ADJ
admet-328	174	26	transporter	transporter	NOUN
admet-328	174	27	[	[	X
admet-328	174	28	24	24	NUM
admet-328	174	29	]	]	PUNCT
admet-328	174	30	.	.	PUNCT
admet-328	175	1	repaglinide	repaglinide	PROPN
admet-328	175	2	also	also	ADV
admet-328	175	3	act	act	VERB
admet-328	175	4	as	as	ADP
admet-328	175	5	a	a	DET
admet-328	175	6	substrate	substrate	NOUN
admet-328	175	7	for	for	ADP
admet-328	175	8	p	p	NOUN
admet-328	175	9	-	-	PUNCT
admet-328	175	10	glycoprotein	glycoprotein	NOUN
admet-328	175	11	which	which	PRON
admet-328	175	12	can	can	AUX
admet-328	175	13	significantly	significantly	ADV
admet-328	175	14	contribute	contribute	VERB
admet-328	175	15	to	to	ADP
admet-328	175	16	potential	potential	ADJ
admet-328	175	17	drug	drug	NOUN
admet-328	175	18	-	-	PUNCT
admet-328	175	19	drug	drug	NOUN
admet-328	175	20	interactions	interaction	NOUN
admet-328	175	21	with	with	ADP
admet-328	175	22	other	other	ADJ
admet-328	175	23	p	p	NOUN
admet-328	175	24	-	-	PUNCT
admet-328	175	25	gp	gp	NOUN
admet-328	175	26	substrate	substrate	NOUN
admet-328	175	27	or	or	CCONJ
admet-328	175	28	inhibitors	inhibitor	NOUN
admet-328	175	29	[	[	X
admet-328	175	30	25	25	NUM
admet-328	175	31	]	]	PUNCT
admet-328	175	32	.	.	PUNCT
admet-328	176	1	figure	figure	NOUN
admet-328	176	2	4	4	NUM
admet-328	176	3	.	.	PUNCT
admet-328	177	1	mean	mean	VERB
admet-328	177	2	percentage	percentage	NOUN
admet-328	177	3	blood	blood	NOUN
admet-328	177	4	glucose	glucose	NOUN
admet-328	177	5	reduction	reduction	NOUN
admet-328	177	6	curves	curve	NOUN
admet-328	177	7	of	of	ADP
admet-328	177	8	repaglinide	repaglinide	NOUN
admet-328	177	9	following	follow	VERB
admet-328	177	10	its	its	PRON
admet-328	177	11	oral	oral	ADJ
admet-328	177	12	administration	administration	NOUN
admet-328	177	13	at	at	ADP
admet-328	177	14	0.5	0.5	NUM
admet-328	177	15	mg	mg	PROPN
admet-328	177	16	/	/	SYM
admet-328	177	17	kg	kg	PROPN
admet-328	177	18	in	in	ADP
admet-328	177	19	control	control	NOUN
admet-328	177	20	and	and	CCONJ
admet-328	177	21	atazanavir	atazanavir	PROPN
admet-328	177	22	(	(	PUNCT
admet-328	177	23	36	36	NUM
admet-328	177	24	mg	mg	PROPN
admet-328	177	25	/	/	SYM
admet-328	177	26	kg	kg	NOUN
admet-328	177	27	)	)	PUNCT
admet-328	177	28	pretreated	pretreate	VERB
admet-328	177	29	normal	normal	ADJ
admet-328	177	30	,	,	PUNCT
admet-328	177	31	diabetic	diabetic	ADJ
admet-328	177	32	and	and	CCONJ
admet-328	177	33	hepatic	hepatic	ADJ
admet-328	177	34	impaired	impaired	ADJ
admet-328	177	35	rats	rat	NOUN
admet-328	177	36	.	.	PUNCT
admet-328	178	1	data	datum	NOUN
admet-328	178	2	are	be	AUX
admet-328	178	3	expressed	express	VERB
admet-328	178	4	as	as	ADP
admet-328	178	5	mean	mean	PROPN
admet-328	178	6	±s.d	±s.d	PROPN
admet-328	178	7	.	.	PUNCT
admet-328	179	1	in	in	ADP
admet-328	179	2	(	(	PUNCT
admet-328	179	3	n=6	n=6	NOUN
admet-328	179	4	)	)	PUNCT
admet-328	179	5	rats	rat	NOUN
admet-328	179	6	.	.	PUNCT
admet-328	180	1	hiv	hiv	PROPN
admet-328	180	2	protease	protease	NOUN
admet-328	180	3	inhibitors	inhibitor	NOUN
admet-328	180	4	have	have	AUX
admet-328	180	5	identified	identify	VERB
admet-328	180	6	as	as	ADP
admet-328	180	7	a	a	DET
admet-328	180	8	substrates	substrate	NOUN
admet-328	180	9	,	,	PUNCT
admet-328	180	10	inhibitors	inhibitor	NOUN
admet-328	180	11	or	or	CCONJ
admet-328	180	12	inducers	inducer	NOUN
admet-328	180	13	of	of	ADP
admet-328	180	14	cyp3a4	cyp3a4	NOUN
admet-328	180	15	,	,	PUNCT
admet-328	180	16	oatp	oatp	ADJ
admet-328	180	17	and	and	CCONJ
admet-328	180	18	p	p	NOUN
admet-328	180	19	-	-	PUNCT
admet-328	180	20	gp	gp	NOUN
admet-328	180	21	.	.	PUNCT
admet-328	181	1	atazanavir	atazanavir	PROPN
admet-328	181	2	is	be	AUX
admet-328	181	3	an	an	DET
admet-328	181	4	extensively	extensively	ADV
admet-328	181	5	metabolized	metabolize	VERB
admet-328	181	6	mainly	mainly	ADV
admet-328	181	7	by	by	ADP
admet-328	181	8	cytochrome	cytochrome	ADJ
admet-328	181	9	p450	p450	ADJ
admet-328	181	10	enzyme	enzyme	NOUN
admet-328	181	11	system	system	NOUN
admet-328	181	12	which	which	PRON
admet-328	181	13	have	have	VERB
admet-328	181	14	capable	capable	ADJ
admet-328	181	15	of	of	ADP
admet-328	181	16	altering	alter	VERB
admet-328	181	17	both	both	CCONJ
admet-328	181	18	p	p	NOUN
admet-328	181	19	-	-	PUNCT
admet-328	181	20	gp	gp	NOUN
admet-328	181	21	and	and	CCONJ
admet-328	181	22	cyp	cyp	ADJ
admet-328	181	23	3a4	3a4	NUM
admet-328	181	24	activity	activity	NOUN
admet-328	181	25	in	in	ADV
admet-328	181	26	-	-	PUNCT
admet-328	181	27	vitro	vitro	X
admet-328	181	28	[	[	X
admet-328	181	29	26	26	NUM
admet-328	181	30	]	]	PUNCT
admet-328	181	31	.	.	PUNCT
admet-328	182	1	atazanavir	atazanavir	PROPN
admet-328	182	2	inhibits	inhibit	VERB
admet-328	182	3	p	p	X
admet-328	182	4	-	-	PUNCT
admet-328	182	5	gp	gp	NOUN
admet-328	182	6	mediated	mediate	VERB
admet-328	182	7	transport	transport	NOUN
admet-328	182	8	and	and	CCONJ
admet-328	182	9	acts	act	NOUN
admet-328	182	10	as	as	ADP
admet-328	182	11	a	a	DET
admet-328	182	12	potent	potent	ADJ
admet-328	182	13	mechanism	mechanism	NOUN
admet-328	182	14	based	base	VERB
admet-328	182	15	inhibitor	inhibitor	NOUN
admet-328	182	16	of	of	ADP
admet-328	182	17	cyp3a4	cyp3a4	PROPN
admet-328	182	18	and	and	CCONJ
admet-328	182	19	it	it	PRON
admet-328	182	20	also	also	ADV
admet-328	182	21	inhibit	inhibit	VERB
admet-328	182	22	the	the	DET
admet-328	182	23	oatp	oatp	ADJ
admet-328	182	24	transport	transport	NOUN
admet-328	182	25	particularly	particularly	ADV
admet-328	182	26	oatp1b1	oatp1b1	NUM
admet-328	182	27	,	,	PUNCT
admet-328	182	28	oatp1b3	oatp1b3	NOUN
admet-328	182	29	and	and	CCONJ
admet-328	182	30	oatp2b1	oatp2b1	PROPN
admet-328	182	31	mediated	mediate	VERB
admet-328	182	32	transport	transport	NOUN
admet-328	182	33	in	in	ADP
admet-328	182	34	liver	liver	NOUN
admet-328	182	35	[	[	X
admet-328	182	36	27	27	NUM
admet-328	182	37	]	]	PUNCT
admet-328	182	38	.	.	PUNCT
admet-328	183	1	the	the	DET
admet-328	183	2	pharmacokinetics	pharmacokinetic	NOUN
admet-328	183	3	(	(	PUNCT
admet-328	183	4	cmax	cmax	NOUN
admet-328	183	5	,	,	PUNCT
admet-328	183	6	auc0	auc0	PROPN
admet-328	183	7	-	-	PUNCT
admet-328	183	8	t	t	PROPN
admet-328	183	9	,	,	PUNCT
admet-328	183	10	auct-∞	auct-∞	PROPN
admet-328	183	11	,	,	PUNCT
admet-328	183	12	t1/2	t1/2	NOUN
admet-328	183	13	,	,	PUNCT
admet-328	183	14	clearance	clearance	NOUN
admet-328	183	15	)	)	PUNCT
admet-328	183	16	and	and	CCONJ
admet-328	183	17	pharmacodynamics	pharmacodynamic	NOUN
admet-328	183	18	(	(	PUNCT
admet-328	183	19	percent	percent	NOUN
admet-328	183	20	blood	blood	NOUN
admet-328	183	21	glucose	glucose	NOUN
admet-328	183	22	reduction	reduction	NOUN
admet-328	183	23	)	)	PUNCT
admet-328	183	24	of	of	ADP
admet-328	183	25	repaglinide	repaglinide	NOUN
admet-328	183	26	were	be	AUX
admet-328	183	27	significantly	significantly	ADV
admet-328	183	28	altered	alter	VERB
admet-328	183	29	in	in	ADP
admet-328	183	30	the	the	DET
admet-328	183	31	atazanavir	atazanavir	PROPN
admet-328	183	32	treated	treat	VERB
admet-328	183	33	normal	normal	ADJ
admet-328	183	34	,	,	PUNCT
admet-328	183	35	diabetic	diabetic	ADJ
admet-328	183	36	and	and	CCONJ
admet-328	183	37	hepatic	hepatic	ADJ
admet-328	183	38	impaired	impaired	ADJ
admet-328	183	39	rats	rat	NOUN
admet-328	183	40	.	.	PUNCT
admet-328	184	1	the	the	DET
admet-328	184	2	significant	significant	ADJ
admet-328	184	3	improvement	improvement	NOUN
admet-328	184	4	of	of	ADP
admet-328	184	5	cmax	cmax	NOUN
admet-328	184	6	and	and	CCONJ
admet-328	184	7	auc	auc	NOUN
admet-328	184	8	of	of	ADP
admet-328	184	9	repaglinide	repaglinide	NOUN
admet-328	184	10	in	in	ADP
admet-328	184	11	healthy	healthy	ADJ
admet-328	184	12	,	,	PUNCT
admet-328	184	13	diabetic	diabetic	ADJ
admet-328	184	14	and	and	CCONJ
admet-328	184	15	hepatic	hepatic	ADJ
admet-328	184	16	impaired	impaired	ADJ
admet-328	184	17	rats	rat	NOUN
admet-328	184	18	could	could	AUX
admet-328	184	19	be	be	AUX
admet-328	184	20	due	due	ADJ
admet-328	184	21	to	to	ADP
admet-328	184	22	cyp	cyp	ADJ
admet-328	184	23	enzyme	enzyme	NOUN
admet-328	184	24	and	and	CCONJ
admet-328	184	25	p	p	NOUN
admet-328	184	26	-	-	PUNCT
admet-328	184	27	gp	gp	NOUN
admet-328	184	28	mediated	mediate	VERB
admet-328	184	29	transport	transport	NOUN
admet-328	184	30	inhibition	inhibition	NOUN
admet-328	184	31	during	during	ADP
admet-328	184	32	the	the	DET
admet-328	184	33	first	first	ADJ
admet-328	184	34	pass	pass	NOUN
admet-328	184	35	metabolism	metabolism	NOUN
admet-328	184	36	.	.	PUNCT
admet-328	185	1	compared	compare	VERB
admet-328	185	2	to	to	ADP
admet-328	185	3	the	the	DET
admet-328	185	4	control	control	NOUN
admet-328	185	5	group	group	NOUN
admet-328	185	6	the	the	DET
admet-328	185	7	atazanavir	atazanavir	PROPN
admet-328	185	8	significantly	significantly	ADV
admet-328	185	9	decreased	decrease	VERB
admet-328	185	10	the	the	DET
admet-328	185	11	clearance	clearance	NOUN
admet-328	185	12	of	of	ADP
admet-328	185	13	thirumaleswara	thirumaleswara	PROPN
admet-328	185	14	goud	goud	PROPN
admet-328	185	15	et	et	PROPN
admet-328	185	16	al	al	PROPN
admet-328	185	17	.	.	PROPN
admet-328	185	18	admet	admet	PROPN
admet-328	185	19	&	&	CCONJ
admet-328	185	20	dmpk	dmpk	PROPN
admet-328	185	21	4(3	4(3	NUM
admet-328	185	22	)	)	PUNCT
admet-328	185	23	(	(	PUNCT
admet-328	185	24	2016	2016	NUM
admet-328	185	25	)	)	PUNCT
admet-328	185	26	269	269	NUM
admet-328	185	27	-	-	SYM
admet-328	185	28	279	279	NUM
admet-328	185	29	278	278	NUM
admet-328	185	30	repaglinide	repaglinide	NOUN
admet-328	185	31	in	in	ADP
admet-328	185	32	healthy	healthy	ADJ
admet-328	185	33	,	,	PUNCT
admet-328	185	34	diabetic	diabetic	ADJ
admet-328	185	35	and	and	CCONJ
admet-328	185	36	hepatic	hepatic	ADJ
admet-328	185	37	impaired	impaired	ADJ
admet-328	185	38	rats	rat	NOUN
admet-328	185	39	,	,	PUNCT
admet-328	185	40	this	this	PRON
admet-328	185	41	could	could	AUX
admet-328	185	42	be	be	AUX
admet-328	185	43	due	due	ADJ
admet-328	185	44	to	to	ADP
admet-328	185	45	the	the	DET
admet-328	185	46	inhibition	inhibition	NOUN
admet-328	185	47	of	of	ADP
admet-328	185	48	cyp	cyp	ADJ
admet-328	185	49	enzyme	enzyme	NOUN
admet-328	185	50	and	and	CCONJ
admet-328	185	51	oatp	oatp	ADJ
admet-328	185	52	transporter	transporter	NOUN
admet-328	185	53	in	in	ADP
admet-328	185	54	the	the	DET
admet-328	185	55	liver	liver	NOUN
admet-328	185	56	.	.	PUNCT
admet-328	186	1	the	the	DET
admet-328	186	2	magnitude	magnitude	NOUN
admet-328	186	3	change	change	NOUN
admet-328	186	4	in	in	ADP
admet-328	186	5	the	the	DET
admet-328	186	6	exposure	exposure	NOUN
admet-328	186	7	of	of	ADP
admet-328	186	8	repaglinide	repaglinide	NOUN
admet-328	186	9	is	be	AUX
admet-328	186	10	more	more	ADV
admet-328	186	11	in	in	ADP
admet-328	186	12	hepatic	hepatic	ADJ
admet-328	186	13	impaired	impaired	ADJ
admet-328	186	14	rats	rat	NOUN
admet-328	186	15	could	could	AUX
admet-328	186	16	be	be	AUX
admet-328	186	17	due	due	ADJ
admet-328	186	18	to	to	ADP
admet-328	186	19	the	the	DET
admet-328	186	20	synergistic	synergistic	ADJ
admet-328	186	21	effect	effect	NOUN
admet-328	186	22	of	of	ADP
admet-328	186	23	oatp	oatp	ADJ
admet-328	186	24	inhibition	inhibition	NOUN
admet-328	186	25	by	by	ADP
admet-328	186	26	atazanavir	atazanavir	NOUN
admet-328	186	27	and	and	CCONJ
admet-328	186	28	liver	liver	NOUN
admet-328	186	29	dysfunction	dysfunction	NOUN
admet-328	186	30	the	the	DET
admet-328	186	31	clearance	clearance	NOUN
admet-328	186	32	of	of	ADP
admet-328	186	33	repaglinide	repaglinide	NOUN
admet-328	186	34	was	be	AUX
admet-328	186	35	significantly	significantly	ADV
admet-328	186	36	decreased	decrease	VERB
admet-328	186	37	in	in	ADP
admet-328	186	38	normal	normal	ADJ
admet-328	186	39	and	and	CCONJ
admet-328	186	40	diabetic	diabetic	ADJ
admet-328	186	41	rats	rat	NOUN
admet-328	186	42	,	,	PUNCT
admet-328	186	43	which	which	PRON
admet-328	186	44	was	be	AUX
admet-328	186	45	due	due	ADJ
admet-328	186	46	to	to	ADP
admet-328	186	47	the	the	DET
admet-328	186	48	inhibition	inhibition	NOUN
admet-328	186	49	of	of	ADP
admet-328	186	50	cyp	cyp	ADJ
admet-328	186	51	enzyme	enzyme	NOUN
admet-328	186	52	and	and	CCONJ
admet-328	186	53	oatp	oatp	ADJ
admet-328	186	54	,	,	PUNCT
admet-328	186	55	p	p	ADJ
admet-328	186	56	-	-	PUNCT
admet-328	186	57	gp	gp	NOUN
admet-328	186	58	transport	transport	NOUN
admet-328	186	59	by	by	ADP
admet-328	186	60	atazanavir	atazanavir	PROPN
admet-328	186	61	.	.	PUNCT
admet-328	187	1	however	however	ADV
admet-328	187	2	,	,	PUNCT
admet-328	187	3	in	in	ADP
admet-328	187	4	hepatic	hepatic	ADJ
admet-328	187	5	impaired	impair	VERB
admet-328	187	6	rats	rat	NOUN
admet-328	187	7	the	the	DET
admet-328	187	8	magnitude	magnitude	NOUN
admet-328	187	9	change	change	NOUN
admet-328	187	10	in	in	ADP
admet-328	187	11	the	the	DET
admet-328	187	12	exposure	exposure	NOUN
admet-328	187	13	of	of	ADP
admet-328	187	14	repaglinide	repaglinide	NOUN
admet-328	187	15	was	be	AUX
admet-328	187	16	more	more	ADJ
admet-328	187	17	,	,	PUNCT
admet-328	187	18	which	which	PRON
admet-328	187	19	could	could	AUX
admet-328	187	20	be	be	AUX
admet-328	187	21	due	due	ADJ
admet-328	187	22	to	to	ADP
admet-328	187	23	the	the	DET
admet-328	187	24	synergistic	synergistic	ADJ
admet-328	187	25	effect	effect	NOUN
admet-328	187	26	of	of	ADP
admet-328	187	27	oatp	oatp	ADJ
admet-328	187	28	inhibition	inhibition	NOUN
admet-328	187	29	by	by	ADP
admet-328	187	30	atazanavir	atazanavir	NOUN
admet-328	187	31	and	and	CCONJ
admet-328	187	32	liver	liver	NOUN
admet-328	187	33	dysfunction	dysfunction	NOUN
admet-328	187	34	.	.	PUNCT
admet-328	188	1	in	in	ADP
admet-328	188	2	hepatic	hepatic	ADJ
admet-328	188	3	impaired	impair	VERB
admet-328	188	4	rats	rat	NOUN
admet-328	188	5	t1/2	t1/2	ADJ
admet-328	188	6	of	of	ADP
admet-328	188	7	repaglinide	repaglinide	NOUN
admet-328	188	8	was	be	AUX
admet-328	188	9	increased	increase	VERB
admet-328	188	10	significantly	significantly	ADV
admet-328	188	11	when	when	SCONJ
admet-328	188	12	compared	compare	VERB
admet-328	188	13	to	to	ADP
admet-328	188	14	the	the	DET
admet-328	188	15	repaglinide	repaglinide	NOUN
admet-328	188	16	alone	alone	PROPN
admet-328	188	17	control	control	PROPN
admet-328	188	18	group	group	NOUN
admet-328	188	19	due	due	ADP
admet-328	188	20	to	to	PART
admet-328	188	21	decrease	decrease	VERB
admet-328	188	22	in	in	ADP
admet-328	188	23	clearance	clearance	NOUN
admet-328	188	24	of	of	ADP
admet-328	188	25	repaglinide	repaglinide	NOUN
admet-328	188	26	.	.	PUNCT
admet-328	189	1	the	the	DET
admet-328	189	2	blood	blood	NOUN
admet-328	189	3	glucose	glucose	NOUN
admet-328	189	4	levels	level	NOUN
admet-328	189	5	were	be	AUX
admet-328	189	6	decreased	decrease	VERB
admet-328	189	7	significantly	significantly	ADV
admet-328	189	8	when	when	SCONJ
admet-328	189	9	repaglinide	repaglinide	NOUN
admet-328	189	10	is	be	AUX
admet-328	189	11	given	give	VERB
admet-328	189	12	in	in	ADP
admet-328	189	13	combination	combination	NOUN
admet-328	189	14	with	with	ADP
admet-328	189	15	atazanavir	atazanavir	PROPN
admet-328	189	16	in	in	ADP
admet-328	189	17	normal	normal	ADJ
admet-328	189	18	,	,	PUNCT
admet-328	189	19	diabetic	diabetic	ADJ
admet-328	189	20	and	and	CCONJ
admet-328	189	21	hepatic	hepatic	ADJ
admet-328	189	22	impaired	impaired	ADJ
admet-328	189	23	groups	group	NOUN
admet-328	189	24	.	.	PUNCT
admet-328	190	1	the	the	DET
admet-328	190	2	increased	increase	VERB
admet-328	190	3	bioavailability	bioavailability	NOUN
admet-328	190	4	(	(	PUNCT
admet-328	190	5	auc	auc	NOUN
admet-328	190	6	and	and	CCONJ
admet-328	190	7	cmax	cmax	NOUN
admet-328	190	8	)	)	PUNCT
admet-328	190	9	of	of	ADP
admet-328	190	10	repaglinide	repaglinide	NOUN
admet-328	190	11	when	when	SCONJ
admet-328	190	12	administered	administer	VERB
admet-328	190	13	with	with	ADP
admet-328	190	14	atazanavir	atazanavir	PROPN
admet-328	190	15	increases	increase	VERB
admet-328	190	16	the	the	DET
admet-328	190	17	plasma	plasma	NOUN
admet-328	190	18	levels	level	NOUN
admet-328	190	19	of	of	ADP
admet-328	190	20	repaglinide	repaglinide	NOUN
admet-328	190	21	and	and	CCONJ
admet-328	190	22	decreases	decrease	VERB
admet-328	190	23	elimination	elimination	NOUN
admet-328	190	24	which	which	PRON
admet-328	190	25	results	result	VERB
admet-328	190	26	in	in	ADP
admet-328	190	27	enhanced	enhanced	ADJ
admet-328	190	28	mean	mean	NOUN
admet-328	190	29	blood	blood	NOUN
admet-328	190	30	glucose	glucose	NOUN
admet-328	190	31	percentage	percentage	NOUN
admet-328	190	32	which	which	PRON
admet-328	190	33	may	may	AUX
admet-328	190	34	further	far	ADV
admet-328	190	35	precipitate	precipitate	VERB
admet-328	190	36	hypoglycemic	hypoglycemic	ADJ
admet-328	190	37	action	action	NOUN
admet-328	190	38	.	.	PUNCT
admet-328	191	1	our	our	PRON
admet-328	191	2	findings	finding	NOUN
admet-328	191	3	were	be	AUX
admet-328	191	4	consistent	consistent	ADJ
admet-328	191	5	with	with	ADP
admet-328	191	6	the	the	DET
admet-328	191	7	report	report	NOUN
admet-328	191	8	by	by	ADP
admet-328	191	9	shitara	shitara	PROPN
admet-328	191	10	,	,	PUNCT
admet-328	191	11	et	et	PROPN
admet-328	191	12	al	al	PROPN
admet-328	191	13	reported	report	VERB
admet-328	191	14	gemfibrozil	gemfibrozil	NOUN
admet-328	191	15	increased	increase	VERB
admet-328	191	16	the	the	DET
admet-328	191	17	auc	auc	NOUN
admet-328	191	18	of	of	ADP
admet-328	191	19	repaglinide	repaglinide	NOUN
admet-328	191	20	approximately	approximately	ADV
admet-328	191	21	8	8	ADV
admet-328	191	22	-	-	ADJ
admet-328	191	23	fold	fold	ADJ
admet-328	191	24	and	and	CCONJ
admet-328	191	25	prolonged	prolong	VERB
admet-328	191	26	its	its	PRON
admet-328	191	27	t1/2	t1/2	NOUN
admet-328	191	28	from	from	ADP
admet-328	191	29	1.3	1.3	NUM
admet-328	191	30	to	to	ADP
admet-328	191	31	3.7	3.7	NUM
admet-328	191	32	in	in	ADP
admet-328	191	33	healthy	healthy	ADJ
admet-328	191	34	subjects	subject	NOUN
admet-328	191	35	[	[	X
admet-328	191	36	28	28	NUM
admet-328	191	37	]	]	PUNCT
admet-328	191	38	.	.	PUNCT
admet-328	192	1	gemfibrozil	gemfibrozil	PROPN
admet-328	192	2	is	be	AUX
admet-328	192	3	a	a	DET
admet-328	192	4	strong	strong	ADJ
admet-328	192	5	inhibitor	inhibitor	NOUN
admet-328	192	6	of	of	ADP
admet-328	192	7	cyp2c8	cyp2c8	ADV
admet-328	192	8	in	in	ADP
admet-328	192	9	vivo	vivo	NOUN
admet-328	192	10	mainly	mainly	ADV
admet-328	192	11	due	due	ADP
admet-328	192	12	to	to	ADP
admet-328	192	13	its	its	PRON
admet-328	192	14	1	1	NUM
admet-328	192	15	-	-	PUNCT
admet-328	192	16	o	o	NOUN
admet-328	192	17	-	-	PUNCT
admet-328	192	18	ß	ß	DET
admet-328	192	19	-	-	ADJ
admet-328	192	20	glucuronide	glucuronide	ADJ
admet-328	192	21	metabolite	metabolite	NOUN
admet-328	192	22	.	.	PUNCT
admet-328	193	1	gemfibrozil	gemfibrozil	PROPN
admet-328	193	2	and	and	CCONJ
admet-328	193	3	its	its	PRON
admet-328	193	4	glucuronide	glucuronide	NOUN
admet-328	193	5	inhibit	inhibit	VERB
admet-328	193	6	the	the	DET
admet-328	193	7	oatp1b1	oatp1b1	NOUN
admet-328	193	8	in	in	ADP
admet-328	193	9	vitro	vitro	NOUN
admet-328	193	10	,	,	PUNCT
admet-328	193	11	suggesting	suggest	VERB
admet-328	193	12	that	that	SCONJ
admet-328	193	13	the	the	DET
admet-328	193	14	involvement	involvement	NOUN
admet-328	193	15	of	of	ADP
admet-328	193	16	drug	drug	NOUN
admet-328	193	17	-	-	PUNCT
admet-328	193	18	drug	drug	NOUN
admet-328	193	19	interaction	interaction	NOUN
admet-328	193	20	between	between	ADP
admet-328	193	21	gemfibrozil	gemfibrozil	NOUN
admet-328	193	22	and	and	CCONJ
admet-328	193	23	repaglinide	repaglinide	NOUN
admet-328	193	24	[	[	X
admet-328	193	25	28	28	NUM
admet-328	193	26	]	]	PUNCT
admet-328	193	27	.	.	PUNCT
admet-328	194	1	kajossari	kajossari	PROPN
admet-328	194	2	et	et	PROPN
admet-328	194	3	al	al	PROPN
admet-328	194	4	reported	report	VERB
admet-328	194	5	that	that	SCONJ
admet-328	194	6	the	the	DET
admet-328	194	7	co	co	NOUN
admet-328	194	8	-	-	NOUN
admet-328	194	9	administration	administration	NOUN
admet-328	194	10	of	of	ADP
admet-328	194	11	repaglinide	repaglinide	NOUN
admet-328	194	12	along	along	ADP
admet-328	194	13	with	with	ADP
admet-328	194	14	the	the	DET
admet-328	194	15	known	know	VERB
admet-328	194	16	p	p	NOUN
admet-328	194	17	-	-	PUNCT
admet-328	194	18	glycoprotein	glycoprotein	NOUN
admet-328	194	19	inhibitor	inhibitor	NOUN
admet-328	194	20	cyclosporine	cyclosporine	VERB
admet-328	194	21	a	a	DET
admet-328	194	22	raised	raise	VERB
admet-328	194	23	the	the	DET
admet-328	194	24	plasma	plasma	NOUN
admet-328	194	25	concentrations	concentration	NOUN
admet-328	194	26	of	of	ADP
admet-328	194	27	repaglinide	repaglinide	NOUN
admet-328	194	28	significantly	significantly	ADV
admet-328	194	29	,	,	PUNCT
admet-328	194	30	probably	probably	ADV
admet-328	194	31	by	by	ADP
admet-328	194	32	inhibiting	inhibit	VERB
admet-328	194	33	its	its	PRON
admet-328	194	34	cyp3a4	cyp3a4	NOUN
admet-328	194	35	-	-	PUNCT
admet-328	194	36	catalyzed	catalyze	VERB
admet-328	194	37	biotransformation	biotransformation	NOUN
admet-328	194	38	and	and	CCONJ
admet-328	194	39	oatp1b1mediated	oatp1b1mediated	ADJ
admet-328	194	40	hepatic	hepatic	ADJ
admet-328	194	41	uptake	uptake	NOUN
admet-328	194	42	.	.	PUNCT
admet-328	195	1	cyclosporine	cyclosporine	PROPN
admet-328	195	2	may	may	AUX
admet-328	195	3	enhance	enhance	VERB
admet-328	195	4	the	the	DET
admet-328	195	5	blood	blood	NOUN
admet-328	195	6	glucose	glucose	NOUN
admet-328	195	7	-	-	PUNCT
admet-328	195	8	lowering	lower	VERB
admet-328	195	9	effect	effect	NOUN
admet-328	195	10	of	of	ADP
admet-328	195	11	repaglinide	repaglinide	NOUN
admet-328	195	12	and	and	CCONJ
admet-328	195	13	increase	increase	VERB
admet-328	195	14	the	the	DET
admet-328	195	15	risk	risk	NOUN
admet-328	195	16	of	of	ADP
admet-328	195	17	hypoglycemia	hypoglycemia	NOUN
admet-328	195	18	in	in	ADP
admet-328	195	19	humans	human	NOUN
admet-328	195	20	[	[	X
admet-328	195	21	29	29	NUM
admet-328	195	22	]	]	PUNCT
admet-328	195	23	.	.	PUNCT
admet-328	196	1	conclusions	conclusion	NOUN
admet-328	196	2	in	in	ADP
admet-328	196	3	this	this	DET
admet-328	196	4	study	study	NOUN
admet-328	196	5	,	,	PUNCT
admet-328	196	6	atazanavir	atazanavir	PROPN
admet-328	196	7	enhanced	enhance	VERB
admet-328	196	8	the	the	DET
admet-328	196	9	bioavailability	bioavailability	NOUN
admet-328	196	10	of	of	ADP
admet-328	196	11	repaglinide	repaglinide	NOUN
admet-328	196	12	after	after	ADP
admet-328	196	13	oral	oral	ADJ
admet-328	196	14	administration	administration	NOUN
admet-328	196	15	,	,	PUNCT
admet-328	196	16	this	this	DET
admet-328	196	17	enhanced	enhanced	ADJ
admet-328	196	18	bioavailability	bioavailability	NOUN
admet-328	196	19	of	of	ADP
admet-328	196	20	repaglinide	repaglinide	NOUN
admet-328	196	21	might	might	AUX
admet-328	196	22	be	be	AUX
admet-328	196	23	mainly	mainly	ADV
admet-328	196	24	due	due	ADJ
admet-328	196	25	to	to	ADP
admet-328	196	26	the	the	DET
admet-328	196	27	possible	possible	ADJ
admet-328	196	28	inhibition	inhibition	NOUN
admet-328	196	29	of	of	ADP
admet-328	196	30	cyp	cyp	ADJ
admet-328	196	31	enzyme	enzyme	NOUN
admet-328	196	32	mediated	mediate	VERB
admet-328	196	33	metabolism	metabolism	NOUN
admet-328	196	34	and	and	CCONJ
admet-328	196	35	p	p	NOUN
admet-328	196	36	-	-	PUNCT
admet-328	196	37	glycoprotein	glycoprotein	ADJ
admet-328	196	38	effect	effect	NOUN
admet-328	196	39	in	in	ADP
admet-328	196	40	the	the	DET
admet-328	196	41	intestine	intestine	NOUN
admet-328	196	42	and	and	CCONJ
admet-328	196	43	in	in	ADP
admet-328	196	44	the	the	DET
admet-328	196	45	liver	liver	NOUN
admet-328	196	46	the	the	DET
admet-328	196	47	reduced	reduce	VERB
admet-328	196	48	the	the	DET
admet-328	196	49	total	total	ADJ
admet-328	196	50	body	body	NOUN
admet-328	196	51	clearance	clearance	NOUN
admet-328	196	52	of	of	ADP
admet-328	196	53	repaglinide	repaglinide	NOUN
admet-328	196	54	is	be	AUX
admet-328	196	55	due	due	ADJ
admet-328	196	56	to	to	ADP
admet-328	196	57	cyp	cyp	ADJ
admet-328	196	58	enzyme	enzyme	NOUN
admet-328	196	59	and	and	CCONJ
admet-328	196	60	oatp	oatp	ADJ
admet-328	196	61	mediated	mediate	VERB
admet-328	196	62	transport	transport	NOUN
admet-328	196	63	inhibition	inhibition	NOUN
admet-328	196	64	.	.	PUNCT
admet-328	197	1	the	the	DET
admet-328	197	2	current	current	ADJ
admet-328	197	3	study	study	NOUN
admet-328	197	4	has	have	AUX
admet-328	197	5	raised	raise	VERB
admet-328	197	6	awareness	awareness	NOUN
admet-328	197	7	of	of	ADP
admet-328	197	8	potential	potential	ADJ
admet-328	197	9	drug	drug	NOUN
admet-328	197	10	-	-	PUNCT
admet-328	197	11	drug	drug	NOUN
admet-328	197	12	interaction	interaction	NOUN
admet-328	197	13	between	between	ADP
admet-328	197	14	the	the	DET
admet-328	197	15	repaglinide	repaglinide	NOUN
admet-328	197	16	and	and	CCONJ
admet-328	197	17	atazanavir	atazanavir	PROPN
admet-328	197	18	in	in	ADP
admet-328	197	19	normal	normal	ADJ
admet-328	197	20	,	,	PUNCT
admet-328	197	21	diabetic	diabetic	ADJ
admet-328	197	22	and	and	CCONJ
admet-328	197	23	hepatic	hepatic	ADJ
admet-328	197	24	impaired	impaired	ADJ
admet-328	197	25	groups	group	NOUN
admet-328	197	26	.	.	PUNCT
admet-328	198	1	the	the	DET
admet-328	198	2	clinical	clinical	ADJ
admet-328	198	3	significance	significance	NOUN
admet-328	198	4	of	of	ADP
admet-328	198	5	this	this	DET
admet-328	198	6	study	study	NOUN
admet-328	198	7	should	should	AUX
admet-328	198	8	be	be	AUX
admet-328	198	9	further	far	ADV
admet-328	198	10	evaluated	evaluate	VERB
admet-328	198	11	in	in	ADP
admet-328	198	12	clinical	clinical	ADJ
admet-328	198	13	studies	study	NOUN
admet-328	198	14	.	.	PUNCT
admet-328	199	1	references	reference	NOUN
admet-328	199	2	[	[	X
admet-328	199	3	1	1	NUM
admet-328	199	4	]	]	X
admet-328	199	5	j.c	j.c	PROPN
admet-328	199	6	.	.	PROPN
admet-328	199	7	koster	koster	PROPN
admet-328	199	8	,	,	PUNCT
admet-328	199	9	m.s	m.s	PROPN
admet-328	199	10	.	.	PUNCT
admet-328	199	11	remedi	remedi	PROPN
admet-328	199	12	,	,	PUNCT
admet-328	199	13	h.	h.	PROPN
admet-328	199	14	qiu	qiu	PROPN
admet-328	199	15	,	,	PUNCT
admet-328	199	16	c.g	c.g	PROPN
admet-328	199	17	.	.	PROPN
admet-328	199	18	nichols	nichols	PROPN
admet-328	199	19	,	,	PUNCT
admet-328	199	20	p.w	p.w	PROPN
admet-328	199	21	.	.	PROPN
admet-328	199	22	hruz	hruz	PROPN
admet-328	199	23	,	,	PUNCT
admet-328	199	24	diabetes	diabete	VERB
admet-328	199	25	52	52	NUM
admet-328	199	26	(	(	PUNCT
admet-328	199	27	2003	2003	NUM
admet-328	199	28	)	)	PUNCT
admet-328	199	29	1696	1696	NUM
admet-328	199	30	-	-	SYM
admet-328	199	31	1700	1700	NUM
admet-328	199	32	.	.	PUNCT
admet-328	200	1	[	[	X
admet-328	200	2	2	2	X
admet-328	200	3	]	]	X
admet-328	200	4	j.t	j.t	PROPN
admet-328	200	5	.	.	PROPN
admet-328	200	6	dipiro	dipiro	PROPN
admet-328	200	7	,	,	PUNCT
admet-328	200	8	r.l	r.l	PROPN
admet-328	200	9	.	.	PROPN
admet-328	200	10	talbert	talbert	PROPN
admet-328	200	11	,	,	PUNCT
admet-328	200	12	g.c	g.c	PROPN
admet-328	200	13	.	.	PROPN
admet-328	200	14	yee	yee	PROPN
admet-328	200	15	,	,	PUNCT
admet-328	200	16	g.r	g.r	PROPN
admet-328	200	17	.	.	PROPN
admet-328	200	18	matzke	matzke	PROPN
admet-328	200	19	,	,	PUNCT
admet-328	200	20	pharmacotherapy	pharmacotherapy	NOUN
admet-328	200	21	:	:	PUNCT
admet-328	200	22	a	a	DET
admet-328	200	23	pathophysiologic	pathophysiologic	ADJ
admet-328	200	24	approach	approach	NOUN
admet-328	200	25	,	,	PUNCT
admet-328	200	26	seventh	seventh	PROPN
admet-328	200	27	edition	edition	NOUN
admet-328	200	28	,	,	PUNCT
admet-328	200	29	mcgraw	mcgraw	PROPN
admet-328	200	30	-	-	PUNCT
admet-328	200	31	hill	hill	NOUN
admet-328	200	32	education	education	NOUN
admet-328	200	33	,	,	PUNCT
admet-328	200	34	llc	llc	PROPN
admet-328	200	35	.	.	PUNCT
admet-328	201	1	page	page	NOUN
admet-328	202	1	no	no	INTJ
admet-328	202	2	:	:	PUNCT
admet-328	202	3	693	693	NUM
admet-328	202	4	-	-	SYM
admet-328	202	5	704	704	NUM
admet-328	202	6	.	.	PUNCT
admet-328	203	1	[	[	X
admet-328	203	2	3	3	X
admet-328	203	3	]	]	PUNCT
admet-328	203	4	m.	m.	NOUN
admet-328	203	5	gonzalez	gonzalez	PROPN
admet-328	203	6	,	,	PUNCT
admet-328	203	7	l.	l.	PROPN
admet-328	203	8	goracci	goracci	PROPN
admet-328	203	9	,	,	PUNCT
admet-328	203	10	g.	g.	PROPN
admet-328	203	11	cruciani	cruciani	PROPN
admet-328	203	12	,	,	PUNCT
admet-328	203	13	i.	i.	NOUN
admet-328	203	14	poggesi	poggesi	PROPN
admet-328	203	15	.	.	PUNCT
admet-328	204	1	expert	expert	ADJ
admet-328	204	2	opinion	opinion	NOUN
admet-328	204	3	drug	drug	NOUN
admet-328	204	4	metabolism	metabolism	NOUN
admet-328	204	5	toxicology	toxicology	NOUN
admet-328	204	6	10	10	NUM
admet-328	204	7	(	(	PUNCT
admet-328	204	8	2014	2014	NUM
admet-328	204	9	)	)	PUNCT
admet-328	204	10	:	:	PUNCT
admet-328	204	11	1397	1397	NUM
admet-328	204	12	-	-	SYM
admet-328	204	13	1408	1408	NUM
admet-328	204	14	.	.	PUNCT
admet-328	205	1	[	[	X
admet-328	205	2	4	4	NUM
admet-328	205	3	]	]	X
admet-328	205	4	g.m	g.m	PROPN
admet-328	205	5	.	.	PROPN
admet-328	205	6	ferron	ferron	PROPN
admet-328	205	7	,	,	PUNCT
admet-328	205	8	r.a	r.a	PROPN
admet-328	205	9	.	.	PROPN
admet-328	205	10	preston	preston	PROPN
admet-328	205	11	,	,	PUNCT
admet-328	205	12	r.j	r.j	PROPN
admet-328	205	13	.	.	PROPN
admet-328	205	14	noveck	noveck	PROPN
admet-328	205	15	,	,	PUNCT
admet-328	205	16	p.	p.	NOUN
admet-328	205	17	pockros	pockro	NOUN
admet-328	205	18	,	,	PUNCT
admet-328	205	19	p.	p.	PROPN
admet-328	205	20	mayer	mayer	PROPN
admet-328	205	21	,	,	PUNCT
admet-328	205	22	j.	j.	PROPN
admet-328	205	23	getsy	getsy	PROPN
admet-328	205	24	,	,	PUNCT
admet-328	205	25	m.	m.	NOUN
admet-328	205	26	turner	turner	PROPN
admet-328	205	27	,	,	PUNCT
admet-328	205	28	m.	m.	PROPN
admet-328	205	29	abell	abell	PROPN
admet-328	205	30	,	,	PUNCT
admet-328	205	31	j.	j.	PROPN
admet-328	205	32	paul	paul	PROPN
admet-328	205	33	,	,	PUNCT
admet-328	205	34	clinical	clinical	ADJ
admet-328	205	35	therapeutics	therapeutic	NOUN
admet-328	205	36	23	23	NUM
admet-328	205	37	(	(	PUNCT
admet-328	205	38	2001	2001	NUM
admet-328	205	39	)	)	PUNCT
admet-328	205	40	1180	1180	NUM
admet-328	205	41	-	-	SYM
admet-328	205	42	1192	1192	NUM
admet-328	205	43	.	.	PUNCT
admet-328	206	1	admet	admet	PROPN
admet-328	206	2	&	&	CCONJ
admet-328	206	3	dmpk	dmpk	PROPN
admet-328	206	4	4(3	4(3	NUM
admet-328	206	5	)	)	PUNCT
admet-328	206	6	(	(	PUNCT
admet-328	206	7	2016	2016	NUM
admet-328	206	8	)	)	PUNCT
admet-328	206	9	269	269	NUM
admet-328	206	10	-	-	SYM
admet-328	206	11	279	279	NUM
admet-328	206	12	pk	pk	NOUN
admet-328	206	13	and	and	CCONJ
admet-328	206	14	pd	pd	NOUN
admet-328	206	15	interaction	interaction	NOUN
admet-328	206	16	between	between	ADP
admet-328	206	17	repaglinide	repaglinide	NOUN
admet-328	206	18	and	and	CCONJ
admet-328	206	19	atazanavir	atazanavir	PROPN
admet-328	206	20	doi	doi	PROPN
admet-328	206	21	:	:	PUNCT
admet-328	206	22	10.5599	10.5599	NUM
admet-328	206	23	/	/	SYM
admet-328	206	24	admet.4.3.328	admet.4.3.328	NUM
admet-328	206	25	279	279	NUM
admet-328	206	26	[	[	X
admet-328	206	27	5	5	NUM
admet-328	206	28	]	]	X
admet-328	206	29	s.k	s.k	PROPN
admet-328	206	30	.	.	PROPN
admet-328	206	31	mastan	mastan	PROPN
admet-328	206	32	,	,	PUNCT
admet-328	206	33	g.	g.	PROPN
admet-328	206	34	chaitanya	chaitanya	PROPN
admet-328	206	35	,	,	PUNCT
admet-328	206	36	k.	k.	PROPN
admet-328	206	37	r.	r.	PROPN
admet-328	206	38	reddy	reddy	PROPN
admet-328	206	39	,	,	PUNCT
admet-328	206	40	k.e	k.e	PROPN
admet-328	206	41	.	.	PROPN
admet-328	206	42	kumar	kumar	PROPN
admet-328	206	43	.	.	PROPN
admet-328	207	1	international	international	PROPN
admet-328	207	2	journal	journal	PROPN
admet-328	207	3	of	of	ADP
admet-328	207	4	pharmtech	pharmtech	ADJ
admet-328	207	5	research	research	NOUN
admet-328	207	6	1	1	NUM
admet-328	207	7	(	(	PUNCT
admet-328	207	8	2009	2009	NUM
admet-328	207	9	)	)	PUNCT
admet-328	207	10	613	613	NUM
admet-328	207	11	-	-	SYM
admet-328	207	12	622	622	NUM
admet-328	207	13	.	.	PUNCT
admet-328	208	1	[	[	X
admet-328	208	2	6	6	NUM
admet-328	208	3	]	]	X
admet-328	208	4	c.r	c.r	PROPN
admet-328	208	5	.	.	PROPN
admet-328	208	6	culy	culy	PROPN
admet-328	208	7	,	,	PUNCT
admet-328	208	8	b.	b.	PROPN
admet-328	208	9	jarvis	jarvis	PROPN
admet-328	208	10	.	.	PUNCT
admet-328	209	1	drugs	drug	NOUN
admet-328	209	2	61	61	NUM
admet-328	209	3	(	(	PUNCT
admet-328	209	4	2001	2001	NUM
admet-328	209	5	)	)	PUNCT
admet-328	209	6	1625–60	1625–60	NOUN
admet-328	209	7	.	.	PUNCT
admet-328	210	1	[	[	X
admet-328	210	2	7	7	NUM
admet-328	210	3	]	]	PUNCT
admet-328	210	4	a.	a.	NOUN
admet-328	210	5	tornio	tornio	NOUN
admet-328	210	6	,	,	PUNCT
admet-328	210	7	m.	m.	NOUN
admet-328	210	8	niemi	niemi	PROPN
admet-328	210	9	,	,	PUNCT
admet-328	210	10	p.j	p.j	PROPN
admet-328	210	11	.	.	PROPN
admet-328	210	12	neuvonen	neuvonen	PROPN
admet-328	210	13	,	,	PUNCT
admet-328	210	14	j.t	j.t	PROPN
admet-328	210	15	.	.	PROPN
admet-328	210	16	backman	backman	PROPN
admet-328	210	17	.	.	PUNCT
admet-328	211	1	trends	trend	NOUN
admet-328	211	2	in	in	ADP
admet-328	211	3	pharmaceutical	pharmaceutical	ADJ
admet-328	211	4	sciences	science	NOUN
admet-328	211	5	33	33	NUM
admet-328	211	6	(	(	PUNCT
admet-328	211	7	2012	2012	NUM
admet-328	211	8	)	)	PUNCT
admet-328	211	9	312321	312321	NUM
admet-328	211	10	.	.	PUNCT
admet-328	212	1	[	[	X
admet-328	212	2	8	8	NUM
admet-328	212	3	]	]	X
admet-328	212	4	t.b	t.b	PROPN
admet-328	212	5	.	.	PROPN
admet-328	212	6	bidstrup	bidstrup	PROPN
admet-328	212	7	,	,	PUNCT
admet-328	212	8	i.	i.	PROPN
admet-328	212	9	bjørnsdottir	bjørnsdottir	PROPN
admet-328	212	10	,	,	PUNCT
admet-328	212	11	u.g	u.g	PROPN
admet-328	212	12	.	.	PROPN
admet-328	212	13	sidelmann	sidelmann	PROPN
admet-328	212	14	,	,	PUNCT
admet-328	212	15	m.	m.	NOUN
admet-328	212	16	søndergård	søndergård	PROPN
admet-328	212	17	,	,	PUNCT
admet-328	212	18	t.	t.	PROPN
admet-328	212	19	kristian	kristian	PROPN
admet-328	212	20	,	,	PUNCT
admet-328	212	21	t.	t.	PROPN
admet-328	212	22	hansen	hansen	PROPN
admet-328	212	23	.	.	PUNCT
admet-328	213	1	british	british	PROPN
admet-328	213	2	journal	journal	PROPN
admet-328	213	3	of	of	ADP
admet-328	213	4	clinical	clinical	ADJ
admet-328	213	5	pharmacology	pharmacology	NOUN
admet-328	213	6	56	56	NUM
admet-328	213	7	(	(	PUNCT
admet-328	213	8	2003	2003	NUM
admet-328	213	9	)	)	PUNCT
admet-328	213	10	305–314	305–314	NUM
admet-328	213	11	.	.	PUNCT
admet-328	214	1	[	[	X
admet-328	214	2	9	9	NUM
admet-328	214	3	]	]	X
admet-328	214	4	j.s	j.s	PROPN
admet-328	214	5	.	.	PROPN
admet-328	214	6	choi	choi	PROPN
admet-328	214	7	,	,	PUNCT
admet-328	214	8	i.	i.	NOUN
admet-328	214	9	choi	choi	PROPN
admet-328	214	10	,	,	PUNCT
admet-328	214	11	d.h	d.h	PROPN
admet-328	214	12	.	.	PROPN
admet-328	214	13	choi	choi	PROPN
admet-328	214	14	.	.	PUNCT
admet-328	215	1	pharmacological	pharmacological	ADJ
admet-328	215	2	reports	report	NOUN
admet-328	215	3	65	65	NUM
admet-328	215	4	(	(	PUNCT
admet-328	215	5	2013	2013	NUM
admet-328	215	6	)	)	PUNCT
admet-328	215	7	1422	1422	NUM
admet-328	215	8	-	-	SYM
admet-328	215	9	1430	1430	NUM
admet-328	215	10	.	.	PUNCT
admet-328	216	1	[	[	X
admet-328	216	2	10	10	NUM
admet-328	216	3	]	]	X
admet-328	216	4	e.s	e.s	PROPN
admet-328	216	5	.	.	PROPN
admet-328	216	6	perloff	perloff	PROPN
admet-328	216	7	,	,	PUNCT
admet-328	216	8	s.x	s.x	PROPN
admet-328	216	9	.	.	PUNCT
admet-328	216	10	duan	duan	PROPN
admet-328	216	11	,	,	PUNCT
admet-328	216	12	p.r	p.r	PROPN
admet-328	216	13	.	.	PROPN
admet-328	216	14	skolnik	skolnik	PROPN
admet-328	216	15	,	,	PUNCT
admet-328	216	16	d.j	d.j	PROPN
admet-328	216	17	.	.	PROPN
admet-328	216	18	greenblatt	greenblatt	PROPN
admet-328	216	19	,	,	PUNCT
admet-328	216	20	l.l	l.l	PROPN
admet-328	216	21	.	.	PROPN
admet-328	216	22	von	von	PROPN
admet-328	216	23	moltke	moltke	PROPN
admet-328	216	24	.	.	PUNCT
admet-328	217	1	american	american	ADJ
admet-328	217	2	society	society	PROPN
admet-328	217	3	of	of	ADP
admet-328	217	4	pharmacology	pharmacology	NOUN
admet-328	217	5	and	and	CCONJ
admet-328	217	6	experimental	experimental	ADJ
admet-328	217	7	therapeutics	therapeutic	NOUN
admet-328	217	8	3	3	NUM
admet-328	217	9	(	(	PUNCT
admet-328	217	10	2005	2005	NUM
admet-328	217	11	)	)	PUNCT
admet-328	217	12	764	764	NUM
admet-328	217	13	-	-	SYM
admet-328	217	14	770	770	NUM
admet-328	217	15	.	.	PUNCT
admet-328	218	1	[	[	X
admet-328	218	2	11	11	NUM
admet-328	218	3	]	]	X
admet-328	218	4	m.b	m.b	PROPN
admet-328	218	5	.	.	PROPN
admet-328	218	6	lucia	lucia	PROPN
admet-328	218	7	,	,	PUNCT
admet-328	218	8	c.	c.	PROPN
admet-328	218	9	golotta	golotta	PROPN
admet-328	218	10	,	,	PUNCT
admet-328	218	11	s.	s.	PROPN
admet-328	218	12	rutella	rutella	PROPN
admet-328	218	13	,	,	PUNCT
admet-328	218	14	e.	e.	PROPN
admet-328	218	15	rastrelli	rastrelli	PROPN
admet-328	218	16	,	,	PUNCT
admet-328	218	17	a.	a.	NOUN
admet-328	218	18	savarino	savarino	PROPN
admet-328	218	19	,	,	PUNCT
admet-328	218	20	r.	r.	PROPN
admet-328	218	21	cauda	cauda	PROPN
admet-328	218	22	.	.	PUNCT
admet-328	219	1	journal	journal	PROPN
admet-328	219	2	of	of	ADP
admet-328	219	3	acquired	acquire	VERB
admet-328	219	4	immune	immune	ADJ
admet-328	219	5	deficiency	deficiency	NOUN
admet-328	219	6	syndrome	syndrome	NOUN
admet-328	219	7	39	39	NUM
admet-328	219	8	(	(	PUNCT
admet-328	219	9	2005	2005	NUM
admet-328	219	10	)	)	PUNCT
admet-328	219	11	635	635	NUM
admet-328	219	12	-	-	SYM
admet-328	219	13	637	637	NUM
admet-328	219	14	.	.	PUNCT
admet-328	220	1	[	[	X
admet-328	220	2	12	12	NUM
admet-328	220	3	]	]	X
admet-328	220	4	d.-h	d.-h	NOUN
admet-328	220	5	.	.	PUNCT
admet-328	221	1	choi	choi	NOUN
admet-328	221	2	,	,	PUNCT
admet-328	221	3	j.-s	j.-	NOUN
admet-328	221	4	.	.	PUNCT
admet-328	222	1	choi	choi	NOUN
admet-328	222	2	,	,	PUNCT
admet-328	222	3	korean	korean	ADJ
admet-328	222	4	journal	journal	NOUN
admet-328	222	5	of	of	ADP
admet-328	222	6	clinical	clinical	ADJ
admet-328	222	7	pharmacology	pharmacology	NOUN
admet-328	222	8	21	21	NUM
admet-328	222	9	(	(	PUNCT
admet-328	222	10	2011	2011	NUM
admet-328	222	11	)	)	PUNCT
admet-328	222	12	215	215	NUM
admet-328	222	13	-	-	SYM
admet-328	222	14	223	223	NUM
admet-328	222	15	.	.	PUNCT
admet-328	223	1	[	[	X
admet-328	223	2	13	13	NUM
admet-328	223	3	]	]	X
admet-328	223	4	s.k	s.k	PROPN
admet-328	223	5	.	.	PROPN
admet-328	223	6	mastan	mastan	PROPN
admet-328	223	7	,	,	PUNCT
admet-328	223	8	k.e	k.e	PROPN
admet-328	223	9	.	.	PROPN
admet-328	223	10	kumar	kumar	PROPN
admet-328	223	11	.	.	PROPN
admet-328	223	12	international	international	PROPN
admet-328	223	13	journal	journal	PROPN
admet-328	223	14	of	of	ADP
admet-328	223	15	diabetes	diabetes	NOUN
admet-328	223	16	mellitus	mellitus	NOUN
admet-328	223	17	2	2	NUM
admet-328	223	18	(	(	PUNCT
admet-328	223	19	2010	2010	NUM
admet-328	223	20	)	)	PUNCT
admet-328	223	21	56	56	NUM
admet-328	223	22	-	-	SYM
admet-328	223	23	60	60	NUM
admet-328	223	24	.	.	PUNCT
admet-328	224	1	[	[	X
admet-328	224	2	14	14	NUM
admet-328	224	3	]	]	X
admet-328	224	4	s.n	s.n	PROPN
admet-328	224	5	.	.	PROPN
admet-328	224	6	bhattachar	bhattachar	PROPN
admet-328	224	7	,	,	PUNCT
admet-328	224	8	d.m	d.m	PROPN
admet-328	224	9	.	.	PROPN
admet-328	224	10	bender	bender	PROPN
admet-328	224	11	,	,	PUNCT
admet-328	224	12	s.a	s.a	PROPN
admet-328	224	13	.	.	PROPN
admet-328	224	14	sweetana	sweetana	PROPN
admet-328	224	15	,	,	PUNCT
admet-328	224	16	j.a	j.a	PROPN
admet-328	224	17	.	.	PROPN
admet-328	224	18	wesley	wesley	PROPN
admet-328	224	19	,	,	PUNCT
admet-328	224	20	discovering	discover	VERB
admet-328	224	21	and	and	CCONJ
admet-328	224	22	developing	develop	VERB
admet-328	224	23	molecules	molecule	NOUN
admet-328	224	24	with	with	ADP
admet-328	224	25	optimal	optimal	ADJ
admet-328	224	26	drug	drug	NOUN
admet-328	224	27	-	-	PUNCT
admet-328	224	28	like	like	ADJ
admet-328	224	29	properties	property	NOUN
admet-328	224	30	.	.	PUNCT
admet-328	225	1	a.c	a.c	PROPN
admet-328	225	2	.	.	PROPN
admet-328	225	3	templeton	templeton	PROPN
admet-328	225	4	,	,	PUNCT
admet-328	225	5	editor	editor	NOUN
admet-328	225	6	.	.	PUNCT
admet-328	226	1	discovery	discovery	NOUN
admet-328	226	2	formulations	formulation	NOUN
admet-328	226	3	:	:	PUNCT
admet-328	226	4	approaches	approach	NOUN
admet-328	226	5	and	and	CCONJ
admet-328	226	6	practices	practice	NOUN
admet-328	226	7	in	in	ADP
admet-328	226	8	early	early	ADJ
admet-328	226	9	preclinical	preclinical	ADJ
admet-328	226	10	development	development	NOUN
admet-328	226	11	,	,	PUNCT
admet-328	226	12	discovering	discover	VERB
admet-328	226	13	and	and	CCONJ
admet-328	226	14	developing	develop	VERB
admet-328	226	15	molecules	molecule	NOUN
admet-328	226	16	with	with	ADP
admet-328	226	17	optimal	optimal	ADJ
admet-328	226	18	drug	drug	NOUN
admet-328	226	19	-	-	PUNCT
admet-328	226	20	like	like	ADJ
admet-328	226	21	properties	property	NOUN
admet-328	226	22	.	.	PUNCT
admet-328	227	1	springer	springer	PROPN
admet-328	227	2	new	new	PROPN
admet-328	227	3	york	york	PROPN
admet-328	227	4	:	:	PUNCT
admet-328	227	5	aaps	aaps	PROPN
admet-328	227	6	press	press	PROPN
admet-328	227	7	,	,	PUNCT
admet-328	228	1	2015	2015	NUM
admet-328	228	2	page	page	NOUN
admet-328	228	3	no	no	INTJ
admet-328	228	4	:	:	PUNCT
admet-328	228	5	49	49	NUM
admet-328	228	6	-	-	SYM
admet-328	228	7	94	94	NUM
admet-328	228	8	.	.	PUNCT
admet-328	229	1	[	[	X
admet-328	229	2	15	15	X
admet-328	229	3	]	]	X
admet-328	229	4	v.	v.	CCONJ
admet-328	229	5	riley	riley	PROPN
admet-328	229	6	,	,	PUNCT
admet-328	229	7	proceedings	proceeding	NOUN
admet-328	229	8	of	of	ADP
admet-328	229	9	the	the	DET
admet-328	229	10	society	society	NOUN
admet-328	229	11	for	for	ADP
admet-328	229	12	experimental	experimental	ADJ
admet-328	229	13	biology	biology	NOUN
admet-328	229	14	and	and	CCONJ
admet-328	229	15	medicine	medicine	NOUN
admet-328	229	16	104	104	NUM
admet-328	229	17	(	(	PUNCT
admet-328	229	18	1960)751–754	1960)751–754	NUM
admet-328	229	19	.	.	PUNCT
admet-328	230	1	[	[	X
admet-328	230	2	16	16	NUM
admet-328	230	3	]	]	PUNCT
admet-328	230	4	p.	p.	PROPN
admet-328	230	5	trinder	trinder	PROPN
admet-328	230	6	.	.	PUNCT
admet-328	231	1	journal	journal	PROPN
admet-328	231	2	of	of	ADP
admet-328	231	3	clinical	clinical	ADJ
admet-328	231	4	pathology	pathology	NOUN
admet-328	231	5	22	22	NUM
admet-328	231	6	(	(	PUNCT
admet-328	231	7	1969	1969	NUM
admet-328	231	8	)	)	PUNCT
admet-328	231	9	158–161	158–161	NUM
admet-328	231	10	.	.	PUNCT
admet-328	232	1	[	[	X
admet-328	232	2	17	17	NUM
admet-328	232	3	]	]	X
admet-328	232	4	r.e	r.e	PROPN
admet-328	232	5	.	.	PROPN
admet-328	232	6	heikkila	heikkila	PROPN
admet-328	232	7	,	,	PUNCT
admet-328	232	8	european	european	PROPN
admet-328	232	9	journal	journal	PROPN
admet-328	232	10	of	of	ADP
admet-328	232	11	pharmacology	pharmacology	NOUN
admet-328	232	12	44	44	NUM
admet-328	232	13	(	(	PUNCT
admet-328	232	14	1977	1977	NUM
admet-328	232	15	)	)	PUNCT
admet-328	232	16	191	191	NUM
admet-328	232	17	-	-	SYM
admet-328	232	18	193	193	NUM
admet-328	232	19	.	.	PUNCT
admet-328	233	1	[	[	X
admet-328	233	2	18	18	NUM
admet-328	233	3	]	]	X
admet-328	233	4	s.	s.	PROPN
admet-328	233	5	robin	robin	PROPN
admet-328	233	6	,	,	PUNCT
admet-328	233	7	k.	k.	PROPN
admet-328	233	8	sunil	sunil	PROPN
admet-328	233	9	,	,	PUNCT
admet-328	233	10	a.c	a.c	PROPN
admet-328	233	11	.	.	PROPN
admet-328	233	12	rana	rana	PROPN
admet-328	233	13	,	,	PUNCT
admet-328	233	14	s.	s.	PROPN
admet-328	233	15	nidhi	nidhi	PROPN
admet-328	233	16	,	,	PUNCT
admet-328	233	17	international	international	ADJ
admet-328	233	18	research	research	NOUN
admet-328	233	19	journal	journal	NOUN
admet-328	233	20	of	of	ADP
admet-328	233	21	pharmacy	pharmacy	NOUN
admet-328	233	22	3	3	NUM
admet-328	233	23	(	(	PUNCT
admet-328	233	24	2012	2012	NUM
admet-328	233	25	)	)	PUNCT
admet-328	233	26	86	86	NUM
admet-328	233	27	-	-	SYM
admet-328	233	28	95	95	NUM
admet-328	233	29	.	.	PUNCT
admet-328	234	1	[	[	X
admet-328	234	2	19	19	NUM
admet-328	234	3	]	]	X
admet-328	234	4	c.	c.	PROPN
admet-328	234	5	johnson	johnson	PROPN
admet-328	234	6	-	-	PUNCT
admet-328	234	7	delaney	delaney	PROPN
admet-328	234	8	,	,	PUNCT
admet-328	234	9	zoological	zoological	ADJ
admet-328	234	10	education	education	NOUN
admet-328	234	11	network	network	NOUN
admet-328	234	12	(	(	PUNCT
admet-328	234	13	1996	1996	NUM
admet-328	234	14	)	)	PUNCT
admet-328	234	15	220	220	NUM
admet-328	234	16	-	-	SYM
admet-328	234	17	250	250	NUM
admet-328	234	18	.	.	PUNCT
admet-328	235	1	[	[	X
admet-328	235	2	20	20	NUM
admet-328	235	3	]	]	PUNCT
admet-328	235	4	l.	l.	PROPN
admet-328	235	5	xiao	xiao	PROPN
admet-328	235	6	-	-	PUNCT
admet-328	235	7	rong	rong	PROPN
admet-328	235	8	,	,	PUNCT
admet-328	235	9	d.	d.	PROPN
admet-328	235	10	xiao	xiao	PROPN
admet-328	235	11	-	-	PROPN
admet-328	235	12	jian	jian	PROPN
admet-328	235	13	,	,	PUNCT
admet-328	235	14	z.	z.	PROPN
admet-328	235	15	yi	yi	PROPN
admet-328	235	16	-	-	PUNCT
admet-328	235	17	fan	fan	PROPN
admet-328	235	18	,	,	PUNCT
admet-328	235	19	d.	d.	PROPN
admet-328	235	20	jue	jue	PROPN
admet-328	235	21	-	-	PUNCT
admet-328	235	22	fang	fang	PROPN
admet-328	235	23	,	,	PUNCT
admet-328	235	24	c.	c.	PROPN
admet-328	235	25	xiao	xiao	PROPN
admet-328	235	26	-	-	PUNCT
admet-328	235	27	yan	yan	PROPN
admet-328	235	28	,	,	PUNCT
admet-328	235	29	z.	z.	PROPN
admet-328	235	30	dafang	dafang	PROPN
admet-328	235	31	,	,	PUNCT
admet-328	235	32	acta	acta	PROPN
admet-328	235	33	pharmaceutica	pharmaceutica	PROPN
admet-328	235	34	sinica	sinica	PROPN
admet-328	235	35	48	48	NUM
admet-328	235	36	(	(	PUNCT
admet-328	235	37	2013	2013	NUM
admet-328	235	38	)	)	PUNCT
admet-328	235	39	547	547	NUM
admet-328	235	40	−553	−553	NOUN
admet-328	235	41	.	.	PUNCT
admet-328	236	1	[	[	X
admet-328	236	2	21	21	NUM
admet-328	236	3	]	]	X
admet-328	236	4	g.	g.	PROPN
admet-328	236	5	singh	singh	PROPN
admet-328	236	6	,	,	PUNCT
admet-328	236	7	r.s	r.s	PROPN
admet-328	236	8	.	.	PROPN
admet-328	236	9	pai	pai	PROPN
admet-328	236	10	,	,	PUNCT
admet-328	236	11	s.	s.	PROPN
admet-328	236	12	mustafa	mustafa	PROPN
admet-328	236	13	.	.	PROPN
admet-328	237	1	journal	journal	PROPN
admet-328	237	2	of	of	ADP
admet-328	237	3	chromatographic	chromatographic	ADJ
admet-328	237	4	separation	separation	NOUN
admet-328	237	5	techniques	technique	NOUN
admet-328	237	6	5	5	NUM
admet-328	237	7	(	(	PUNCT
admet-328	237	8	2015	2015	NUM
admet-328	237	9	)	)	PUNCT
admet-328	237	10	1	1	NUM
admet-328	237	11	-	-	SYM
admet-328	237	12	5	5	NUM
admet-328	237	13	.	.	PUNCT
admet-328	238	1	[	[	X
admet-328	238	2	22	22	NUM
admet-328	238	3	]	]	PUNCT
admet-328	238	4	p.	p.	NOUN
admet-328	238	5	neerati	neerati	PROPN
admet-328	238	6	,	,	PUNCT
admet-328	238	7	j.	j.	PROPN
admet-328	238	8	gade	gade	PROPN
admet-328	238	9	.	.	PUNCT
admet-328	239	1	european	european	PROPN
admet-328	239	2	journal	journal	PROPN
admet-328	239	3	of	of	ADP
admet-328	239	4	pharmaceutical	pharmaceutical	PROPN
admet-328	239	5	sciences	science	NOUN
admet-328	239	6	42	42	NUM
admet-328	239	7	(	(	PUNCT
admet-328	239	8	2011	2011	NUM
admet-328	239	9	)	)	PUNCT
admet-328	239	10	285–289	285–289	NUM
admet-328	239	11	.	.	PUNCT
admet-328	240	1	[	[	X
admet-328	240	2	23	23	NUM
admet-328	240	3	]	]	X
admet-328	240	4	p.n	p.n	PROPN
admet-328	240	5	.	.	PROPN
admet-328	240	6	van	van	PROPN
admet-328	240	7	heiningen	heiningen	PROPN
admet-328	240	8	,	,	PUNCT
admet-328	240	9	v.	v.	PROPN
admet-328	240	10	hatrop	hatrop	PROPN
admet-328	240	11	,	,	PUNCT
admet-328	240	12	k.	k.	PROPN
admet-328	240	13	kramer	kramer	PROPN
admet-328	240	14	nielsen	nielsen	PROPN
admet-328	240	15	,	,	PUNCT
admet-328	240	16	k.t	k.t	PROPN
admet-328	240	17	.	.	PROPN
admet-328	240	18	hansen	hansen	PROPN
admet-328	240	19	,	,	PUNCT
admet-328	240	20	j.j	j.j	PROPN
admet-328	240	21	.	.	PROPN
admet-328	240	22	van	van	PROPN
admet-328	240	23	lier	lier	PROPN
admet-328	240	24	,	,	PUNCT
admet-328	240	25	n.c	n.c	PROPN
admet-328	240	26	.	.	PROPN
admet-328	240	27	de	de	PROPN
admet-328	240	28	merbel	merbel	PROPN
admet-328	240	29	,	,	PUNCT
admet-328	240	30	b.	b.	PROPN
admet-328	240	31	oosterhuis	oosterhuis	PROPN
admet-328	240	32	,	,	PUNCT
admet-328	240	33	j.h.g	j.h.g	PROPN
admet-328	240	34	.	.	PUNCT
admet-328	240	35	jonkman	jonkman	PROPN
admet-328	240	36	.	.	PUNCT
admet-328	241	1	european	european	ADJ
admet-328	241	2	journal	journal	PROPN
admet-328	241	3	of	of	ADP
admet-328	241	4	clinical	clinical	ADJ
admet-328	241	5	pharmacology	pharmacology	NOUN
admet-328	241	6	55	55	NUM
admet-328	241	7	(	(	PUNCT
admet-328	241	8	1999	1999	NUM
admet-328	241	9	)	)	PUNCT
admet-328	241	10	521	521	NUM
admet-328	241	11	-	-	SYM
admet-328	241	12	525	525	NUM
admet-328	241	13	.	.	PUNCT
admet-328	242	1	[	[	X
admet-328	242	2	24	24	NUM
admet-328	242	3	]	]	PUNCT
admet-328	242	4	c.	c.	PROPN
admet-328	242	5	sall	sall	PROPN
admet-328	242	6	,	,	PUNCT
admet-328	242	7	j.	j.	PROPN
admet-328	242	8	brian	brian	PROPN
admet-328	242	9	houston	houston	PROPN
admet-328	242	10	,	,	PUNCT
admet-328	242	11	a.	a.	NOUN
admet-328	242	12	galetin	galetin	PROPN
admet-328	242	13	.	.	PUNCT
admet-328	243	1	the	the	DET
admet-328	243	2	american	american	ADJ
admet-328	243	3	society	society	PROPN
admet-328	243	4	for	for	ADP
admet-328	243	5	pharmacology	pharmacology	NOUN
admet-328	243	6	and	and	CCONJ
admet-328	243	7	experimental	experimental	ADJ
admet-328	243	8	therapeutics	therapeutic	NOUN
admet-328	243	9	40	40	NUM
admet-328	243	10	(	(	PUNCT
admet-328	243	11	2012	2012	NUM
admet-328	243	12	)	)	PUNCT
admet-328	243	13	1279	1279	NUM
admet-328	243	14	-	-	SYM
admet-328	243	15	1289	1289	NUM
admet-328	243	16	.	.	PUNCT
admet-328	244	1	[	[	X
admet-328	244	2	25	25	NUM
admet-328	244	3	]	]	X
admet-328	244	4	c.k	c.k	PROPN
admet-328	244	5	.	.	PROPN
admet-328	244	6	lee	lee	PROPN
admet-328	244	7	,	,	PUNCT
admet-328	244	8	j.s	j.s	PROPN
admet-328	244	9	.	.	PROPN
admet-328	244	10	choi	choi	PROPN
admet-328	244	11	,	,	PUNCT
admet-328	244	12	j.s	j.s	PROPN
admet-328	244	13	.	.	PROPN
admet-328	244	14	bang	bang	PROPN
admet-328	244	15	.	.	PUNCT
admet-328	245	1	korean	korean	PROPN
admet-328	245	2	journal	journal	PROPN
admet-328	245	3	of	of	ADP
admet-328	245	4	physiology	physiology	NOUN
admet-328	245	5	and	and	CCONJ
admet-328	245	6	pharmacology	pharmacology	NOUN
admet-328	245	7	17	17	NUM
admet-328	245	8	(	(	PUNCT
admet-328	245	9	2013	2013	NUM
admet-328	245	10	)	)	PUNCT
admet-328	245	11	245	245	NUM
admet-328	245	12	-	-	SYM
admet-328	245	13	251	251	NUM
admet-328	245	14	.	.	PUNCT
admet-328	246	1	[	[	X
admet-328	246	2	26	26	NUM
admet-328	246	3	]	]	X
admet-328	246	4	e.s	e.s	PROPN
admet-328	246	5	.	.	PROPN
admet-328	246	6	perloff	perloff	PROPN
admet-328	246	7	,	,	PUNCT
admet-328	246	8	s.x	s.x	PROPN
admet-328	246	9	.	.	PUNCT
admet-328	246	10	duan	duan	PROPN
admet-328	246	11	,	,	PUNCT
admet-328	246	12	p.r	p.r	PROPN
admet-328	246	13	.	.	PROPN
admet-328	246	14	skolnik	skolnik	PROPN
admet-328	246	15	,	,	PUNCT
admet-328	246	16	d.j	d.j	PROPN
admet-328	246	17	.	.	PROPN
admet-328	246	18	greenblatt	greenblatt	PROPN
admet-328	246	19	,	,	PUNCT
admet-328	246	20	l.l	l.l	PROPN
admet-328	246	21	.	.	PROPN
admet-328	246	22	von	von	PROPN
admet-328	246	23	moltke	moltke	VERB
admet-328	246	24	.	.	PUNCT
admet-328	247	1	the	the	DET
admet-328	247	2	american	american	ADJ
admet-328	247	3	society	society	PROPN
admet-328	247	4	for	for	ADP
admet-328	247	5	pharmacology	pharmacology	NOUN
admet-328	247	6	and	and	CCONJ
admet-328	247	7	experimental	experimental	ADJ
admet-328	247	8	therapeutics	therapeutic	NOUN
admet-328	247	9	33	33	NUM
admet-328	247	10	(	(	PUNCT
admet-328	247	11	2005	2005	NUM
admet-328	247	12	)	)	PUNCT
admet-328	247	13	764	764	NUM
admet-328	247	14	-	-	SYM
admet-328	247	15	770	770	NUM
admet-328	247	16	.	.	PUNCT
admet-328	248	1	[	[	X
admet-328	248	2	27	27	NUM
admet-328	248	3	]	]	X
admet-328	248	4	l.	l.	PROPN
admet-328	248	5	griffin	griffin	PROPN
admet-328	248	6	,	,	PUNCT
admet-328	248	7	p.	p.	PROPN
admet-328	248	8	annaert	annaert	NOUN
admet-328	248	9	,	,	PUNCT
admet-328	248	10	k.l.r	k.l.r	PROPN
admet-328	248	11	.	.	PUNCT
admet-328	248	12	brower	brower	PROPN
admet-328	248	13	.	.	PUNCT
admet-328	249	1	journal	journal	PROPN
admet-328	249	2	of	of	ADP
admet-328	249	3	pharmaceutical	pharmaceutical	PROPN
admet-328	249	4	sciences	science	NOUN
admet-328	249	5	100	100	NUM
admet-328	249	6	(	(	PUNCT
admet-328	249	7	2011	2011	NUM
admet-328	249	8	)	)	PUNCT
admet-328	249	9	3636	3636	NUM
admet-328	249	10	-	-	SYM
admet-328	249	11	3654	3654	NUM
admet-328	249	12	.	.	PUNCT
admet-328	250	1	[	[	X
admet-328	250	2	28	28	NUM
admet-328	250	3	]	]	X
admet-328	250	4	y.	y.	PROPN
admet-328	250	5	shitara	shitara	PROPN
admet-328	250	6	,	,	PUNCT
admet-328	250	7	m.	m.	PROPN
admet-328	250	8	hirano	hirano	PROPN
admet-328	250	9	,	,	PUNCT
admet-328	250	10	h.	h.	PROPN
admet-328	250	11	sato	sato	PROPN
admet-328	250	12	,	,	PUNCT
admet-328	250	13	y.	y.	PROPN
admet-328	250	14	sugiyama	sugiyama	PROPN
admet-328	250	15	,	,	PUNCT
admet-328	250	16	journal	journal	NOUN
admet-328	250	17	of	of	ADP
admet-328	250	18	pharmacology	pharmacology	NOUN
admet-328	250	19	and	and	CCONJ
admet-328	250	20	experimental	experimental	ADJ
admet-328	250	21	therapeutics	therapeutic	NOUN
admet-328	250	22	311	311	NUM
admet-328	250	23	(	(	PUNCT
admet-328	250	24	2004	2004	NUM
admet-328	250	25	)	)	PUNCT
admet-328	250	26	228–236	228–236	NUM
admet-328	250	27	.	.	PUNCT
admet-328	251	1	[	[	X
admet-328	251	2	29	29	NUM
admet-328	251	3	]	]	X
admet-328	251	4	l.i	l.i	PROPN
admet-328	251	5	.	.	PROPN
admet-328	251	6	kajosaari	kajosaari	PROPN
admet-328	251	7	,	,	PUNCT
admet-328	251	8	m.	m.	NOUN
admet-328	251	9	niemi	niemi	PROPN
admet-328	251	10	,	,	PUNCT
admet-328	251	11	m.	m.	NOUN
admet-328	251	12	neuvonen	neuvonen	PROPN
admet-328	251	13	,	,	PUNCT
admet-328	251	14	j.	j.	PROPN
admet-328	251	15	laitila	laitila	PROPN
admet-328	251	16	,	,	PUNCT
admet-328	251	17	p.j	p.j	PROPN
admet-328	251	18	.	.	PROPN
admet-328	251	19	neuvonen	neuvonen	PROPN
admet-328	251	20	,	,	PUNCT
admet-328	251	21	j.t	j.t	PROPN
admet-328	251	22	.	.	PROPN
admet-328	251	23	backman	backman	PROPN
admet-328	251	24	.	.	PUNCT
admet-328	252	1	clinical	clinical	ADJ
admet-328	252	2	pharmacology	pharmacology	NOUN
admet-328	252	3	and	and	CCONJ
admet-328	252	4	therapeutics	therapeutic	NOUN
admet-328	252	5	78	78	NUM
admet-328	252	6	(	(	PUNCT
admet-328	252	7	2005	2005	NUM
admet-328	252	8	)	)	PUNCT
admet-328	252	9	388	388	NUM
admet-328	252	10	-	-	SYM
admet-328	252	11	399	399	NUM
admet-328	252	12	.	.	PUNCT
admet-328	253	1	©	©	PROPN
admet-328	253	2	2016	2016	NUM
admet-328	253	3	by	by	ADP
admet-328	253	4	the	the	DET
admet-328	253	5	authors	author	NOUN
admet-328	253	6	;	;	PUNCT
admet-328	253	7	licensee	licensee	PROPN
admet-328	253	8	iapc	iapc	PROPN
admet-328	253	9	,	,	PUNCT
admet-328	253	10	zagreb	zagreb	PROPN
admet-328	253	11	,	,	PUNCT
admet-328	253	12	croatia	croatia	PROPN
admet-328	253	13	.	.	PUNCT
admet-328	254	1	this	this	DET
admet-328	254	2	article	article	NOUN
admet-328	254	3	is	be	AUX
admet-328	254	4	an	an	DET
admet-328	254	5	open	open	ADJ
admet-328	254	6	-	-	PUNCT
admet-328	254	7	access	access	NOUN
admet-328	254	8	article	article	NOUN
admet-328	254	9	distributed	distribute	VERB
admet-328	254	10	under	under	ADP
admet-328	254	11	the	the	DET
admet-328	254	12	terms	term	NOUN
admet-328	254	13	and	and	CCONJ
admet-328	254	14	conditions	condition	NOUN
admet-328	254	15	of	of	ADP
admet-328	254	16	the	the	DET
admet-328	254	17	creative	creative	ADJ
admet-328	254	18	commons	common	NOUN
admet-328	254	19	attribution	attribution	NOUN
admet-328	254	20	license	license	NOUN
admet-328	254	21	(	(	PUNCT
admet-328	254	22	http://creativecommons.org/licenses/by/3.0/	http://creativecommons.org/licenses/by/3.0/	PROPN
admet-328	254	23	)	)	PUNCT
admet-328	254	24	http://www.ncbi.nlm.nih.gov/pubmed/12817528	http://www.ncbi.nlm.nih.gov/pubmed/12817528	NUM
admet-328	254	25	http://link.springer.com/search?facet-creator=%22allen+c+templeton%22	http://link.springer.com/search?facet-creator=%22allen+c+templeton%22	PROPN
admet-328	254	26	http://creativecommons.org/licenses/by/3.0/	http://creativecommons.org/licenses/by/3.0/	PROPN